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OVERVIEW 
Acute myocardial ischemic syndromes are apparently 
related to the underlying pathophysiology leading to the 
clinical instability. Depending on the completeness and the 
duration of blood deprivation, different clinical syndromes 
result, such as sudden death, acute transmural infarction, 
nontransmural infarction, or unstable angina. Recent clinical, 
angiographic, and pathologic studies have emphasized the 
important pathophysiologic link between unstable angina, acute 
myocardial infarction, and early postinfarction angina. 
The term unstable angina is used for prolonged episodes 
of myocardial ischemia at rest in the absence of detectable 
myocardial necrosis. However, in the acute situation, when a 
patient presents with chest pain and electrocardiographic 
signs of ischemia, the distinction between unstable angina and 
myocardial infarction is often difficult. The uncertainty of 
outcome in a specific patient forces one to provide maximal 
treatment. The prime goal of any intervention in this 
situation must primarily be the preservation or early 
restoration of antegrade flow in the ischemia-related artery, 
in order to resolve myocardial ischemia and to prevent 
(further) myocardial necrosis, and so to improve both short-
and long-term mortality and morbidity. Despite the latest 
substantial improvements in surgical techniques, cardioplegia, 
anaesthesia, and postoperative care, there is still no 
consensus as to the safety of surgery in the management of 
these subsets of patients. As an attractive alternative to 
coronary artery bypass surgery, percutaneous transluminal 
coronary angioplasty would logically play an important role in 
the management of patients with acute myocardial ischemic 
syndromes. 
In cha~ter II of this thesis, the immediate and two-year 
follow-up results of coronary angioplasty in 200 consecutive 
patients with unstable angina are described. Furthermore, 
clinical, electrocardiographic, angiographic and angioplasty 
related variables are analyzed to identify predictors for 
unfavorable early and late outcome. The results indicate that 
coronary angioplasty for unstable angina can be performed 
effectively with a high initial success rate and an excellent 
long-term prognosis. 
However, the procedural complications are definitely more 
frequent in this setting than with elective angioplasty. The 
reasons for the relatively high complication rate are again 
apparently related to the underlying pathophysiology leading 
to the clinical instability such as plaque fissuring with 
platelet aggregation and formation of a partial or even 
intermittent occlusive thrombus. These processes will lead to 
a critical reduction in myocardial blood supply and coronary 
angioplasty, designed to enlarge the stenosed lumen, may 
effectively interrupt this process. On the other hand, 
coronary angioplasty itself may cause further injury of the 
already ulcerated intima and may have the potential to 
intensify the ongoing thrombogenic process in some of the 
patients with acute ischemic syndromes. This may lead to an 
increased frequency of abrupt closure of the artery during the 
procedure. This is a strong argument for adjunctive therapy 
with thrombolytic agents in the acute stage of the disease. 
Therefore, intracoronary streptokinase was adopted to the 
procedure in those patients with abrupt reclosure of the 
artery immediately after dilatation. The results of this 
additional strategy are discussed in chapter III. 
In addition to the fact that coronary angioplasty can be 
performed effectively in patients with unstable angina, 
analysis of the global and regional left ventricular function 
further demonstrates the benefit of correcting these 
obstructive lesions, as shown in chapter IV. 
Limitation of myocardial infarct size through salvage of 
ischemic myocardium in the region undergoing necrosis is the 
major goal in the management of patients with acute myocardial 
infarction. The concept of limiting infarct size by early 
recanalization has been proven in clinical practice to be 
effective and the beneficial effects of thrombolytic agents in 
acute myocardial infarction on infarct size, left ventricular 
function and patient survival have been convincingly shown. 
However, the very efficacy of this initial treatment has 
created a new problem: the management of patients with 
residual stenosis whose ischemic symptoms persist after 
thrombolysis. In order to maintain the initial benefit 
achieved by thrombolysis, it is necessary to deal with the 
underlying obstruction. Coronary angioplasty may play a 
valuable role in attaining these goals. 
The role of coronary angioplasty immediately following 
thrombolysis in acute myocardial infarction is shown in 
chapters V and VI. Chapter V describes our experience with 
coronary angioplasty immediately after intracoronary 
streptokinase in 115 consecutive patients with acute 
myocardial infarction. The aim of the study described in 
chapter VI was to investigate whether immediate angioplasty 
after thrombolysis provided additional benefit in the 
preservation of regional myocardial function in the infarct 
zone by reviewing the results of the Netherlands multicenter 
trial of thrombolytic therapy in which selected patients 
underwent angioplasty. Preservation of global and regional 
left ventricular function with low mortality rate and other 
major cardiac events suggest that immediate coronary 
angioplasty after thrombolysis can be safely used to provide 
complete reperfusion in the setting of acute myocardial 
infarction and, in some patients, reperfusion may need to be 
supplemented by additonal revascularization procedure such as 
angioplasty in order to optimize the chances of obtaining full 
functional recovery. 
However, current available data on the use of coronary 
angioplasty are conflicting and no clear answers as yet have 
emerged about the additional value of angioplasty in acute 
myocardial infarction. The precise role, timing, and rationale 
for coronary angioplasty in acute myocardial infarction is 
still unsettled and requires further evaluation. 
The high incidence of recurrent myocardial infarction and 
unstable angina in patients with non-Q wave myocardial 
infarction call for some prophylactic measure to prevent 
further loss of myocardium, for one might postulate that these 
patients are left with an "incomplete infarction" with an area 
of the myocardium "at risk" and might therefore benefit from 
revascularization of the relevant artery. The short- and 
long-term results of 114 consecutive patients treated with 
coronary angioplasty for severe angina after a non-Q wave 
myocardial infarction are described in chapter VII. The high 
initial success rate and the low incidence of subsequent death 
and late recurrent myocardial infarction, as well as the 
sustained symptomatic benefit suggest that coronary 
angioplasty is an effective initial treatment strategy in 
patients with angina after a non~Q wave myocardial infarction. 
Chapter VIII analyzes the serial global and regional left 
ventricular function in patients undergoing coronary 
angioplasty early after a non-Q wave myocardial infarction. 
The results demonstrate not only that repeated ischemic 
attacks early after a non-Q wave myocardial infarction may 
lead to prolonged regional myocardial dysfunction, but more 
importantly, that this "stunned" myocardium has the potential 
to achieve normal contraction after successful coronary 
angioplasty. 
Coronary angioplasty has now obtained a definitive place 
in the management of acute myocardial ischemic syndromes. The 
results of the present thesis show not only that coronary 
angioplasty can be performed safely and effectively in the 
management of patients with acute myocardial ischemic 
syndromes, but also that myocardial function may recover after 
successful coronary angioplasty. Research should be increased 
to further improve the technique, to accurately define the 
indications for and to study the extent (single-vessel versus 
multivessel dilatation) and the timing of dilatation in this 
group of acutely ill patients. 
----------------------
CHAPTER I 
INTRODUCTION 
Acute myocardial ischemic syndromes encompass the 
clinical entities of unstable angina, acute myocardial 
infarction, and early postinfarction angina. Similarities as 
well as differences compound the various clinical 
presentations. Clinically there may be considerable overlap 
between the groups. Additionally, it is common for a patient 
who presents with one clinical coronary syndrome to evolve 
either suddenly or at a later date to another syndrome. 
Although our understanding of the pathophysiology of 
acute myocardial ischemic syndromes is incomplete, recent 
studies allow a better understanding of precipitating 
mechanisms leading to clinical presentation of our patients 
with acute ischemic syndromes. In the past few years there 
has been increasing clinical, angiographic, and pathologic 
evidence to suggest that the acute changes that initially 
occur in the coronary artery endothelium are similar in these 
patients with acute ischemic syndromes (1-15). It has become 
evident that the endothelial ulceration that occurs adjacent 
to an atherosclerotic plaque, the subsequent platelet adhesion 
and aggregations, and eventually thrombosis are the important 
underlying processes in acute ischemic syndromes. Several re-
cent studies have emphasized this important pathophysiologic 
link between unstable angina, acute myocardial infarction and 
early postinfarction angina. The data which implicate these 
processes comes from a variety of sources, including careful 
histological studies (2,3) postmortem coronary angiography 
(4), antiplatelet studies in unstable angina (5,6) and 
thrombolysis in acute myocardial infarction ( 7, 8) , surgical 
findings following acute coronary occlusion (9), identifi-
cation and recognition of specific morphology both angie-
graphically (9-12) and angioscopically (13), and platelet 
activity studies (14,15). 
The underlying culprit in coronary artery disease is the 
atherosclerotic coronary artery plaque. A stable 
atherosclerotic plaque develops neovascularization at its 
base. These vessels are fragile and may rupture with bleeding 
into plaque. The acute ischemic syndromes are initiated by 
injury to this atherosclerotic plaque. The initial stimulus 
that leads to ulceration of the endothelium overlying an 
atherosclerotic plaque has not yet been identified. Rheologic, 
hemodynamic and vasomotor stresses may initiate and propagate 
plaque damage, leading to further luminal narrowing. Plaque 
injury exposes circulating blood elements such as platelets to 
collagen and atherosclerotic debris within the plaque. 
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Interaction at the damaged vessel wall with circulating 
catecholamines and local release of platelet-derived 
vasoconstrictor and thrombogenic substances such as 
thromboxane A2, leucotrienes, histamine and serotonin, or an 
imbalance of these relative to vasodilating and antithrombotic 
such as prostacyclin, endothelial-dependent relaxant factor 
and plasminogen activator, can lead to intraluminal thrombus, 
stenosis, constriction or coronary spasm (16-19). An immediate 
decrease in coronary flow or distal platelet emboli may lead 
to acute transient ischemia, subsequent malignant ventricular 
arrhythmias and sudden cardiac death. This process may 
stabilize because of endogeneous thrombolysis with or without 
subsequent expansion of the plaque leading to stable angina. 
Whether this new remodeled plaque is more prone to future 
injury is unknown. However, since blood flow is related to the 
fourth power of the coronary diameter, small changes in lumen 
diameter may worsen ischemia. Furthermore, critical lesions 
seem to have a high propensity to progression to total 
occlusion (20-23). These mechanisms may ultimately lead to a 
partially or totally occlusive thrombus or the thrombus may 
fragment either acutely or chronically with peripheral 
embolization. Other factors such as the severity of 
pre-existing stenosis, the extent of collateral circulation, 
the perfusion pressure, the intensity of anti-adhesion, 
deaggregation and vasodilation forces, and endogeneous 
thrombolysis will also influence the changes in coronary blood 
flow. In a complex interplay the balance between these 
competing forces determines whether the mass of the formed 
thrombus is partially or totally occlusive, or whether its 
presence is transient or permanent. Depending on the 
completeness and the duration of blood deprivation (a product 
of both intraluminal event and the available collateral flow), 
different clinical syndromes result, such as sudden death, 
acute transmural infarction, non-transmural infarction, or 
unstable angina (Fig. 1). 
In unstable angina, the process is limited to endothelial 
ulceration, platelet aggregation and thrombus formation, which 
may be intermittent, or more permanent in the presence of an 
adequate collateral supply (2,3,10,13,24). Myocardial 
infarction is related to the same process but with the 
formation of a totally occlusive thrombus. When the balance 
between intracoronary thrombus and antithrombotic natural and 
pharmacologic factors lean toward continued thrombus 
formation, persistent total coronary occlusion leading to 
acute myocardial infarction may occur (1, 10,24-27). If the 
coronary artery remains occluded for a long period (more than 
15 minutes), then myocardial necrosis will occur. If very 
early clot lysis occurs or an adequate collateral supply is 
present infarction will be smaller (non-Q wave myocardial 
infarction) and if not or late clot lysis occurs, infarction 
will be larger (Q wave myocardial infarction) (9, 28) • In a 
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patient with non-Q wave infarction, rethrombosis and 
reocclusion often occur, leading to repeat myocardial 
infarction affecting the same myocardial region (28,29). 
The term unstable angina is used for prolonged episodes 
of myocardial ischemia at rest (chestpain with electrocardio-
graphic changes) in the absence of detectable myocardial 
necrosis. In retrospect, when the symptoms have subsided, 
unstable angina can be distinguished from myocardial infarc-
tion by the lack of elevation of serum cardiac enzymes. 
However, in the acute situation, when a patient presents with 
chest pain and electrocardiographic signs of ischemia, the 
distinction between unstable angina and myocardial infarction 
is often difficult. Treatment of patients in this situation is 
facilitated by the fact that the initial goal of therapy is 
the same: to resolve myocardial ischemia and to prevent 
(further) myocardial necrosis. In practice this means the 
preservation or early restoration of antegrade flow in the 
ischemia-related artery. 
Percutaneous transluminal angioplasty, to widen the lumen 
of a stenotic vessel by means of an intravascular catheter, 
was first performed by Dotter and Judkins in 1964 (30). This 
technique proved effective in peripheral arteries. However, it 
took until 1977 before Gruentzig used this method, to dilate 
the coronary arteries of conscious man (31). In the ten years 
since the beginning of coronary angioplasty, this technique 
has expanded from a curiosity to a major therapeutic 
alternative for patients needing revascularization. Subsequent 
improvements in equipment and technique have established 
coronary angioplasty as a major treatment mode for stable 
angina in patients with single vessel disease. Recently, the 
initial restricted indications have been widened to include 
dilatation of complex lesions, multi vessel lesions and vein 
grafts. As an attractive alternative to coronary artery bypass 
surgery, percutaneous transluminal coronary angioplasty would 
logically play an important role in the management of patients 
with acute myocardial ischemic syndromes. The advantages of 
coronary angioplasty over coronary artery bypass surgery in 
these critically ill patients are that the intrinsic risk of 
major surgery and anesthesia can be avoided, it is easy and 
rapid to implement, and there is a reduction of hospital stay 
and costs. 
The present thesis describes our experience with coronary 
angioplasty in the management of patients with acute ischemic 
syndromes. The efficacy of coronary angioplasty in patients 
with unstable angina pectoris is described in chapters II-IV; 
chapters V and VI deal with the results of coronary 
angioplasty immediately following thrombolysis in patients 
with acute myocardial infarction; and finally, the role of 
coronary angioplasty in the management of patients with angina 
pectoris after a non-Q-wave myocardial infarction is discussed 
in chapters VII and VIII. 
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CHAPTER II 
CORONARY ANGIOPLASTY FOR UNSTABLE ANGINA: IMMEDIATE AND LATE 
RESULTS IN 200 CONSECUTIVE PATIENTS WITH IDENTIFICATION OF 
RISK FACTORS FOR UNFAVORABLE EARLY AND LATE OUTCOME 
ABSTRACT 
Two hunderd patients (164 men ; mean age 56 years, range 36 to 
74) with unstable angina (chest pain at rest, associated with 
ST-T changes) underwent coronary angioplasty. In 65 patients 
with multivessel disease, only the "culprit" lesion was 
dilated. The initial success rate was 89.5% (179 of 200 
patients). At least one major procedure-related complication 
occurred in 21 patients (10.5%): death in 1, myocardial 
infarction in 16, and urgent surgery in 18. All patients were 
followed-up for 2 years. There were 5 late deaths, 8 late 
non-fatal myocardial infarctions and angina pectoris recurred 
in 52 patients. The restenosis rate was 32% (51 of 158) in the 
patients with initial successful angioplasty who had repeat 
angiography. At 2-year follow-up after attempted coronary 
angioplasty in all 200 patients, the total incidence rate of 
death was 3% (1 procedure-related and 5 late deaths), of 
non-fatal myocardial infarction 12% (16 procedure-related and 
8 late after angioplasty), and 13% (26 patients) were still 
symptomatic although they had improved in functional class. 
Multivariate analysis showed that variables indicated an 
increased risk a) for major procedure-related complications 
were: ST-segment elevation, persistent negative T wave and 
stenosis more than 65% (odds ratio 3.7, 3.7 and 3.3, 
respectively); b) for angiographic restenosis were: presence 
of collaterals, ST-segment depression, multi vessel disease, 
left anterior descending coronary artery stenosis, and history 
of recent onset of symptoms (odds ratio: 2.2, 2.0, 1.9, 1.9, 
and 0.54, respectively); and c) for late coronary events 
(recurrence of angina, late myocardial infarction or late 
death) were: multivessel disease, total occluded vessel and 
ST-segment elevation (odds ratio 3. 7, 2.8 and 0.44, 
respectively). Thus, coronary angioplasty for unstable angina 
can be performed with a high initial success rate, but at an 
increased risk of major complications. The prognosis is 
favorable after initial successful coronary angioplasty. 
INTRODUCTION 
The general term 
patients who present 
unstable angina is used to encompass 
with a wide variety of symptoms, 
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electrocardiographic changes, coronary anatomy and left 
ventricular function (1-3). This explains the wide divergence 
in prognosis reported by several studies (2,3). A subgroup of 
patients with unstable angina, who have chest pain at rest 
associated with electrocardiographic changes, have a poor 
short- and long-term prognosis (4-7). These patients must be 
considered as a different subgroup from the patients with new 
onset or progressive angina, who have a prognosis that is only 
slightly worse than that of patients with chronic stable 
angina pectoris (8-10). Management of unstable angina pectoris 
has evolved progressively and recently, coronary angioplasty 
has been shown to be a relatively safe and effective treatment 
for unstable angina (11-20). 
In this study, we describe the innnediate and 2-year 
follow-up results of coronary angioplasty in 200 consecutive 
patients with chest pain at rest associated with 
electrocardiographic changes. Furthermore, clinical, 
electrocardiographic, angiographic and angioplasty related 
variables were analyzed to identify predictors for a) major 
complications during attempted coronary angioplasty, or b) 
restenosis, recurrence of angina, late myocardial infarction 
or late death after initial successful coronary angioplasty. 
PATIENTS AND METHODS 
During the period from January 1983 to January 1985, a 
total of 2887 patients were admitted to our coronary care 
unit. Of these, 442 patients were considered to have unstable 
angina pectoris. Unstable angina was defined as chest pain at 
rest lasting for at least 15 minutes, associated with 
documented electrocardiographic ST-T changes and no subsequent 
signs of cardiac necrosis (cardiac enzyme increase less than 
twice normal and no development of a pathologic Q wave) • 
Patients were treated with a combination of nitrates, 
beta-blockers, Calcium-antagonists and heparin. They all 
underwent coronary angiography. Patients with refractory 
unstable angina underwent either emergency coronary 
angioplasty or bypass surgery. Elective angioplasty or surgery 
was performed in stabilized patients if they had persisting 
exertional angina detected either clinically or with exercise 
testing. 
Patients were selected for surgery if they had 
multivessel disease with one or more critical stenoses 
supplying a large area of viable myocardium in addition to the 
ischemia-related vessel or if they had left main stem disease. 
Selected for coronary angioplasty were patients with single or 
multivessel disease in whom the culprit lesion was technically 
suitable for angioplasty (21). 
The culprit lesion in cases with multivessel disease was 
identified by the localization of electrocardiographic ST-T 
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changes during chest pain. Electrocardiographic changes in 
leads I,AVL, and V 1-v 6 were related to lesions of the left 
anterior descending artery and changes in leads II, III, AVF 
with either the right coronary artery or the left circumflex 
artery. Furthermore, certain angiographic characteristics 
(such as severity and morphology of the lesion, the presence 
of an intracoronary thrombus and degree of antegrade filling) 
served as an aid in the detection of the culprit lesion. 
Table I: Extent of coronary artery disease and the details of 
management of patients with unstable angina 
Unstable angina 
Refractory to pharmacologic 
treatment 
emergency PTCA 
emergency CABG 
Initially stabilized with 
pharmacologic treatment 
elective PTCA 
elective CABG 
pharmacologically 
Total number of patients 
n 
114 
87 
86 
73 
82 
442 
extent of 
coronary artery disease 
ov 1V 2V 3V LM 
0 78 24 12 0 
0 3 16 45 23 
0 57 19 9 1 
0 4 13 49 7 
14 11 24 25 8 
14 153 96 140 39 
PTCA = percutaneous transluminal coronary angioplasty; 
CABG = coronary aorta bypass grafting LM = left main coronary 
artery; 0,1,2,3 V = 0,1,2,3 vessel disease, respectively. 
Twohundred patients (164 men, 36 women) with a mean age 
of 56 (range 36 to 74) years underwent coronary angioplasty 
and comprise the study group. Single vessel disease was 
present in 135 patients and multivessel disease in 65 
patients. The mean global left ventricular ejection fraction 
was 0.59±0.10. The extent of coronary artery disease and the 
actual management of these patients are shown in table I. The 
characteristics of the undilated segments of the 65 patients 
with multivessel disease undergoing dilatation of only the 
culprit lesion are shown in table II. Patients were 
categorized into three groups according to their history: 
a) recent onset unstable angina, defined as chest pain for the 
first time within 1 month prior to coronary angioplasty; 
b) worsening angina, defined as chronic stable angina that had 
progressed to chest pain at rest; and 
c) early postinfarction unstable angina, defined as occurrence 
of a myocardial infarction within one month prior to coronary 
angioplasty. 
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The documented electrocardiographic ST-T changes 
associated with chest pain at rest were classified, in ranking 
order of severity, as follows: 
1) transient ST-segment elevation (at least 0.1 mV) during 
chestpain with return to (nearly) normal or to the ST-segment 
level that existed before the onset of chest pain at rest; 
2) transient ST-segment depression (at least 0.1 mV) during 
chestpain with return to (nearly) normal or to the ST-segment 
level that existed before the onset of chest pain at rest; 
3) development of permanent negative T waves (at least 0.1 mV) 
during or after disappearance of chest pain at rest without 
documented ST-segment elevation or depression; 
4) transient minimal ST-T changes: ST-segment elevation or 
depression (less than 0.1 mV), minimal T wave inversion (less 
than 0.1 mV), pseudonormalization ofT wave, T wave amplitude 
increase or decrease during chestpain. 
Table II: Characteristics of non-dilated coronary stenoses in 
65 patients with multivessel disease and PTCA of the 
culprit lesion only 
UNDILATED LESIONS PER PATIENT 
1 lesion 2 lesion 
Number of undilated lesions 44 42 
Technically suitable for CABG 41 36 
Technically suitable for PTCA 22 18 
Non-dilated LAD 6 2 
Non-dilated RCA/CX 38 40 
Stenosis to infarcted myocardium 15 6 
PTCA = percutaneous transluminal coronary angioplasty; CABG 
Coronary aorta bypass grafting; LAD = left anterior descending 
coronary artery; RCA = right coronary artery; CX = left 
circumflex artery. 
Coronary Angiography 
Coronary angiograms were obtained in multiple views, 
including hemiaxial projections. A consensus of two 
angiographers was used to evaluate the coronary angiograms. 
The degree of coronary obstruction was assessed with the use 
of a caliper system and was given in percentage of luminal 
diameter. The length of the lesion was measured in relation to 
the length of the inserted balloon. A lesion was considered 
long if it was greater than 1 em. Lesions were categorized 
into concentric lesions (symmetric, hourglass coronary 
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narrowings) and eccentric lesions (asymmetric narrowings). 
Collateral circulation was considered present when they were 
angiographically visible. For this study, only the presence of 
collateral circulation to the ischemia related vessel was 
noted. An intracoronary thrombus was defined as 1) contrast 
medium staining at the site of an abrupt occlusion of the 
vessel or 2) the presence of an intracoronary filling defect 
(22). 
Coronary Angioplasty 
Coronary angioplasty was performed with a steerable 
dilatation system. A 7F pacing electrode catheter was 
positioned in the right atrium. At the beginning of the 
procedure, heparin 100 mg and acetylsalicylic acid 250 mg were 
administered intravenously and low molecular weight dextran 
was infused slowly. Electrocardiogram and aortic pressure were 
monitored continuously. To prevent coronary spasm, 
intracoronary nifedipine or isosorbide dinitrate was given 
(23). Initial balloon inflation pressure was 2.0 atmospheres, 
with subsequent inflations ranging to 12 atmospheres. 
Inflation was maintained according to electrocardiographic 
changes, degree of blood pressure drop or induced pain; it 
never lasted longer than 60 seconds. Balloon inflations were 
repeated until there was a significant reduction in the 
transstenotic pressure gradient and a reduction in the 
severity of the obstruction as judged from repeat angiograms 
made immediately after the dilatation. Coronary angioplasty 
was considered to be successful if a reduction in the severity 
of the obstruction to less than 50% luminal diameter narrowing 
was obtained or if the transstenotic gradient index was 
reduced to less than 0.30 (mean proximal pressure minus mean 
distal pressure divided by mean aortic pressure). Furthermore, 
it was required that acute ischemic symptoms were completely 
relieved and that no progression to myocardial infarction or 
death had occurred (24). All procedures were carried out with 
cardiac surgical team on standby. 
Coronary intimal dissection was defined according to the 
National Heart, Lung, and Blood Institute Percutaneous 
Transluminal Coronary Angioplasty Registry (25) by 1) the 
presence of angiographically evident intimal damage producing 
an intraluminal filling defect; 2) extraluminal extravasation 
of contrast material; and 3) linear luminal density or luminal 
staining. 
The diagnosis of a (peri)procedural myocardial infarction 
was determined by the development of a new pathologic Q wave 
(0.03 msec) or typical increase in cardiac enzymes (more than 
twice normal level). 
After the procedure, all patients were monitored for 24 
hours in the coronary care unit where electrocardiograms and 
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enzyme levels were measured. They were discharged after 2-3 
days, and treatment with nifedipine (40-60 mg daily) and 
acetylsalicylic acid (500 mg daily) was maintained for 6 
months. 
Follow-Up 
Clinical follow-up information was obtained either by 
personal interview, by information obtained from the referring 
physician or by questionaire. Patients were evaluated for the 
occurrence of death, myocardial infarction or recurrence of 
angina pectoris. The majority of the patients underwent 
exercise testing with thallium 201 scintigraphy and repeat 
angiography. 
Patients performed symptom-limited exercise on a bicycle 
ergometer with stepwise increments of 10 Watts every minute. 
The three orthogonal leads XYZ of the Frank lead system were 
recorded. An ischemic response was defined as at least a 0.1 
mV ST-segment depression, 0.08 seconds after the J point. The 
maximum workload achieved was expressed as a percentage of the 
normal workload predicted for age, sex and height. Thallium 
201 exertional scintigraphic imaging was performed in the 
anterior and left anterior oblique 45° and 65° views, 
immediately after injection of 1.5 mCi of thallium 201 at peak 
stress. The post-exercise images were obtained four hours 
later. Images were obtained using a Searle Phogamma V camera 
and processed with computer interface as described previously 
(26). Defects with redistribution were considered to represent 
exercise induced ischemia. Persistent defects without redis-
tribution were considered to represent scars. 
Repeat angiograms were obtained in multiple views, 
including hemiaxial views for the left coronary artery. 
Restenosis was defined as an increase of the luminal diameter 
stenosis of the dilated lesion above 50%. 
Data Analysis 
The following four (ontoward) outcome events were 
defined: 1) major procedure-related complications (death, 
myocardial infarction, or urgent bypass surgery); 2) 
procedure-related death or myocardial infarction; 3) late 
coronary event (recurrence of angina pectoris, myocardial 
infarction, or death within one year); and 4) restenosis (at 
least 50% narrowing of the dilated artery at repeat 
angiography. The 'late coronary event' outcome was defined 
only for patients with initial successful angioplasty. The 
outcome event 'restenosis' was defined only for patients with 
initial successful angioplasty who subsequently underwent 
repeat angiography. 
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We used a composite logistic prediction function to 
determine which pre-treatment characteristics were 
independently related to the risk for each of the above 
(ontoward) outcome events. Of the clinical characteristics, we 
considered sex, age, history of angina, presence of previous 
myocardial infarction, and the presence of refractory 
versus stabilized symptoms. The electrocardiographic data 
included the presence of ST-segment displacement of at least 
0.1 mV, T-wave inversion of at least 0.1 mV, and minor 
ST-segment displacement or T-wave inversion. The angiographic 
data included site and severity of the lesion, length and 
eccentricity of the lesion, the presence of multivessel 
disease, the extensiveness of collateral flow, the presence of 
an intracoronary thrombus, and the global ejection fraction. 
Procedural characteristics were also involved in the 
construction of the risk model for 'late coronary event' and 
in that for 'restenosis'; these included duration of 
inflation, maximal inflation pressure, the occurence of a 
dissection, and the postdilation transstenotic pressure 
gradient. 
In univariate analysis, the relation between predictors 
(e.g. sex) and outcome was expressed as a relative risk (or 
risk ratio) that is, as the ratio of the rate of the 
respective outcome event observed in patients belonging to one 
category relative to that observed in the other category. For 
instance, the risk associated with gender is the rate of the 
outcome event in males divided by that in females. Continuous 
variables were dichotomized. The 95% confidence limits of the 
relative risk estimates are also given (27). If the 95% 
confidence interval does not contain the value 1, the 
association of the predictor and outcome is statistically 
significant at the 5% level. 
The objective of multivariate logistics analysis was to 
find the combination of characteristics that predicted 
(unfavorable) outcome as accurately as possible. As a general 
principle, indicator variables were used. These are variables 
that assume the value of 1 if the property considered is 
present and 0 if absent. The BMDP package was used which 
selects stepwise predictor variables based on the maximum 
likelihood ratio (MLR). This provides a measure of 
significance and has an asymptotic chi-square distribution. 
Thus, variables were included into the model if they led to a 
substantial improvement of the log-likelihood (p value less 
than 0.10), or if their removal led to a substantial decrease 
(p value less than 0.15). Forward selection and backward 
elimination of the variables into the model yielded the same 
models. The regression coefficients have a direct 
epidemiologic implication: each coefficient represents the log 
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odds of unfavorable outcome controlling for the other 
variables in the model. Its antilogarithm is the relative risk 
for the property considered. As an example, if the regrepsibn 
coefficient for ST-elevation is 1, its antilogarithm (e ) is 
2. 7. This means that the risk of unfavorable outcome within 
one year for patients with ST-elevation is 2.7 times as high 
as that for patients who had no ST-elevation. In fact, the 
coefficients concern relative odds, which are a good 
approximation for the relative risk, since the frequency of 
unfavorable outcome is relatively low. 
Table IV: Univariate analysis of variables to predict 
immediate and late unfavorable outcome 
Procedure-related complications 
(death, MI, acute surgery) 
stenosis more than 65% 
Coronary events at 1-year 
(death, MI, recurrent angina) 
worsening angina 
previous MI 
ST-elevation 
ST-depression 
stenosis more than 65% 
total occlusion 
MV-disease 
collaterals 
Angiographic restenosis 
ST-depression 
total occlusion 
MV-disease 
collaterals 
dissection 
n 
llO 
73 
67 
53 
30 
93 
16 
58 
30 
28 
14 
51 
29 
40 
Risk Ratio 
2.6 
1.4 
1.5 
0.6 
1.4 
1.4 
1.9 
2.3 
1.5 
1.5 
1.7 
1.6 
1.6 
1.4 
95% CI 
1.0- 6.7 
0.9 2.2 
1.0 - 2.4 
0.3 - 1.0 
0.8 - 2.2 
0.9- 2.3 
1.0 - 3.0 
1.5- 3.7 
0.9 - 2.5 
0.9- 2.3 
0.9 - 2.7 
1.0- 2.5 
1.0- 2.4 
0.9- 2.1 
Only the significant variables are tabulated. CI confidence 
interval; MI = myocardial infarction; MV = multivessel. 
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RESULTS 
Initial Success Rate and Major Procedure-Related Complications 
The overall initial success rate was 89.5% ( 179 of 200 
patients). A major complication (death, myocardial infarction 
or urgent surgery) occurred in 10.5% (21 of 200 patients). The 
initial success rate and major complication rate for the 
relevant clinical subsets are tabulated in table III. The 
results of univariate analysis are presented in table IV. The 
majority of the analyzed variables were insignificant. The 
significant risk factors using multivariate analysis of 
variables predictive for an increased risk of a major 
complication and procedure-related myocardial infarction are 
shown in table V. 
Table V: Risk factors to predict procedure-related major 
complications, restenosis and coronary events at 1 
year 
Risk factor 
ST-elevation 
persistent neg. T-wave 
stenosis more than 65% 
constant 
ST-elevation 
persistent neg. T-wave 
constant 
collaterals 
ST-depression 
multivessel disease 
LAD-stenosis 
Coefficient S.E. O.R. 95% CI 
procedure-related major complication 
(death, MI, and urgent surgery) 
1.3 0.63 3.7 1.1 -12.6 
1.3 0.63 3.7 1.0 -13.1 
1.2 0.54 3.3 0.93- 6.9 
-3.7 0.67 
procedure-related myocardial 
1.2 0.71 3.3 
1.2 0.73 3.3 
-3.3 0.59 
angiographic 
0. 77 
0.68 
0.66 
0.64 
infarction 
0.84-13.4 
0.84-13.4 
worsening AP or post-MI AP 
constant 
0.62 
-2.0 
restenosis 
0.44 
0.45 
0.37 
0.41 
0.38 
0.49 
2.2 
2.0 
1.9 
1.9 
1.6 
0.92-5.1 
0.82-4.8 
0.94-4.0 
0.86-4.2 
1.3-5.7 
coronary events at 1 year (recurrent AP, 
MI and late death) 
multivessel disease 1.3 0.36 3.7 1.8 -7.5 
total occlusion 1.0 0.56 2.8 0.94-8.4 
ST-elevation -0.82 0.42 0.44 0. 2 -1.0 
constant -1.3 0.26 
For abbrevations see tables I-IV. 
Table VI: Clinical follow-up after attempted coronary 
angioplasty in 200 patients with unstable angina 
Follow-up 6 months 6-12 months 12-24 months 
successful PTCA (n-179) 
late death 2 0 2 
new myocardial infarction 3 2 2 
recurrent Angina 37 (20) 10 (3) 3 (1) 
Repeat PTCA 18 (ll) (3*) 3 2 (1) 0*) 
Bypass surgery 
Pharmacologic therapy 
late death 
new myocardial infarction 
recurrent Angina Pectoris 
8 
ll 
0 
0 
2 
(5) 3 (1) 
(4) 7 (2) 
unsuccessful PTCA 
1 
1 
0 
1 
0 
(n=21) 
0 
0 
0 
( ) patients with multivessel disease; * new stenosis at 
non-dilated site; PTCA = percutaneous transluminal coronary 
angioplasty. 
Table VII: Cumulative incidence of major coronary events 
(death, myocardial infarction), bypass surgery, 
repeat PTCA, and functional class at initial 
attempt and at 6, 12 and 24 months 
(1*) 
inital 6 months 12 months 24 months 
attempt 
N 200 199 197 196 
death 1 3 4 6 
MI 16 19 22 24 
CABG 18 26 29 30 
Repeat PTCA 18 21 23 
Functional class* 
I 0 178 170 168 
II 0 17 22 22 
III 86 2 4 4 
IV ll4 0 0 0 
* New York Heart Association; MI Myocardial infarction; 
CABG = Coronary aorta bypass grafting; PTCA = Percutaneous 
transluminial coronary angioplasty. 
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EXERCISE THALLIUM 201 SCINTIGRAPHY AFTER 
SUCCESSFUL PTCA IN PATIENTS WITH UNSTABLE ANGINA 
% 
100 
80 
60 
40 
20 
0 
85% 
69% 
workload achieved 
~ 80% ;a. 90% 
I 
29% 
18% 
13% ~ I I 
AP TL201 
+ + 
Fig. 1. Workload achieved > 80% or > 90% predicted for age, sex and height. 
AP+ : exercise induced angina pectoris; 
sr ~ : exercise induced ischemic Sf-segment depression; 
TL 201 + : reversible perfusion defect. 
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Clinical Follow-Up and Angiographic Stenosis 
The data from clinical follow-up after successful and 
unsuccessful coronary angioplasty are shown in table VI. The 
majority ·of coronary events occurred within 6 months after the 
procedure. The total need for bypass surgery (acute and 
elective) at 1 year was 14% and at 2 years 15% (table VII). 
The total incidence of myocardial infarction (either 
procedure-related or late, or both) at 1 year was 11% and at 2 
years 12%. The total incidence of death at 1 year was 2% and 
at 2 years 3%. At 1-year follow-up, 85% of all the patients 
were in New York Heart Association functional class I, 11% in 
class II and 2% in class III (table VII). 
Exercise testing and thallium 201 scintigraphy following 
successful angioplasty were performed in 157 and 146 patients 
respectively, 1. 7±3. 8 months after the procedure. Twenty-two 
patients did not perform an exercise test because of physical 
handicap in 5, death in 2, refusal in 1 and in 14 patients the 
cause was unknown. The majority of the patients achieved a 
workload of more than 80% of the predicted value and 
experienced no angina during the test. A reversible thallium 
perfusion defect could be induced in 29% of the patients (fig. 
1). 
A repeat angiogram was performed in 158 patients, 5.1±4.8 
months after successful angioplasty. Twenty-one patients were 
not recatheterized because of death in 2, late myocardial 
infarction in 1, relative contraindication in 3 and refusal in 
15 patients. Of the latter group, 4 patients had recurrent 
angina. Angiographic restenosis was present in 32% (51 of 158 
patients). Nine patients (18%) with restenosis did not 
experience angina. The results of univariate analysis are 
presented in table IV. The majority of the analyzed variables 
were insignificant. 
The significant risk factors using multivariate analysis 
of variables predictive for late coronary events or 
angiographic restenosis after a successful procedure are shown 
in table V. Multi vessel disease was shown to be a rather 
strong predictor for late coronary events. This was mainly due 
to the persistence of undilated lesions. 
Dilatation of Only the Culprit Lesion in Multivessel Disease 
The initial success rate and major complication rate were 
comparable in patients with single vessel disease and 
dilatation of that particular lesion (89% and 11%, 
respectively) and in patients with multivessel disease and 
dilatation of the culprit lesion only (91% and 9%, 
respectively). The angiographic restenosis rate was comparable 
in patients with culprit lesion dilatation and multivessel 
disease to that in patients with single vessel disease 
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COMPARISON OF EXERCISE THALLIUM 201 SCINTIGRAPHY AFTER 
DILATATION OF CULPRIT LESION IN PATIENT WITH MUL TIVESSEL 
DISEASE AND PATIENTS WITH SINGLE VESSEL DISEASE 
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Fig. 2. For abbreviations see figure 1. 
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P=0.001 P=0.02 
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(18/51:35% versus 33/107:31%). 
Persistent or recurrent angina was significantly more 
frequent in patients with incomplete revascularization than in 
those with complete revascularization at 6 months and 1 year, 
17/135 (13%) versus 20/65 (31%) at 6 months and 24/135 (18%) 
versus 23/65 (35%) at 1 year, as shown in tables III and VI. 
In patients with dilatation of the culprit lesion and 
multivessel disease, the maximal work capacity achieved during 
stress testing was less, while the occurrence of exercise 
induced ischemic ST-segment depression and reversible 
perfusion defect was more frequent than in patients with 
single vessel disease and dilatation of that particular lesion 
(fig. 2). 
DISCUSSION 
Immediate and Late Results of Coronary Angioplasty for 
Unstable Angina 
Patients described as having unstable angina as 
originally advocated by Conti and associates (1) can be 
divided into three subgroups: a) recent onset angina; b) 
progressive effort angina with a deteriorating clinical 
pattern superimposed on chronic stable angina; and c) episodes 
of prolonged ischemic pain at rest. Patients belonging to 
subgroups a and b have a reasonably good prognosis with most 
patients having a satisfactorily initial response to medical 
therapy (8-10). These patients can usually be evaluated for 
myocardial revascularization on an elective basis. In this 
study, we reserved the term unstable angina for patients 
belonging to subgroup c; that is, patients with prolonged 
episodes of chest pain at rest. The prognosis for this 
subgroup is worse, especially if ischemic symptoms persist 
(4-7). We believe that immediate control of ischemia with 
stepwise intensification of pharmacologic treatment is the 
cornerstone in managing these patients. If despite this 
tailored pharmacologic approach patients continue to have 
attacks of ischemia, prolongation of what must be regarded as 
ineffective treatment should be avoided and an attempt at 
myocardial revascularization, either acute bypass surgery, or 
acute angioplasty, should be institituted without delay, in an 
attempt to prevent progression to myocardial infarction and so 
to improve prognosis. 
In our study, the initial success rate of coronary 
angioplasty was 90%, and the major complication rate was 10%. 
This is comparable to the recently reported initial success 
rates of 70% to 93%, and major complication rates of 3% to 12% 
(14-20). The procedure-related death rate was low (0.5%) and 
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compared favorably with reported death rates of 0% up to even 
5.4% (14-20). The procedure-related myocardial infarction rate 
was 8% and the need for acute surgery was 9%, which are within 
the range of 4% to 12% and 1.5% to 12%, respectively, reported 
by others (14-21). Our results and those reported by others 
(14-21) reveal a high level of major complications of coronary 
angioplasty in patients with unstable angina. This major 
complication rate is definitely higher than the rate of 3% to 
4% reported for coronary angioplasty in patients with stable 
angina (28,29). The reasons for this high major complication 
rate may be related to the clinical instability of these 
patients, and more specifically the higher frequency of 
complicated lesions (severe, eccentric lesions) due to a 
different underlying pathology and an increased risk of abrupt 
closure due to the formation of an acute occlusive thrombus 
(30). A thrombus may form more readily since unstable angina 
is related to plaque fissuring with denudation of the intima, 
adhesion and aggregation of platelets and partial (non)-
occlusive thrombus formation (31-34). In such a milieu, 
intracoronary instrumentation or balloon trauma may easily 
lead to a total occlusive thrombus. 
After initial successful angioplasty the prognosis is 
excellent with a low number of deaths (1% at 1 year and 2% at 
2 years) and a low occurence of late myocardial infarction (3% 
at 1-year and 4% at 2-year follow-up). This is in keeping with 
other reports (14-20). 
The results of electrocardiographic exercise testing and 
thallium 201 scintigraphy, performed approximately 2 months 
after an initial successful angioplasty, indicated good 
functional recovery and absence of evidence of ischemia in 
the majority of the patients. 
Angiographic restenosis occurred in 32% of the patients 
within 6 months of the procedure. The angiogram was repeated 
in 88% of all patients with successful coronary angioplasty, 
so that this study fairly accurately reflects the actual 
restenosis rate and is only minimally biased by the refusal of 
asymptomatic patients to undergo a second angiogram. This rate 
does not appear to be higher than the restenosis rate of 25% 
to 30% for stable angina (35,36), although it has been 
suggested that the restenosis rate in unstable angina is 
somewhat higher (12, 35, 36). At 1-year follow-up the recurrence 
rate of angina after an initial successful angioplasty was 
26%; the majority occurring within 6 months after the 
procedure. 
Thus, at 1-year follow-up of all the 200 patients who had 
an attempted coronary angioplasty, 4 patients (2%) died (1 
procedure-related and 3 late deaths), 22 patients (11%) 
sustained a nonfatal myocardial infarction (16 
procedure-related and 6 late), 26 patients (13%) were, 
although they had experienced some improvement, still 
symptomatic (New York Heart Association class II and III), and 
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170 patients (85%) were symptom-free. However, to achieve this 
result, bypass surgery was necessary in 29 (15%) patients (18 
acute surgery and 11 late, elective surgery) and 21 (11%) 
patients underwent repeat coronary angioplasty. 
Predictors of Early and Late Unfavorable Outcome 
In an attempt to improve patient selection for coronary 
angioplasty and to identify high risk patients, univariate and 
multivariate analysis was performed on potential clinical and 
angiographic predictors of a major complication. It has been 
suggested that unstable angina per se is a risk factor for 
early (37) and late unfavorable outcome (12,35,36). In 
patients undergoing elective angioplasty, major complications 
were shown to be associated with patient-related variables: 
female gender (38-41), patients older than 60 years (40), 
multivessel disease (38), angina more than 6 months (40), 
prior coronary bypass surgery (40); and with lesion-related 
variables: eccentricity (38-40, 42), calcified lesion (38-40), 
lesion length (38-40,42), "complicated" lesion (43), 
intracoronary thrombus (44), and vein graft lesion (40). In 
our study, which differs from the above cited studies in that 
only patients with unstable angina were analyzed, we found 
that the changes of the electrocardiogram during an ischemic 
attack (ST-segment elevation or persistent negative T waves) 
and the severity of the stenosis were associated with an 
increased risk of a major procedure-related complication. 
Transient ST-segment elevation is thought to reflect 
transmural ischemia and is associated with more severe 
ischemia than ST-segment depression which represents 
subendocardial ischemia (45). The development of new T wave 
inversion, which persists, may be related to minimal cell 
necrosis not detected by current enzyme measurement techniques 
and represents severe coronary artery stenosis (46). These 
patients are known to have a poor overall prognosis (46,47). 
We could not establish a relation between the presence of 
intracoronary thrombus detected angiographically and an 
increased risk of major complications as have others (44). 
However, this is not surprising since angiography is a very 
insensitive method for detecting intracoronary thrombus. 
Careful postmortem sectioning (30-32) and angioscopic 
examination (34) of the coronary arteries have shown that 
plaque rupture and thrombus formation almost invariably occur 
in patients with unstable angina and have established the role 
of thrombus in the pathogenesis of this condition. 
Angiographic restenosis after coronary angioplasty 
(12,35,36) has been shown to be associated with patient-
related variables: male (35), diabetes (48-50), duration of 
angina less than 2 months (35,36,49,50), variant angina (51), 
multivessel disease (52), smoking (49,50) , hypercholestero-
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lemia (49,50); lesion-related variables: total or greater than 
90% occlusion (35,36,50,52,53), left anterior descending 
coronary lesion (36,52), vein graft stenosis (35,54,55); and 
procedure-related variables: no dissection (36), greater than 
30% residual stenosis (36) , greater than 15 mmHg residual 
pressure gradient (35,36). 
In our study, we found a higher angiographic restenosis 
in patients with angiographically visible collaterals to the 
dilated vessel, multivessel disease, left anterior descending 
coronary stenosis, and with transient ST-segment depression 
during an ischemic attack. Coronary events at 1 year including 
recurrent angina pectoris, late myocardial infarction or late 
death were associated with multivessel disease and total 
occlusion. Multivessel disease was a risk factor due to the 
persistence of undilated coronary artery lesions. 
Dilatation of Only the Culprit Lesion in Multivessel Disease 
The foremost consideration in the acute treatment of 
unstable angina must be the preservation of myocardial 
function. Coronary angioplasty of only the "culprit lesion" in 
patients with refractory unstable angina and multivessel 
disease has been shown to be an effective therapeutic 
alternative to coronary bypass surgery (21,56). Improvement in 
myocardial function has been demonstrated using this strategy 
(57). This approach was used because multiple dilatations in 
these unstable patients may increase the risk of major 
complications and there is a risk of performing unnecessary 
dilatations because of the difficulty in assessing the 
significance of any additional stenosis in the acute setting. 
The initial success rate and major complication rate of 
coronary angioplasty in patients with single vessel disease 
and dilatation of that particular vessel were comparable to 
those with multivessel disease and dilatation of only the 
culprit lesion. The angiographic restenosis rate was higher, 
although not statistically significant, in patients with 
multivessel disease compared to those with single vessel 
disease. However, recurrent or persistent angina pectoris at 6 
months follow-up was significantly higher in patients with 
multivessel disease (31%) than in patients with single vessel 
disease (13%). Incomplete dilatation was also associated with 
increased occurrence of stress-induced angina pectoris, 
significant ST-segment depression, reversible perfusion 
defect, and reduced exercise tolerance. 
We believe that angioplasty of the culprit lesion in 
patients with unstable angina and multivessel disease should 
be regarded as an initial treatment strategy in those whose 
symptoms do not respond adequately to pharmacologic treatment. 
In most patients, this approach will have a longterm success, 
but in some further dilatations or even bypass surgery will be 
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required, so that this strategy does not provide a definitive 
longterm treatment in all patients. However, the subsequent 
interventions can be performed on a more elective basis with 
less risk. This strategy warrants further evaluation in a 
randomized controlled study. 
CONCLUSION 
The initial success rate of coronary angioplasty in 
patients with unstable angina is 90%. The hazards of 
dilatation in patients with unstable angina are high and 
clearly exceed the hazards of dilatation in those with stable 
angina. The total major complication rate in patients with 
unstable angina is about twice of that in patients with stable 
angina. No strong single or set of predictors of unfavorable 
outcome has been identified, but the procedure appears to be 
more hazardous in patients who have chest pain at rest 
associated with transient ST-segment elevation or who develop 
persistent negative T waves. 
After an initially successful procedure, the prognosis is 
excellent with a low late death rate and a low late myocardial 
infarction rate. The angiographic restenosis rate or angina at 
6 months is approximately 30% and therefore appears comparable 
with that obtained in patients with stable angina. However, 
these results apply to selected patients with predominantly 
single vessel disease and well preserved left ventricular 
function. 
At present, it seems reasonable to consider such patients 
for coronary angioplasty, although the risks of the procedure 
in this acute setting are relatively high. However, the 
alternative, coronary bypass surgery in these patients, is 
also associated with a rather high complication rate (58-62) •. 
Currently, randomized trials comparing the results of coronary 
angioplasty and surgery in patients with unstable angina are 
lacking. There is a compelling need for randomized trials to 
compare the results of both strategies and to provide de-
finitive answers on the relative merits of both treatment 
strategies. 
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CHAPTER III 
CORONARY ANGIOPLASTY IN PATIENTS WITH UNSTABLE ANGINA 
PECTORIS: IS THERE A NEED FOR THROMBOLYSIS? 
ABSTRACT 
Management of unstable angina has evolved progressively and 
recently, coronary angioplasty has been shown to be an 
effective treatment strategy for unstable angina. However, the 
procedure-related major complication rate is higher when 
compared to angioplasty in stable angina. The underlying 
pathophysiology may explain this higher complication rate. 
Rupture of an atherosclerotic plaque associated with thrombus 
formation is frequent in the pathogenesis of unstable angina. 
These processes lead to a critical reduction in myocardial 
blood supply, and coronary angioplasty may effectively 
interrupt this process. On the other hand, coronary 
angioplasty itself may cause further injury of the already 
ulcerated intima and may have the potential to intensify the 
ongoing thrombogenic process and may lead to an increased 
frequency of abrupt closure of the artery during the 
procedure. Therefore, intracoronary streptokinase was adopted 
to the procedure in those patients with abrupt closure of the 
artery immediately after dilatation in order to attempt to 
improve the immediate result. Coronary angioplasty was 
attempted in 200 consecutive patients with unstable angina. 
Initial success in crossing the obstructed artery was achieved 
in 196 patients. Of these, however ,an abrupt closure 
immediately after dilatation occurred in 21 patients, of whom 
12 were treated additionally with intracoronary streptokinase 
and success was achieved in 9 patients without evidence of 
necrosis or emergency bypass surgery. Of · the remaining 9 
patients, 4 were successfully re-dilated with a larger size 
balloon, 4 underwent urgent surgery (1 death post-operatively) 
and 1 was treated conventionally. Final success was achieved 
in 188 patients (94%) without evidence of myocardial necrosis, 
emergency surgery, or death. These beneficial results suggest 
that in some cases coronary angioplasty may need to be 
supplemented by additional intracoronary thrombolysis in order 
to improve immediate outcome by avoiding urgent surgery and 
procedure-related myocardial infarction. 
INTRODUCTION 
The clinical syndrome of unstable angina causes great 
concern to clinicians because of the perceived high risk of 
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progression to myocardial infarction or cardiac death (1, 2) • 
Only limited information is available on the merits of 
pharmacological treatment, bypass surgery, or coronary 
angioplasty from controlled randomized trials in these 
patients. Management of unstable angina has evolved despite 
this lack of trial data, and recently, coronary angioplasty 
had been shown to be relatively safe with significant 
symptomatic relief. However, the major complication rate 
(myocardial infarction, emergency bypass surgery, and 
inhospital mortality) is rather high when compared to patients 
with stable angina (3-5). In an early series of 200 patients 
with unstable angina (3), we reported that coronary 
angioplasty can be performed with a high initial success rate 
(89.5%), but at an increased risk of major procedure-related 
complications ( 10. 5%) • The reasons for this relatively high 
complication rate are apparently related to the underlying 
pathophysiology leading to the clinical instability and an 
increased risk of abrupt closure after attempted angioplasty 
due to the formation of an acute occlusive thrombus (6,7). The 
present study was therefore undertaken to investigate whether 
additional thrombolytic therapy in case of abrupt vessel 
cl0sure could improve the immediate results of coronary 
angioplasty in patients with unstable angina pectoris. 
PATIENTS AND METHODS 
Between January 1986 and December 1987, coronary 
angioplasty was attempted in 200 consecutive patients with 
unstable angina pectoris. They represented 20% of our total 
coronary angioplasty population during the study period. All 
were treated intensively with beta-blockers, calcium 
antagonists, intravenous nitroglycerin and heparin. Patients 
were selected for angioplasty if the ischemia-related lesion 
was suitable for dilatation. The stenotic artery was 
considered to be ischemia-related in patients with single 
vessel disease, while in patients with multi-vessel disease 
the ischemia-related artery was determined by correlation with 
documented resting ST segment changes, as described previously 
(3). 
Unstable angina pectoris was defined as symptoms of 
angina at rest lasting for at least 15 minutes associated with 
ST-T changes without evidence of further myocardial necrosis, 
as defined by either cardiac enzyme elevation (creatinine 
kinase twice of the normal value) or development of new 
pathologic Q waves. Intracoronary thrombus was defined as a 
definite contrast filling defect or contrast staining during 
angiography in at least 2 orthogonal views by at least 2 
angiographers. In addition, patients with ischemia-related 
occluded vessel were considered to have thrombus. 
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Coronary angioplasty was performed with preformed guiding 
catheters, steer able dilating balloon catheters, and a 
pneumatic inflation device. A 7 French pacing electrode 
catheter was positioned in the right atrium. Before the 
procedure, heparin 10.000 U and acetylsalicylic acid 250 mg 
were administered intravenously. Two electrocardiographic 
leads and aortic pressure were monitored continuously. Initial 
balloon inflation pressure was 2 atmospheres with subsequent 
inflations ranging to 12 atmospheres. All procedures were 
carried out with cardiac surgical team on standby. The current 
study differs from the previous one (3) in the management of 
acute complication during angioplasty. In case of abrupt 
vessel closure after angioplasty, emergency recanalization was 
attempted by repeat dilatation using the same or a larger size 
balloon. If this approach failed, acute surgery was performed 
in those patients with major coronary dissection, while 
intracoronary streptokinase was given to those patients in 
whom abrupt occlusion was presumably due to acute thrombosis. 
After the procedure, all patients were followed for 24 hours 
in the coronary care unit, where electrocardiograms and 
cardiac enzyme levels were monitored. A peri-interventional 
myocardial infarction was diagnosed if either new pathologic Q 
waves developed or an abnormal cardiac enzyme elevation was 
documented. 
Angioplasty was considered successful when a reduction of 
the severity of the obstruction to less than 50% luminal 
diameter narrowing was achieved with abolition of acute 
ischemic symptoms and without progression to myocardial 
infarction, emergency surgery or death. Only the ischemia-
related vessel was dilated in the majority of the patients 
with multivessel disease (60 out of 80 patients). The clinical 
and angiographic characteristics are shown in table I. 
Table I: Clinical and angiographic characteristics 
n 200 
Age (median, yr) 59 (range 29-83) 
YJ.ale 148 (74%) 
Time from angiography to PTCA (median, days) 2 (range 0-75) 
Postinfarction unstable angina 94 (47%) 
Previous CABG/PTCA 39 (20%) 
Single vessel disease 120 (60%) 
Double vessel disease 56 (28%) 
Triple vessel disease 24 (12%) 
Single vessel dilatation 180 (90%) 
Multi vessel dilatation 20 (10%) 
Angiographic evidence of thrombus 43 (22%) 
Total/functional occlusion 29 (15%) 
CABG = coronary artery bypass surgery; PTCA percutaneous 
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RESULTS 
In the 200 patients who underwent coronary angioplasty 
for unstable angina pectoris, 221 lesions were dilated (115 in 
left anterior descending, 49 in left circumflex, 48 in right 
coronary artery and 9 in bypass graft). Single-vessel 
dilatation was performed in 180 patients, including 25 
multilesion dilatations in the same artery. Double artery 
dilatation was performed in 19 patients and triple artery 
dilatation in I. 
Technical failure to cross the lesion occurred in 4 
patients in whom the artery was found to be occluded at the 
time of attempted angioplasty; 3 of these underwent elective 
coronary bypass surgery and 1 was treated conservatively. 
While the obstructed artery could be crossed and dilated in 
196 patients. Of these, however, an abrupt closure immediately 
after attempted dilatation occurred in 21 patients (11%). This 
was presumably due to occlusive thrombus in 12 patients who 
were therefore treated with 250,000 units of intracoronary 
streptokinase, and success was achieved in 9 of these patients 
without evidence of further necrosis or emergency surgery. 
Major coronary dissection was observed in 4 patients who 
underwent emergency bypass surgery. Of the remaining 5 
patients, in whom the mechanism of abrupt occlusion was 
uncertain, 4 were successfully re-dilated using a larger size 
balloon and 1 was treated conservatively (table II). From 
these 21 patients with abrupt closure after attempted 
angioplasty, 12 had angiographic evidence of intracoronary 
thrombus prior to angioplasty. 
Peri-interventional myocardial infarction, defined by 
either cardiac enzyme elevation or new Q waves, was documented 
in 6 patients, of whom 4 underwent emergency bypass surgery 
with 1 death postoperatively (table II). 
Table II: Management and outcome of patients with acute 
reclosure during the procedure 
Re-dilatation* 
Intracoronary (IC) streptokinase 
IC streptokinase + acute surgery 
Acute surgery 
Conservative 
Total 
n 
4 
10 
2 
4 
1 
21 
* prolonged inflations with a larger size balloon. 
** 1 patient died post-operatively. 
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myocardial 
infarction 
0 
1 
1 
3** 
1 
6 
Thus, from these 200 patients who underwent coronary 
angioplasty for unstable angina, final success in dilating the 
obstructed artery was achieved in 188 patients (209 lesions) 
without evidence of myocardial necrosis, emergency surgery, or 
death. 
These results show high initial success rate of coronary 
angioplasty in patients with unstable angina pectoris with 
lower major complication rate when compared with the results 
of our previous study (3) in which thrombolytic therapy was 
not applied in case of acute closure during the procedure 
(table III). 
Table III: Clinical data and major complications compared to 
previous reported results (3) 
Previous data 
n 
Males (%) 
Age (yr) 
Previous infarction (%) 
Multivessel disease (%) 
Multivessel dilatations (%) 
Total occlusion (%) 
Intracoronary thrombus (%) 
Abrupt vessel closure (%) 
Initial success rate (%) 
Major complications* (%): 
Death (%) 
Myocardial infarction (%) 
Emergency surgery (%) 
200 
82 
56 
37 
33 
0 
13 
15 
11.5 
89.5 
10.5 
0.5 
8 
9 
Present data 
200 
74 
59 
47 
40 
10 
15' 
22 
10.5 
94 
4 
0.5 
3 
3 
* Either death, myocardial infarction, or emergency surgery. 
Thrombolytic therapy had not been used in our previous 
reported study (3). 
DISCUSSION 
Coronary angioplasty, as an alternative to bypass 
surgery, has recently been shown to be effective in the 
treatment of unstable angina pectoris (3, 8-23) with initial 
success rate up to 91% and low procedure related death (up to 
2%). However, these results are obtained in selected patients 
with predominantly single vessel disease and well preserved 
left ventricular function, and the results should be 
interpreted with this in mind. Nevertheless, the rate of major 
complication (procedure related myocardial infarction and 
emergency. surgery) is rather high and varies between 8% to 13% 
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(3,8-23); although Meyer et al (13) reported a lower 
complication rate. This complication rate of angioplasty in 
patients with unstable angina pectoris is definitely higher 
than the complication rate (3% to 4%) reported for angioplasty 
in those with stable angina pectoris (4,5). 
Table IV: Results of fibrinolytic or anticoagulant treatment 
in patients with unstable angina 
Angiographic 
evidence 
Study n Treatment of lysis (%) 
Vetrovec et al.(37) 13 IC SK 77 
Mandelkorn et al.(28) 9 IC SK 44 
Shapiro et al.(38) 18 IC SK 67 
Clinical outcome 
Lawrence et al.(39) 20 IV SK (24 hr) 5% Sudden death 
+ coumadin (6 months) 
20 coumadin 40% Sudden death/MI 
(6 months) 
Telford & Wilson(40) 100 heparin + 3% MI (7 days) 
atenolol 
114 placebo or 15% MI (7 days) 
atenolol 
Gold et al. (41) 24 IV tPA or 40% reduction in 
placebo recurrent ischemia 
(7 days) 
Topol et al.(42) 40 IV tPA or Improved pacing 
threshold to 
placebo ischemia (7 days) 
IC = intracoronary; IV = intravenous; SK = streptokinase; 
tPA = tissue plasminogen activator; MI = myocardial infarction. 
The reasons for this high complication rate are 
apparently related to the underlying pathophysiology. Almost 
all patients with unstable angina pectoris have a high grade 
fixed coronary stenosis (24, 25) and on top of this fixed 
stenosis other dynamic conditions may also play a role, such 
as plaque fissuring with platelet aggregation, increased 
vasomotor tone, and formation of a partial or even 
intermittent occlusive thrombus (26-30). Evidence derived from 
postmortem pathologic studies (29,30), from postmortem 
coronary arteriography (31) , from serial coronary 
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arteriography (25,32,33), from lysis of intracoronary thrombi 
(34), from surgery during acute coronary syndromes (35), and 
from intraoperative angioscopy (36) has confirmed the 
importance of coronary thrombosis. Further clinical evidence 
to support the role of intracoronary thrombus comes from the 
observation that thrombolytic therapy in patients with 
unstable angina did lyse the thrombus in a considerable number 
of patients (table IV) (28, 37-42). In addition, ·the role of 
platelets in intracoronary thrombus is also shown by the 
reduction of the incidence of mortality and nonfatal 
myocardial infarction after administration of aspirin in 
patients with unstable angina (43,44). 
The formation of an intracoronary thrombus is an active, 
dynamic process. Identification of such a thrombus with 
angiography depends on the timing of the angiogram after the 
acute event, the size of the intracoronary thrombus at the 
time of the angiogram, the severity of illness in the 
populations studied, and the angiographic criteria used for 
identification (28,45-48). The angiographic presence of an 
intracoronary thrombus is reported to be between 1% and 52% 
(table V). Angiographic criteria probably underestimate the 
frequency of thrombosis in patients with unstable angina 
pectoris since a mural (nonocclusive) thrombus superimposed on 
an atherosclerotic plaque cannot always be identified with 
currently available techniques. In a pilot study using 
intraoperative angioscopy, intracoronary thrombi that were 
undetectable on review of coronary angiograms were detected in 
7 of the 10 patients with unstable angina (36). 
Table V: Angiographic evidence of intracoronary (IC) thrombus 
Study n 
Holmes et al.(45) 1202 
Vetrovec et al.(46) 129 
Mandelkorn et al.(28) 9 
Capone et al.(47) 119 
Capone et al.(47) 44 
Zack et al. (48) 83 
IC thrombus 
n % 
16 1 
8 6 
4 44 
44 37 
23 52 
10 12 
Time between 
acute event and 
angiography 
less than 3 months 
less than 1 month 
less than 2 months 
less than 14 days 
less than 24 hours 
less than 3 months 
(ZA) 
(2A) 
(3) 
(ZA) 
(2A) 
(1, ZA, 2B) 
( ) = definition of intracoronary (IC) thrombus: 1) occlusive 
thrombus; 2) nonocclusive thrombus, A) intraluminal defect, 
B) intraluminal staining; 3) reduction in severity of stenosis 
after streptokinase infusion. 
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Several studies have emphasized the important 
pathophysiologic link between unstable angina and non-Q wave 
myocardial infarction (29,30,49-52). In unstable angina, the 
pathophysiologic process is limited to endothelial ulceration, 
platelet aggregation and thrombus formation, which may be 
intermittent, or more permanent in the presence of an adequate 
collateral supply. Myocardial infarction is related to the 
same process but with the formation of a totally occlusive 
thrombus. When the balance between intracoronary thrombus and 
antithrombotic natural and pharmacologic factors lean toward 
continued thrombus formation, persistent total coronary 
occlusion leading to acute myocardial infarction may occur. If 
the coronary artery remains occluded for a long period (more 
than 15 minutes), then myocardial necrosis will occur. If very 
early clot lysis occurs with or without embolization to the 
distal coronary bed, or if an adequate collateral supply is 
present, infarction will be limited (non-Q wave myocardial 
infarction), whereas it will be extended (Q wave myocardial 
infarction) when no or late clot lysis occurs. In addition, in 
a patient with non-Q wave infarction, rethrombosis and 
reocclusion often occur, leading to repeat myocardial 
infarction affecting the same myocardial region (52). 
These data suggest that rupture of an atherosclerotic 
plaque with associated thrombus formation is frequent both in 
the pathogenesis of unstable angina and myocardial infarction. 
These processes will lead to a critical reduction in 
myocardial blood supply and coronary angioplasty, designed to 
enlarge the stenosed lumen, may effectively interrupt this 
process and may normalize myocardial blood flow. However, 
coronary angioplasty may act as a two-edged sword, because 
angioplasty itself may cause further injury to the plaque and 
the already ulcerated intima (53), which has the potential to 
intensify the ongoing thrombogenic process. This may lead to 
an increased frequency of abrupt total occlusion during the 
procedure. 
The reported incidence rates of abrupt closure after 
attempted angioplasty vary between 2 and 12% (7,11,54,55). The 
management of this serious complication has changed over the 
past ten years and remains controversial. There was a time 
when all patients with acute occlusion underwent emergency 
surgery. In earlier reported series (56-58), emergency surgery 
was performed in 5 to 13% of the patients in whom angioplasty 
was attempted. More recent reports show a decline in emergency 
coronary bypass surgery to 2%, along with an increase in the 
frequency of myocardial infarction without surgery (59). About 
40-60% of patients who have emergency surgery after 
angioplasty have evidence of myocardial infarction, despite 
prompt operation, and mortality rates range from 0-6.4% (57-
62). 
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Identification of factors associated with increased 
occlusion rates might be of great value in optimizing patient 
selection and developing treatment strategies for preventing 
this complication. Although the extent of myocardial ischemia 
resulting from acute occlusion usually may be predicted from 
the patient's diagnostic angiogram, the occurence of abrupt 
occlusion is not foreseeable. However, in the patients 
presented here, there was a correlation between the presence 
of intracoronary thrombus before angioplasty and the 
subsequent development of complete coronary artery occlusion 
after attempted angioplasty. In patients with pre-existing 
intracoronary thrombus, abrupt occlusion occurred in 28% 
(12/43) compared with 6% (9/157) in those without angiographic 
evidence of intracoronary thrombus. This finding is consistent 
with other reports (7,63). This leads us to believe that the 
mechanism of occlusion in this series was an ongoing 
thrombogenic process, while coronary spasm as an alternative 
cause of abrupt occlusion was unlikely since intracoronary 
nitroglycerine and nifedipine were routinely administered. In 
addition, the use of intensive anticoagulant therapy: 
intravenous heparin 2-4 days prior to the procedure and 
routine premedication with intravenous aspirin (250 mg) 
combined with heparin (10.000 U) during the dilatation did not 
prevent abrupt vessel occlusion from occurring either during 
dilatation or immediately after what appeared to be 
successful dilatation. This is consistent with other clinical 
and experimental reports (7,63-65), showing that platelet 
thrombus deposition occurred despite continuous heparin use. 
Since thrombolytic therapy combined with coronary 
angioplasty has been widely and safely used in the setting of 
acute myocardial infarction, it would be justified to apply 
this rescue strategy in our unstable patients with abrupt 
vessel occlusion after angioplasty. Therefore, since 1986 
emergency redilatation (with the same or an oversized balloon) 
or intracoronary thrombolysis or combination of both have been 
adopted as a treatment of this complication. Intracoronary 
streptokinase was given in our patients in whom abrupt closure 
of the coronary artery immediately after dilatation was 
presumably due to acute thrombosis. Out of the 4 cases with 
major coronary dissection who underwent emergency surgery, 3 
had myocardial infarction. In contrast, only 2 out of 12 
patients who received intracoronary streptokinase had evidence 
of myocardial infarction. These findings compare favorably 
with those of our previous series (table III), suggesting that 
in some cases thrombolytic therapy may improve immediate 
outcome of angioplasty in unstable angina by avoiding urgent 
surgery and procedure-related myocardial infarction. However, 
because this was a retrospective study we can only speculate 
about the reasons for the improvement in the result. Subtle 
but nevertheless potentially important factors that may have 
contributed to the improved results include: increased 
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operator experience, the exclusive use of better X-ray 
equipment and advanced angioplasty systems, optimization of 
balloon size, longer observation period in the catheterization 
laboratory after dilatation, and less stringent criteria for 
repeat dilatation when the arterial segment appeared to be 
hazy on the angiogram. Although all of these procedural 
modifications may be exerting a favorable influence on the 
outcome of dilatation, we believe that thrombolytic therapy 
itself has led to the more effective resolution of acute 
complications that occur during attempted angioplasty. 
Recent published randomized placebo-controlled trials of 
rtPA in unstable angina further confirm the potential of 
fibrinolytic therapy in this setting, particularly in patients 
with angiographic evidence of intracoronary thrombus (41,42). 
However, Ambrose et al (66) recently reported that 
intracoronary streptokinase was usually ineffective in 
reducing the percent stenosis of the angina-producing vessel, 
measured quantitatively, in patients with unstable angina and 
non-Q wave myocardial infarction. Besides, there may have been 
no thrombus present at the time of angiography due to 
spontaneous lysis or due to heparin therapy, it is possible in 
some patients with unstable angina that the thrombus deposited 
at the site of plaque disruption is already organized within 
the coronary artery at the time of clinical presentation (30) 
and therefore is resistant to short infusions of 
streptokinase. To achieve thrombolysis, it may be necessary to 
give the thrombolytic therapy within hours of onset of 
unstable symptoms. Furthermore, results of a small randomized 
placebo-controlled trial of rt-PA in unstable angina (41) have 
shown that a prolonged (12 hours) infusion of rtPA with 
heparin effectively lyses thrombus and leads to stabilization 
of the clinical syndrome when compared with heparin alone. In 
this randomized trial, angiographic evidence of intracoronary 
thrombus was detected in 73% of placebo-treated and none in 
the rtF A-treated patients. A highly significant correlation 
was observed between the presence of thrombus and recurrent 
angina. However, bleeding was observed in 67% of the 
rtPA-treated patients and none in the placebo group. 
In our institution thrombolysis has been used as a 
treatment of complication and not as a primary or preventive 
therapy. The reason for this, is that, it will be not 
justified and maybe unsafe to treat preventively all patients 
with unstable angina, since only 10% of the patients will 
present with acute complications. Secondly, that the 
haemorrhagic risks inherent to the thrombolytic therapy using 
either specific clot lysing agents or systemic fibrinolytic 
agents are not negligible and therefore may not be imposed to 
this population as a whole. 
Future studies should be directed towards the place of 
thrombolytic therapy in the management of patients with 
unstable angina, especially in those refractory to 
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pharmacologic therapy. Firstly, thrombolytic therapy as a 
cool-off strategy. Secondly, as a preventive strategy in order 
to avoid acute complication during coronary angioplasty. And 
finally, as a rescue strategy in case of abrupt vessel 
occlusion during attempted angioplasty. At present, we are 
conducting a double blind randomized trial of intravenous rtPA 
versus placebo in patients with unstable angina refractory to 
pharmacologic therapy who will undergo coronary angioplasty 
within 24 hours. Until further information becomes available 
we would propose the following practical approach. Patients 
with unstable angina should initially receive prompt 
management with stepwise intensification of pharmacologic 
therapy including antiplatelet drug and anticoagulation with 
heparin in an attempt to achieve stability. Early angiographic 
and revascularization is indicated if this approach fails and 
ischemic episodes continue in spite of maximal medical 
management. Coronary angioplasty is indicated When the 
stenosis, technically suitable for dilatation, is found to be 
responsible for the unstable state. An intravenous 
thrombolytic agent should be given prior to angioplasty in 
patients with angiographic evidence of intracoronary thrombus. 
In case of abrupt vessel occlusion during attempted 
angioplasty, intracoronary streptokinase and redilatation 
should be carried out. 
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CHAPTER IV 
EFFECTS OF SUCCESSFUL PERCUTANEOUS TRANSLUMINAL CORONARY 
ANGIOPLASTY ON GLOBAL AND REGIONAL LEFT VENTRICULAR FUNCTION 
IN UNSTABLE ANGINA PECTORIS 
ABSTRACT 
Sixty-eight patients (58 men, 10 women, mean age 56.3 years, 
range 31 to 72) with unstable angina pectoris, either 
initially stabilized with or refractory to optimal 
pharmacologic treatment, were studied to determine whether 
regional dysfunction due to stunning of the myocardium caused 
by attacks of chest pain at rest could be improved with 
percutaneous transluminal coronary angioplasty (PTCA). 
Patients were ·included in the study if they had successful 
single vessel PTCA, no angiographic restenosis, no reocclusion 
or late myocardial infarction and 2 serial left 
ventriculograms of sufficient quality to allow automated 
contour analysis before and after PTCA. Global ejection 
fraction increased significantly (from 56% to 60%; p = 0.05) 
only after successful dilatation of a stenosis of the left 
anterior descending coronary artery. Analysis of regional wall 
displacement showed significant improvement of regional wall 
motion in the areas supplied by the dilated vessel of either 
the left anterior descending, the left circumflex or the right 
coronary artery. Thus, regional myocardial dysfunction, due to 
stunning of the myocardium in patients with unstable angina 
improves after successful PTCA. 
INTRODUCTION 
Profound and prolonged myocardial ischemia that does not 
progress to necrosis may stun cardiac muscle and produce 
functional, metabolic and structural changes (1-3). In 
patients with unstable angina, abnormalities in regional 
resting cardiac wall motion may be a result of prolonged 
attacks of transient ischemia. Regional myocardial 
dysfunction has been shown to improve after restoration of an 
adequate blood flow in animal experiments (4-6), after 
coronary bypass surgery (7-10) and after coronary artery 
reperfusion in acute myocardial infarction, either by clot 
lysis or direct percutaneous transluminal coronary angioplasty 
(PTCA) ( 11-13) • 
This study determines whether regional myocardial 
dysfunction due to stunning of the myocardium caused by 
attacks of transient ischemia at rest can be improved with 
successful PTCA in patients with unstable angina. 49 
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Figure 1. A, example of the computer output showing the end-diastolic (ED) and 
end-systolic (ES) contours of the 30° right anterior oblique left ventriculogram. 
Systolic regional wall displacement was determined along a system of20 coord-
inates on the pattern of actual endocardial wall motion in normal persons and 
generalized as a mathematic expression amenable to automatic data process-
ing. 1s-18 B, the left ventricular end-diastolic cavity is seperated into 20 half-
slices. The volume of each half slice is computed according to the given for-
mula, where R =radius and l =left ventricular long-axis length. C, the regional 
contribution to global ejection fraction (CREF) is determined from the systolic 
decrease of volume of the half slice that corresponds to a particular wall seg-
ment. The systolic volume change is mainly a consequence of the decrease of 
radius (R) of the half slice. When normalized for end-diastolic volume, the sys-
tolic segmental volume change was considered as a parameter of regional 
pump function. During systole this parameter expresses quantitatively the con-
tribution of a particular segment to global ejection fraction. The sum of the 
values for all20 segments equals the global ejection fraction. D, shaded zones 
representthe 10th to the 90th percentillearea of CREFvalues in normal persons. 
On the x axis, the CREF values of the anterior and inferoposteriorwall areas are 
displayed (%),while on they axis the segment numbers of the anterior wall (1-
10) and of the inferoposterior wall (11-20) are depicted. The segmental CREF 
values in theanterobasal (segments 1 to5), anterolateral (segments5 to9), apex 
(segments 9 to 12), inferoapical (segments 12 to 16) and posterobasal (seg-
ments 16 to 20) wall regions were analyzed. 
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METHODS 
Between February 1983 and June 1985, 150 patients with 
unstable angina pectoris underwent PTCA. Unstable angina 
pectoris was defined as chest pain at rest lasting for at 
least 15 minutes, accompanied by electrocardiographic ST-T 
changes and no subsequent signs of myocardial necrosis. 
Sixty-eight patients (58 men, 10 women, mean age 56.3 years, 
range 31 to 72) who fulfilled the following criteria were 
selected for this study: successful single artery dilatation 
in patients with unstable angina pectoris; no angiographic 
restenosis, reocclusion or late reinfarction during follow-up; 
and serial left ventriculograms of sufficient quality to allow 
automated contour analysis before PTCA and at follow-up 
catheterization. 
Thirty-two percent of patients had had a myocardial 
infarction; 19% had collaterals to the infarct-related vessel. 
The mean number of documented attacks of pain was 2.8 ± 2 and 
the mean time between the last attack of pain and the left 
ventriculogram before PTCA was 43 ± 48 hours. Treatment 
consisted of a combination of intravenous nitroglycerin, 
beta-adrenergic receptor antagonists and calcium antagonists. 
Fourty-four patients (65%) who underwent emergency PTCA were 
refractory to treatment. Initial stabilization was achieved in 
24 patients (35%), but they remained symptomatic on slight 
exertion. These patients underwent elective PTCA. 
PTCA was performed with a steerable balloon catheter 
system. In patients with multivessel disease only the 
ischemia-related vessel was dilated (14). PTCA was considered 
successful if the severity of obstruction was reduced to less 
than 50% of the luminal diameter, with abolition of acute 
ischemic symptoms and no progression to myocardial infarction 
or death. 
After discharge, treatment with nifedipine, 40 to 60 mg 
daily and acetylsalicilic acid, 500 mg daily, was continued 
for a period of 6 months. Sixty-three of the 68 ·patients 
underwent exercise thallium-201 scintigraphy at a mean of 2.8 
months (range 1 to 4) after PTCA. Patients performed 
symptom-limited exercise on the bicycle ergometer with 
stepwise increments of 20 Watts every minute. The 3 orthogonal 
leads XYZ of the Frank lead system were recorded. An ischemic 
response was defined as at least 0.1 mV of ST-segment 
depression of 0. 08 second after the J point. The maximal 
workload achieved was expressed as a percentage of the normal 
workload predicted for age, sex and body length. Thallium 
exertional scintigraphic imaging was performed in the 
anterior, left anterior oblique 45° and 65° views, immediately 
after injection of 1. 5 mCi of thallium-201 at peak stress. 
Postexercise images were recorded 4 hours later. Images were 
obtained using a Searle Phogamma V camera. Defects with 
redistribution were considered to represent reversible 
ischemia. 51 
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figure 2. left ventricular regional wall motion in 38 patients with a stenosis of 
the proximal left anterior descending (LAD) coronary artery, in 16 patients with a 
stenosis of the right coronary artery (RCA), and in 14 patients with a stenosis in 
the left circumflex coronary artery (LCX) before and after percutaneous translu-
minal coronary angioplasty (PTCA). 
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All patients underwent follow-up catheterization a mean 
of 3.1 ± 2 months after PTCA. A restenosis was defined as an 
increase of the luminal diameter stenosis of the dilated 
lesion of more than 50%. 
Analysis of Global and Regional Left Ventricular Function 
The coronary angiograms were recorded before left 
ventricular (LV) angiograms. Global and regional LV function 
were studied from the 30" right anterior oblique LV 
cineangiogram using an automated hardwired endocardial contour 
detector linked to a minicomputer. This method of analysis has 
been described in detail (15-18). Figure 1 shows an example of 
computer output showing the end-diastolic and end-systolic 
contours of the left ventriculogram and system of coordinates 
along which segmental wall displacement is determined. 
The inter- and intra-observer variability of automated 
assessment of global and regional LV performance ranged 
between 1.6 and 2.3% standard error of the estimate for global 
ejection fraction; and for summed regional contribution to 
ejection fraction anterobasal, anterolateral, apex, 
inferoapical and posterobasal segments, respectively, between 
0.4 and 2.3% standard errors of the estimate. 
Statistics 
Results are expressed as mean ± standard deviation. 
Statistics were determined with 2 tailed Student t-test. A p 
value of less than 0. 05 was considered statistically 
significant. 
RESULTS 
Global and regional LV function before and after PTCA 
were analyzed for all patients and grouped according to the 
dilated vessel (Tables I and II, Figure 2). Global ejection 
fraction was significantly improved in patients who underwent 
PTCA of the left anterior descending artery due to a decrease 
in end-systolic volume, whereas no significant change in 
serial global LV function was observed in patients with PTCA 
of the right or left circumflex coronary artery (Table I). 
Computer- assisted regional wall motion analysis showed 
improvement in motion of the initially abnormal segments in 
all three subsets of patients, whereas the regional wall 
motion decreased to a small extent in initially normal 
segments (Figure 2, Table II). 
The results of thallium-201 scintigraphy are shown in 
figure 3. Most of the patients had no signs of myocardial 
ischemia with a normal exercise tolerance. 53 
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RESULTS OF THALLIUM 201 SCINTIGRAPHY IN 
63 PATIENTS PERFORMED AFTER SUCCESSFUL PTCA 
100 
50 
0 
86% 
max workload ecg 
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reversible 
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defect 
Figure 3. Results of exercise thallium-201 scintigraphy in 63 patients after suc-
cessful percutaneous transluminal coronary angioplasty. ecg = electro-
cardiogram 
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DISCUSSION 
In patients undergoing successful PTCA, anatomic 
improvement correlates well with elimination of angina (19), 
improved function on atrial pacing (20) and conventional 
exercise testing (21-23), improved perfusion with myocardial 
scintigraphy (21,22) and radionuclide ventriculography (24), 
and restoration to a nearly normal coronary flow reserve (25). 
The myocardium is capable of recovering function lost as 
a result of ischemia after adequate reperfusion. Whole or 
partial recovery may occur after successful coronary artery 
bypass surgery (9,10,26-28). 
In this study, we demonstrated that successful PTCA was 
accompanied by improvement in global LV function in patients 
with dilatation of a lesion of the left anterior descending 
coronary artery and by significant improvement of LV regional 
wall motion in the initially impaired regional segments of the 
areas perfused by the left anterior descending, circumflex and 
right coronary arteries. The improvement (left anterior 
descending group) or maintenance (right coronary artery and 
left circumflex groups) of LV global ejection fraction was 
primarily due to improvement of the initially abnormal 
regional wall motion, even after the disappearance of the 
compensatory actions of the initially enhanced function of the 
non-ischemic segments. 
Limitations 
Myocardial dysfunction as a result of prolonged ischemia 
may improve spontaneously when the ischemic attacks resolve 
spontaneously either as part of a natural healing process or 
as a result of pharmacologic therapy (29). Ideally, the 
effects of PTCA on LV function should be determined in a 
randomized controlled study, but it is difficult to justify 
this type of study in our group of patients due to severity 
of the disease. We believe that the normalization of antegrade 
flow after PTCA, evidenced by repeat angiography and no signs 
of ischemia in most of the patients who underwent exercise 
thallium-201 scintigraphy, is the main reason for the observed 
recovery of myocardial function. 
Differences in pharmacologic treatment before and after 
PTCA, in particular the use of beta-adrenergic blockade before 
PTCA, may also play a role in the observed difference of LV 
function. However, we have shown that regional wall motion 
improved selectively in the areas that received better blood 
supply after PTCA rather than in the ventricle as a whole. 
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CHAPTER V 
CORONARY ANGIOPLASTY IMMEDIATELY AFTER THROMBOLYSIS IN 115 
CONSECUTIVE PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 
ABSTRACT 
Between September 1981 and May 1986, coronary angioplasty 
immediately after intracoronary thrombolysis was attempted in 
115 patients with acute myocardial infarction. The present 
study describes our experience with this combined procedure. 
Primary success was achieved in 102 patients (89%). Before 
discharge, 79 of these patients agreed to be restudied 
angiographically. The infarct-related vessel was still patent 
in 71 patients (patency rate of 90%). Sequential left 
ventricular angiograms of adequate quality sufficient to allow 
automated analysis were obtained in 58 patients. Global 
ejection fraction improved significantly from 52 ± 10% to 55 ± 
9% (p 0.01) from the acute to the chronic stage. In 
patients with anterior infarction, the increase in global 
ejection fraction was primarily the result of significant 
improvement of the regional myocardial function of the infarct 
zone. No significant changes in global and regional myocardial 
function could be seen in patients with inferior infarction. 
However, when patients in whom the infarct-related vessel was 
reoccluded at follow-up angiography are excluded from 
analysis, the global and regional myocardial function did 
improve significantly irrespective of the location of the 
infarct. Median clinical follow-up of 20 (range 4 to 50) 
months resulted in an overall mortality rate of 4%. 
Preservation of global and regional left ventricular function 
with a low mortality rate suggests that immediate coronary 
angioplasty after thrombolysis can be safely used to provide 
reperfusion in the setting of acute myocardial infarction and 
that this combined procedure may be the optimal mode of 
therapy. Further randomized studies are warranted to precisely 
define the role of coronary angioplasty in acute myocardial 
infarction. 
INTRODUCTION 
Limitation of myocardial infarct size through salvage of 
ischemic myocardium is the major goal in the management of 
patients with acute myocardial infarction. Several methods for 
re-establishing blood flow during acute myocardial infarction 
in an attempt to prevent or reduce cell necrosis have 
generated particular interest. 
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Since the first clinical demonstration by Rentrop et al 
(1), we and many others have demonstrated that rapid 
recanalization can be achieved by intracoronary infusion of 
streptokinase in approximately 80% of patients (2-12). 
However, a frequent finding after recanalization is severe 
residual coronary stenosis that may restrict antegrade flow 
and limit the recovery of regional left ventricular function. 
Therefore, additional interventions, such as coronary bypass 
surgery and coronary angioplasty, have been advocated in this 
setting to improve this incomplete restoration of flow and 
maximize myocardial salvage (13-15). 
The present study describes our experience with 
angioplasty immediately after intracoronary thrombolysis as 
primary therapy in the management of selected patients with 
acute myocardial infarction. 
METHODS 
Between September 1981 and May 1986, a total of 4400 
patients were admitted to the coronary care unit of the 
Thoraxcenter; of these patients, 1100 had an acute myocardial 
infarction. Intracoronary thrombolytic therapy was given to 
243 patients. Coronary angioplasty immediately after 
thrombolysis was attempted in 115 patients with acute 
myocardial infarction, and these patients formed our study 
population. Patients selected were less than 70 years of age 
and had no history of hemorrhagic diathesis or previous 
cerebral vascular accident. All patients had chest pain of 
less. than 4 hours duration at the time of admission and had 
ST-segment elevation typical of myocardial infarction on their 
electrocardiogram. Informed consent was obtained from all 
patients. Immediately after admission, an infusion of 
nitroglycerin was started and as soon as possible the patients 
were transferred to the catheterization laboratory. 
Prophylactic lidocaine (2 mg/min) was given intravenously. 
Pre-treatment was similar for all patients and was aimed at 
the rapid achievement of an optimal hemodynamic state by means 
of light sedation and by controlling the heart rate between 60 
and 90 bpm and systolic blood pressure between 100 and 140 
mmHg. Complications such as left ventricular failure or rhythm 
disturbances were treated appropriately. The combination of 
hypotension (systolic pressure below 90 mmHg) and sinus 
tachycardia (heart rate over 100 bpm) led to temporary 
exclusion. If the hemodynamic condition of the patient 
improved quickly, inclusion in the study was still possible. 
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Clinical Characteristics 
Clinical data for all patients are shown in table I. When 
patients were subdivided into 2 groups based on the location 
of the infarct (51 patients with inferior and 64 with anterior 
infarction), all data were distributed evenly, including a 
history of previous myocardial infarction and previous bypass 
surgery. Similarly, maintenance therapy and hemodynamic state 
at the time of admission were the same in both groups. 
Table I: Baseline characteristics 
anterior inferior 
characteristics infarction infarction total 
n 64 51 ll5 
Male/female 54/10 42/9 96/19 
Median age (yr) 55 57 56 
Previous infarction 11 8 19 
Previous bypass surgery 2 3 5 
Previous PTCA 1 1 2 
History of angina: 
less than 4 weeks 22 14 36 
more than 4 weeks 12 15 27 
Therapy before admission: 
beta-blocker 18 ll 29 
nitrates 15 10 25 
Ca-antagonist 14 8 22 
anti-coagulant 6 3 9 
diuretics 7 3 10 
digitalis 1 0 1 
none 38 33 71 
7/2/3 10/3/1 17/5/4 Killip Class II/III/IV 
Single/double/triple VD 41/14/9 33/ll/7 74/25/16 
Initial EF (%) 51±10 55±10 52±10 
Peak CK (U/L) 960±701 947±738 955±709 
PTCA = percutaneous transluminal coronary angioplasty; 
VD vessel disease, EF = global ejection fraction; 
CK = creatinine phosphokinase. 
Intracoronary Thrombolysis and Coronary Angioplasty 
Initial coronary angiography and administration of 
intracoronary streptokinase were performed as previously 
described (2-4, 15-19). Briefly, intracoronary perfusion witJ3 
0 -'---J.....,---'---
80 81 82 83 84 85 86 
May 
YEAR 
Fig. 1. Breakdown of 243 patients treated with thrombolytic therapy since 
1980. Increasing number of patients receiving additional percutaneous trans-
luminal coronary angioplasty (PTCA) is shown (n = 115). TR, Thrombolytic 
therapy; TR (+) PTCA, thrombolytic therapy immediately followed by coron-
ary angioplasty. 
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streptokinase was carried out at a rate of 4000 units/minute 
to a maximum of 250,000 units. Coronary angiography was 
repeated every 15 minutes until the vessel was patent or until 
chest pain had disappeared. Coronary angioplasty was performed 
after thrombolysis when the residual stenosis was 60% or more 
and when the procedure was judged to be technically and 
organizationally feasible. The increasing number of patients 
receiving additional coronary angioplasty is shown in figure 
1. In fact, for the year 1986, analyzed until May, all but 2 
patients were treated with additional coronary angioplasty 
immediately after thrombolysis. Successful dilatation was 
defined as an improvement in the diameter stenosis from more 
than 60% to less than 50% and restenosis as a return to more 
than 50%. Left ventriculography in the right anterior oblique 
projection was performed at the end of the procedure. All 
patients received heparin followed by acenocoumarol at least 
until they were discharged from the hospital. In addition, 
nifedipine, 10 mg 6 times daily, and, aspirin, 500 mg, were 
given to all patients. From the patients who agreed to 
follow-up catheterization, coronary and left ventricular 
angiography were performed before they were discharged. 
Analysis of Global and Regional Left Ventricular Function 
Global and regional left ventricular function was studied 
in the 30° right anterior oblique view by means of an 
automated hardwired endocardial contour detector linked to a 
mini-computer (20). For each analyzed cineframe, left 
ventricular volume was computed according to Simpson's rule. 
After the end-diastolic and end-systolic frames were 
identified, stroke volume, global ejection fraction and total 
cardiac index were computed. In figure 2A, examples of the 
end-diastolic and end-systolic contours of the left 
ventriculogram, as displayed by the analysis system, are 
shown. Systolic regional wall displacement was determined 
along a system of 20 coordinates on the pattern of actual 
endocardial wall motion in normal individuals (21) and 
generalized as a mathematical expression amenable to automatic 
data processing (22,23). For each segment, segmental volume 
was computed from the local radius (R) and the height of each 
segment (1/10 of left ventricular long-axis length (L) 
according to the formula: 1/20 TI R2 L). When normalized for 
end-diastolic volume, the systolic segmental volume change was 
considered as a parameter of regional pump function (fig. 2,B 
and C). During systole this parameter expresses quantitatively 
the contribution of a particular segment to global ejection 
fraction, termed regional contribution to global ejection 
fraction (CREF) (22). It follows that the sum for all segments 
equals the global ejection fraction. The cross-hatched zones 
in figure 2D represent the segmental CREF values between the 
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Fig. 2. A, Example of computer output showing end-diastolic and end-sys-
tolic contours of 30-degree right anterior oblique left ventriculogram. Sys-
tolic regional wall displacement was determined along a system of 20 coordi-
nates on pattern of actual endocardial wall motion in normal individuals and 
generalized as mathematical expression amenable to automatic data pro-
cessing. 20-23• B, left ventricular end-diastolic cavity divided into 20 half 
slices. Volume of each half slice is computed according to given formula. R, 
radius; l, left ventricular long-axis length. C, Regional contribution to global 
ejection fraction (CREF) is determined from systolic decrease of volume of 
half slice corresponding to particular wall segment Systolic volume change 
is mainly consequence of decrease of radius (R) of half slice. When normal-
ized for end-diastolic volume, systolic segmental volume change was con-
sidered a parameter of regional pump function. D, Shaded zones represent 
tenth to ninetieth percentile areas of CREF values in normal individuals. On 
the X axis CREF values of anterior and inferoposterior wall areas are dis-
played(%); on they axis segment numbers of anterior wall (1-10) and infero-
posterior wall (11-20) are shown. Segmental CREF values in anterobasal 
(segments 1-5), anterolateral (segments 5-9), apex (segments 9-12), infer-
oapical (segments 12-16) and posterobasal (segments 16-20) wall regions 
were analyzed. 
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tenth and ninetieth percentiles, as determined from 20 normal 
individuals. The segmental CREF-values in the anterobasal 
(segments 1 to 5), anterolateral (segments 5 to 9), apical 
(segments 9 to 12), inferior (segments 12 to 16) and 
posterobasal (segments 16 to 20) wall regions were analyzed. 
Clinical Follow-Up 
All patients were followed at the outpatient clinic for 
at least one year after admission, and survival status was 
assessed for all patients at six month intervals. Recurrent 
myocardial infarction, angina pectoris, cardiac failure, 
bypass surgery, and percutaneous trans luminal coronary 
angioplasty were recorded. 
Statistical Analysis 
Data are expressed as mean ± SD. Paired Student t tests 
were applied to the hemodynamic data. 
RESULTS 
Since September 1981, we have attempted coronary 
angioplasty of the infarct-related vessel in 115 patients 
(fig. 3); in 102 of them the infarct-related vessel was 
successfully dilated (primary success rate of 89%) • In 13 
patients, attempted angioplasty was unsuccessful; one patient 
died of cardiogenic shock during the procedure and · 4 other 
patients underwent coronary artery bypass surgery 1 to 27 
(mean 9) days after the initial procedure. Of the remaining 8 
patients, 2 subsequently developed stable angina (New York 
Heart Association class II) controlled by pharmacologic 
treatment and 6 were asymptomatic. Follow-up angiography was 
performed in 4 patients in whom the attempted angioplasty was 
unsuccessful. An occluded infarct-related vessel was found in 
2 patients, one of whom was asymptomatic at follow-up, whereas 
the infarct-related vessel was still patent in 2 other 
patients, one of whom underwent coronary artery bypass surgery 
and one who was asymptomatic at follow-up. Of the 102 
successfully treated patients, 4 patients died 59 (range 7 to 
120) days after the initial procedure, 8 subsequently 
developed a non-fatal recurrent infarction, 10 underwent 
elective bypass surgery 87 (range 21 to 231) days after the 
initial procedure, and 8 underwent successful repeat coronary 
angioplasty 6.5 (range 0.5 to 30) months after the initial 
procedure. Of the rema1n1ng patients, 17 subsequently 
developed stable angina (New York Heart Association class II) 
that was controlled by pharmacologic treatment and 55 were 
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PTCA FOLLOWING THROMBOLYSIS IN AMI 
FAILURE 
death 
re-MI 
re-PTCA 
Rx-med 
ASYMPTOMATIC 
Rx-med 
CABG 
death 
Fig. 3. Short- and long-term follow-up in 115 consecutive patients undergo-
ing coronary angioplasty immediately after thrombolysis. re-MI, Recurrent 
myocardial infarction; CABG, coronary artery bypass graft; re-PTCA, repeat 
coronary angioplasty; Rx-med, controlled by pharmacologic treatment 
asymptomatic and were receiving no antianginal therapy at 
follow-up. 
Before discharge, 79 of 102 patients who underwent 
successful angioplasty agreed to be restudied 
angiographically. In 71 patients the infarct-related vessel 
remained patent. On the other hand, 8 stenotic lesions that 
had been successfully recanalized and dilated at the acute 
stage were found to be reoccluded at the time of follow-up 
angiography before discharge. This observation suggests a 
reocclusion rate of 10% (8 of 79) when recanalization is 
immediately followed by angioplasty. Among these 8 patients 
with reocclusion, one died during the hospital stay as a 
result of recurrent infarction with cardiogenic shock, 2 
subsequently developed non-fatal recurrent infarction, 3 had 
residual angina controlled by pharmacologic treatment, and 2 
were asymptomatic. Patient population, infarct-related vessel, 
and primary success and reocclusion rates at follow-up are 
shown in·figure 3 and table II. 
Table II: Angiographic data 
Follow-up angiography after 
initially successful PTCA 
attempted primary n re- re-
IRV PTCA success occlusion stenosis 
LM 2 2 2 0 1 
LAD 58 53 40 1 6 
LCX 12 10 8 1 3 
RCA 40 35 29 6 5 
Bypass graft 3 2 0 0 0 
Total 115 102 79 8 15 
IRV = infarct-related vessel; PTCA = percutaneous transluminal 
coronary angioplasty; LM = left main coronary artery; LAD = 
left anterior descending coronary artery; LCX = left 
circumflexus; RCA = right coronary artery. 
Global and Regional Left Ventricular Function 
Sequential left ventricular angiograms of sufficient 
quality to allow automated contour analysis were obtained from 
58 patients (25 with inferior and 33 with anterior 
infarction). The global ejection fraction increased 
significantly (p = 0. 01) from 52 :!: 10% to 55 :!: 9%. The 
significant increase in end-diastolic volume was accentuated 
by the inclusion of patients with reocclusion of the infarct-
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related vessel after initially successful angioplasty. When 
these patients with reocclusion are excluded from analysis, 
the end-diastolic volume did not change significantly, as 
shown in table III. 
Figure 4 shows the sequential changes in regional 
myocardial function from the acute to the chronic stage in the 
patients in whom left ventriculography was performed at the 
time of acute and follow-up catheterization. In patients with 
anterior infarction, the increase in global ejection fraction 
(from 51 ± 10% to 55 ± 10%; p = 0.05) was primarily due to a 
significant improvement in regional contribution to ejection 
fraction of the infarct zone, as shown in figure 4. In 
contrast, in the group of patients with inferior infarction, 
the regional contribution to ejection fraction of the infarct 
zone remained unchanged. However, when patients in whom the 
infarct-related vessel was found to be reoccluded at follow-up 
angiography are excluded from analysis, the regional 
myocardial function of the infarct zone did improve 
significantly irrespective of the infarct location as shown in 
figure 5. 
Clinical Follow-Up 
Results of median clinical follow-up of 20 months after 
admission (range 4 to 50 months) are shown in table IV. The 
survival rate was 96%, and infarct location did not affect 
longterm survival (mortality rate of 5% versus 4%). In 
addition, incidences of non-fatal recurrent infarction (7%), 
bypass surgery (12%), and repeat PTCA (7%) were also low in 
this study population. Among the remaining 80 patients, 19 had 
~table angina (New York Heart Association, class II), 12 with 
anterior and 7 with inferior infarction. 
Table IV: Clinical follow-up (median of 20 months) 
Anterior Inferior 
infarction infarction All 
Mortality 3 (5%) 2 (4%) 5 (4%) 
Recurrent infarction 2 (3%) 6 (12%) 8 (7%) 
~Bypass surgery 10 (16%) 4 (8%) 14 (12%) 
Repeat-PTCA 4 (6%) 4 (8%) 8 (7%) 
Angina NYHA class II 12 (19%) 7 (14%) 19 (17%) 
Without symptoms 33 (52%) 28 (55%) 61 (53%) 
Total 64 51 115 
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ANTERIOR lNFARCTION ( N • 33) 
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INFERIOR INFARCTION ( N • 25 l 
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GLOBAL EJECTION FRACTION (%) : 52 ± 9-54 ± 7 
Fig. 4. Sequential changes in regional contribution to global ejection fraction 
from acute (at admission, solid line) to predischarge (dotted line) stage in 
patients with anterior (left-sided) and inferior (right sided) infarction treated 
by combined procedure of intracoronary thrombolysis and angioplasty. In 
patients with anterior infarction, significant increase in global ejection frac-
tion was primarily due to significant improvement in regional myocardial 
function of infarct zone (anterior, segment 1 to 10) even after disappearance 
of compensatory actions of initially enhanced function of noninfarct zone 
(posterior). In group of patients with inferior infarction, regional myocardial 
function of infarct zone remained unchanged. 
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Fig. 5. Sequential changes in regional myocardial function as shown in Fig. 
4, after exclusion of patients in whom infarct-related vessel was found to be 
reoccluded at follow-up angiography before discharge. 
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DISCUSSION 
The present study reports our experience with angioplasty 
immediately after intracoronary thrombolysis in the management 
of patients with acute myocardial infarction. As our study was 
not randomized and did not include a control group, we can 
make no definitive statements about the effects of angioplasty 
on early death and other major cardiac events, and the results 
should be interpreted with this in mind. 
Although the current results might be biased by the 
selection of those patients who were hemodynamically stable 
and in whom it was judged to be technically and 
organizationally suitable for angioplasty, the findings are in 
agreement with earlier observations that the recovery of 
regional function is greatest in patients with the lowest 
residual stenosis after the intervention (4,24-27). 
Serial left ventricular angiograms of sufficient quality 
to allow automated contour analysis were available for 58 of 
the 115 patients (50%) in this study. The lack of serial 
ventriculograms of all subjects is another limitation of this 
study. To investigate possible selection bias, we compared 
these 58 patients with 57 patients from whom no serial 
contrast ventriculograms were obtained and found no difference 
between groups (table V). Although these data are reassuring, 
they do not definitely exclude selection bias. 
Table V: Characteristics of patients with (A) and without (B) 
sufficient serial left ventricular angiograms 
A B total 
characteristics (n=58) (n=57) (n=ll5) 
Male/female 51/7 45/12 96/19 
Median age (yr) 56 56 56 
Anterior/inferior infarction 33/25 31/26 64/51 
No therapy before admission 37 34 71 
Killip class II/III/IV 9/2/1 8/3/3 17/5/4 
Previous infarction/CABG/PTCA 14 12 26 
Single/double/triple VD 36/17/5 38/8/11 74/25/16 
Peak CK (U/L) 850±596 1123±845 955±709 
Recurrent infarction 5 3 8 
CABG/repeat-PTCA 12 10 22 
Mortality 3 2 5 
CABG = coronary artery bypass graft; PTCA = percutaneous 
transluminal coronary angioplasty; VD = vessel disease; 
CK = creatinine phosphokinase. 
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Primary Success and Late Patency 
In this series, the primary success rate for angioplasty 
immediately after thrombolysis was 89% and was similar or even 
more favorable when compared with other reports (26-35) in 
which the range was 65% to 91% (table VI). This implies that 
this combined procedure can be safely used to provide 
reperfusion in the setting of acute myocardial infarction. 
Although many studies have shown that rapid recanalization can 
be achieved by intracoronary thrombolysis with a reperfusion 
rate comparable to that of the combined procedure (intracor-
onary thrombolysis followed by additional angioplasty), 
analysis of serial global and regional left ventricular 
function demonstrated the benefit of correcting these residual 
obstructive lesions .(13,26,36,37). This approach seems 
rational if an isolated occlusion is only minimally opened 
with streptokinase, since it is these residual high-grade 
stenoses that are the most likely to reocclude (15,29,38,39). 
Reocclusion during the hospital stay occurred in 10% of 
patients in whom initially successful angioplasty was 
performed after thrombolysis; this is in accordance with our 
earlier observation (15) and those of other investigators 
(table VI). According to other reports (15,28,29,38,39), 
reocclusion is dependent on the degree of luminal narrowing 
after reperfusion. More recently, this was confirmed by Erbel 
et al (27), who reported a reocclusion rate of 7% in patients 
after successful angioplasty, 32% after unsuccessful 
angioplasty with high-grade residual stenosis, and 20% after 
successful thrombolysis alone. Serruys et al (15) showed a 
reocclusion rate of 6% in patients undergoing additional 
angioplasty af.ter thrombolysis and 17% in patients undergoing 
thrombolysis alone. These results suggest that reperfusion may 
need to be supplemented by additional revascularization 
procedures, such as coronary bypass surgery and angioplasty, 
and any intervention should not be postponed, since 
reocclusion rate is highest in the first 5 days after 
thrombolysis (27) and any reduction in perfusion may impede 
myocardial recovery. 
Global and Regional Left Ventricular Function 
In many of the previous randomized trials (5-12), 
successful reperfusion with intracoronary thrombolysis alone 
did not bring about an improvement in global left ventricular 
function. In a recently published report of a randomized 
trial, Erbel et al (27) also found no significant changes in 
global ejection fraction, even in those patients treated with 
additional angioplasty after intracoronary thrombolysis. In 
contrast, our study shows that successful reperfusion with 
angioplasty was associated with a significant improvement in 
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global left ventricular function. This was in agreement with 
the data from a randomized trial of intracoronary 
streptokinase versus coronary angioplasty, recently published 
by O'Neill et al (26). On the other hand, both randomized 
trials (26,27) showed significant improvement in regional 
myocardial function of the infarct zone after coronary 
angioplasty; a finding consistent with ours. 
The initial ejection fraction was found to be higher in 
patients with inferior compared to anterior myocardial 
infarction (40). Timmis et al (41) showed that patients with 
an initial global ejection fraction of less than 50%, who were 
successfully treated with intracoronary streptokinase, had 
significant gains in left ventricular function at follow-up 
catheterization before discharge regardless of infarct 
location, whereas those with an initial global ejection 
fraction of more than 50% did not. In the present series, the 
initial global ejection fraction in patients with inferior 
infarction was higher (55 ± 10%) compared to those with 
anterior infarction (51 ± 10%) but did not reach statistical 
significance (table I). This lack of difference may be due to 
the fact that patients were selected on the basis of them 
having a clinically stable hemodynamic state before they 
underwent any invasive investigation and treatment, which also 
explains the high proportion of patients in Killip classes I 
and II. The significant increase in global ejection fraction 
in the present study was primarily the result of a significant 
improvement in the regional myocardial function of the infarct 
zone in the group of patients with anterior infarction, as 
shown in figure 4. Whereas in the group of patients with 
inferior infarction this improvement did not occur. This 
finding is in accordance with other reports (27). A possible 
explanation for the lack of improvement in inferior wall 
myocardial function might be the disproportionately high 
incidence of reocclusion in those patients with a lesion of 
the right coronary artery. When patients with reocclusion of 
the dilated artery are excluded from analysis, the regional 
wall motion of the infarct zone improved significantly 
irrespective of the infarct location, as shown in figure 5. 
This is in accordance with previous studies that have shown 
that failure of recanalization or reocclusion after initially 
successful recanalization of an occluded vessel is associated 
with poor improvement in regional myocardial function (4). 
A higher mortality rate was found in patients with 
anterior infarction (19%) compared to those with inferior 
infarction (5%)(42). The overall mortality rate of 4% in our 
patient population, with an in-hospital mortality rate of 3%, 
was similar, or even more favorable, when compared to other 
reports (table VI). The fact that patients with anterior 
infarction treated by intracoronary thrombolysis followed by 
angioplasty had a low mortality rate (5%) and was similar to 
those with inferior infarction (4% mortality rate) again 
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suggests that reperfusion may need to be supplemented by 
additional revascularization procedures to optimize the 
chances of obtaining full functional recovery. The additional 
value of immediate angioplasty in preserving global and 
regional left ventricular function and limiting infarct size 
may help to explain the observed reduction in the mortality 
rate and other major cardiac events. On the other hand, the 
need for acute revascularization in patients with inferior 
infarction is still open to discussion. 
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CHAPTER VI 
VALUE OF IMMEDIATE CORONARY ANGIOPLASTY FOLLOWING 
INTRACORONARY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION 
ABSTRACT 
A total of 533 patients with acute myocardial infarction of 
less than 4-h duration were enrolled in the multicenter 
randomized trial of intracoronary thrombolysis compared to 
conventional treatment. In two of the five participating 
centers, an additional coronary angioplasty immediately after 
thrombolysis was attempted in 46 patients. According to the 
treatment allocation and early and late patency of the 
infarct-related vessel, patients were subdivided into three 
groups: conventionally treated (group A); successful coronary 
angioplasty following thrombolysis with persistent patent 
infarct-related vessel (group B); and late patency of the 
infarct-related vessel postthrombolytic therapy without 
angioplasty (group C). The highest global ejection fractions 
were observed in group B (54±10%) and group C (55±13%), while 
the lowest ejection fraction was found in group A (47±14%). 
The sequential changes in global ejection fraction from the 
acute to the chronic stage was + 4% (p = 0. 05) in group B, 
while no significant changes could be demonstrated in group C. 
Furthermore, in the group successfully treated by angioplasty, 
the improvement in global ejection fraction was more 
pronounced and persisted up to three months after the 
intervention. This was supported by analysis of regional 
myocardial function of the infarct zone (+ 16% improvement, p 
= 0. 01) • The long-term clinical follow-up (median 24 months) 
of the patients successfully treated by combined procedure of 
thrombolysis and angioplasty (group B) was most favourable 
with a lower incidence of re-infarction (6%), and late 
coronary bypass surgery (13%) and/or (re)-percutaneous 
transluminal coronary angioplasty (3%) was performed less 
frequently. 
These results suggest that reperfusion may need to be 
supplemented by additional revascularization procedures in 
order to optimize the chances of obtaining full functional 
recovery and so to improve the prognosis. 
INTRODUCTION 
Since the first study by Rentrop et al (1), we and many 
others have demonstrated that rapid recanalization can be 
achieved by intracoronary streptokinase in approximately 80% 
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CONVENTIONAl THROMBOlYSIS 
264 269 
GROUP A ! 
ACUTE ANGIOGRRAPHY 
234 
• 
I 
• 
TR+PTCA TR ALONE 
46 188 
! ! 
PRIMARY SUCCESS 44 154 
! ! 
FOLLOW-UP ANGIOGRAPHY 37 121 
l ! 
LATE PATENCY 31 102 
GROUP 8 GROUP C 
Fig. 1. Flow chart. TR, thrombolysis; PTCA, percutaneous transluminal cor-
onary angioplasty. 
of patients (2-5). The large multicenter trial conducted by 
the Interuniversity Cardiology Institute in the Netherlands 
has documented that early recanalization is associated with a 
limitation of infarct size, preservation of left ventricular 
function, and improved survival when compared to conventional 
treatment (6-8). However, a frequent finding after 
recanalization is severe recurring or residual coronary 
stenosis which may restrict antegrade flow and limit the 
recovery of regional left ventricular function. Therefore, 
additional interventions, such as coronary angioplasty, have 
been advocated in this setting to improve this incomplete 
restoration of flow and maximize myocardial salvage (4,9-22). 
The aim of this study was to investigate whether 
immediate angioplasty after thrombolysis indeed provided 
additional benefit in the preservation of regional myocardial 
function in the infarct zone by retrospectively reviewing the 
results of the Netherlands multicenter trial of thrombolytic 
therapy (6-8) in which selected patients underwent 
angioplasty. 
PATIENTS AND METHODS 
Between June 1981 and March 1985, 533 patients with an 
acute myocardial infarction were enrolled in a multicenter 
randomized trial of intracoronary thrombolysis compared to 
conventional treatment; 264 patients were allocated to 
conventional and 269 to thrombolytic therapy. The initial 
protocol (23-26) was modified in two ways: the first was as a 
result of data which suggested that reocclusion of the 
coronary artery occurred predominately in patients with severe 
residual stenosis (4,12,15, 16). It was therefore decided to 
proceed to immediate coronary angioplasty in such patients at 
two of the five participating centers (predominately the 
Thoraxcenter, Rotterdam). This combined procedure was 
performed in 46 out of 269 patients allocated to thrombolysis 
(fig. 1). The second change (January 1984) was to introduce 
intravenous streptokinase (500,000 U) at the time of admission 
to hospital (6-8,27-29). During the study period consecutive 
patients up to the age of 70 years with chest pain and ECG 
signs of typical myocardial infarction, who arrived within 
four hours of the onset of symptoms, were admitted to the 
trial, as described in previous reports (6-8,23-26,30-34). 
As the object of this study was to assess the additional 
value of a successful coronary angioplasty as compared to 
successful thrombolysis alone, the study population was 
retrospectively divided into three groups: 
group A: patients allocated to conventional treatment 
(n=264); 
group B: patients recanalized by coronary angioplasty 
following thrombolysi.s with persistent patency of the 
infarct-related vessel at follow-up angiography (n=31); 83 
group C: patients recanalized by thrombolysis without 
angioplasty with subsequent late patency of the 
infarct-related vessel (n=102). 
Patients with persistent occlusion in spite of attempted 
recanalization procedures (n=36) and patients with initial 
patency after recanalization in whom the infarct-related 
vessel was found reoccluded at follow-up angiography (n=25) 
were excluded from analysis in this study. The necessary 
angiographic data was unobtainable in the remaining 75 
patients; the recanalization procedure could not be performed 
in spite of allocation to thrombolysis (n=35) , or the late 
patency of the infarct-related vessel could not be evaluated 
(n=40). 
Electrocardiographic Assessment (31,32) 
ST-segment elevation of at least 0.1 mV in one or more 
extremity leads, 0.2 mV in one or more precordial leads, or at 
least 0.2 mV ST-segment depression in one or more precordial 
leads compatible with posterior infarction were analyzed. The 
sum of ST-segment elevation on the ECG was defined for 
anterior infarcts as the sum of ST-segment elevation in leads 
I, aVL, V1-V6 and for inferior infarcts as the sum of 
ST-segment elevation in I,II,III, AVL, AVF, V5, V6 and 
ST-segment depression in V1-V4. 
Measurement of Serum Alpha-Hydroxybutyrate Dehydrogenase 
Serum alpha-hydroxybutyrate dehydrogenase levels were 
determined on admission, every 12 hours for the first two 
days and then every 24 hours until 5 days after admission. 
Cumulative release of alpha-hydroxy butyrate dehydrogenase 
(HBDH) in the first 72 hours was calculated from these data as 
described earlier (33,35). In two of the 5 participating 
hospitals total lactate dehydrogenase was measured instead and 
converted to alpha-hydroxybutyrate dehydrogenase by exchange 
of standards. 
Intracoronary Thrombolysis and Coronary Angioplasty 
Initial coronary angiography and the administration of 
intracoronary streptokinase was performed as previously 
described (6-8). Briefly, intracoronary streptokinase was 
carried out at a rate of 4,000 units per minute to a maximum 
of 250,000 units. Coronary angiograms were repeated every 15 
minutes. Coronary angioplasty was attempted in 46 patients in 
whom it was judged to be technically and organizationally 
feasible. It was carried out only when the residual stenosis 
84 
was 60% or more after thrombolysis. Successful dilatation was 
defined as an improvement in the diameter stenosis from 
greater than 60% to less than 50%. Left ventriculography was 
performed at the end of the procedure. From the patients who 
agreed to follow-up catheterization, coronary and left 
ventricular angiography were obtained both in the control and 
the thrombolysis-treated group, either before discharge or 4-8 
weeks after the acute phase. 
Radionuclide Angiography 
Radionuclide angiography was carried out at the bedside 
on the first or second day after admission and repeated before 
hospital discharge and at three months. Gated images were 
obtained with 20 frames in each heart cycle after in vivo 
labelling with 15 mCi Technetium 99m. Data were analyzed by a 
fully automated computer program on a DEC-gamma 11 or an ADAC 
system (36), or with a MDS or a Philips data analysis system. 
Analysis of Global and Regional Left Ventricular Function 
Global and regional left ventricular function was studied 
from the 30° right anterior oblique view using an automated 
hardwired endocardial contour detector linked to a 
mini-computer. This method of analysis has been described in 
detail previously (37-40) • Figure 2 shows examples of the 
end-diastolic (ED) and end-systolic (ES) contours of the left 
ventriculogram as well as the segmental contribution to the 
global ejection fraction, as displayed by the analysis system. 
Clinical Follow-Up 
All patients were followed at the outpatient clinic for 
at least one year after admission and survival status was 
assessed at six month intervals. Recurrent myocardial 
infarction, angina pectoris, cardiac failure, bypass surgery 
and coronary angioplasty were recorded. 
Statistical Analysis 
Data are expressed as mean ± SD. Paired or unpaired 
Student t tests were applied to the hemodynamic data whenever 
appropriate. 
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Fig. 2. A: Example of the computer output showing the end-diastolic (ED) 
and end-systolic (ES) contours of the 30' RAO left ventriculogram. Systolic 
regional wall displacemen1 was determined along a system of 20 coordinates 
on the pattern of actual endocardial wall motion in normal individuals and 
generalized as a mathematical expression amenable to automatic data pro-
cessing [38-40]. B: The left ventricular end-diastolic cavity is divided into 20 
half-slices. The volume of each half-slice is computed according to the given 
formula; R is radius and l is left ventricular long axis length. C: The regional 
contribution to global ejection fraction (CREF) is determined from the sys-
tolic decrease of volume of the half slice which corresponds to a particular 
wall segment. The systolic volume change is mainly a consequence of the 
decrease of radius (R) of the half-slice. When normalized for end-diastolic 
volume, the systolic segmental volume change was considered as a parame-
ter of regional pump function. D: The shaded zones represent the 10th-90th 
percentiles area of CREF values in normal individuals. On the x-axis the 
CREF values of the anterior and inferoposterior wall areas are displayed (% ), 
while on they-axis the segment numbers of the anterior wall (1-10) and of 
the inferoposterior wall (11-20) are depicted. 
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RESULTS 
Early and Late Angiographic Findings 
Table I shows the results of early and late angiography. 
Coronary angioplasty was attempted in 46 patients and was 
successful in 44 patients, including 5 patients with occluded 
vessel after intracoronary streptokinase in whom subsequent 
mechanical perforation and angioplasty was performed. Table II 
details the angiographic data concerning the infarct-related 
vessel, primary success, and the reocclusion rate. The 
patients with a persistent patent infarct-related vessel with 
angioplasty (group B) and without (group C) and patients 
allocated to conventional treatment (group A) formed our study 
population (fig. 1). 
Table II: Angiographic data 
angiographic 
attempted primary follow-up after 
IRV PTCA success successful PTCA reocclusion 
LAD 29 27 23 1 
LCX 2 2 2 1 
RCA 15 15 12 4 
Total 46 44 (96%) 37 (84%) 6 (16%) 
angiographic 
follow-up after 
attempted primary successful TR 
IRV TR alone success alone reocclusion 
LM 1 1 0 
LAD 75 61 50 5 
LCX 36 31 24 5 
RCA 74 60 46 8 
Bypass 2 1 1 1 
Total 188 154 (82%) 121 (79%) 19 (16%) 
IRV = infarct-related vessel; PTCA - percutaneous 
transluminal coronary angioplasty; TR = thrombolysis; LM = 
left main coronary artery; LAD = left anterior descending 
coronary artery; LCX = circumflexus; RCA = right coronary 
artery. 
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Table III: Baseline Characteristics 
N 
Female 
Age (yr; mean ± SD) 
Anterior infarction 
Previous infarction 
Previous CABG 
Time to admission 
(median, min) 
Sum of ST elevation 
(median, Illill) 
Controls 
(group A) 
264 
41 (16%) 
55 ± 8 
116 
60 (23%) 
8 (3%) 
90 
12 
TR + PTCA 
(group B) 
31 
4 (13%) 
57 ± 8 
22 
8 (26%) 
0 
95 
14 
TR alone 
(group C) 
102 
18 (18%) 
55 ± 10 
50 
12 (12%) 
1 (1%) 
90 
12 
Baseline characteristics of the three subdivided groups: 
TR+PTCA= recanalization with angioplasty following 
thrombolysis with late patency; TR alone = recanalization 
following thrombolysis alone with late patency; CABG = 
coronary bypass surgery. 
Baseline Data 
The baseline data were distributed evenly, including the 
median time delay for hospital admission, infarct location, 
history of previous myocardial infarction and previous bypass 
surgery (Table III). 
Global and Regional Left Ventricular Function 
Acute angiography (at admission) was performed only in 
patients allocated to thrombolysis, while late angiography 
(before discharge or at 4-8 weeks) was performed in the 
thrombolysis as well as in the control group. 
The global left ventricular volume data determined from 
contrast angiography are presented in table IV. At the chronic 
stage, the highest global ejection fractions were observed in 
patients with persistent patent infarct-related vessel after 
thrombolysis either with (group B, 54±10%) or without (group 
C, 55±13%) angioplasty, while the lowest ejection fraction was 
found in the control group (group A, 47±14%). 
In table IV, the sequential changes in global ejection 
fraction from the acute to chronic stage are also shown. In 
the angioplasty group (group B), the global ejection fraction 
improved significantly by 4. 2% (p 0. 05), while no 
significant change in global ejection fraction could be 
demonstrated in the subset of patients undergoing successful 
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Table IV: Left ventricular volumes 
EDV 2 
AEDV 
ESV 2 
AESV 
EF 2 
AEF 
Controls (A) 
95 ± 37 
(n=180) 
53 ± 31 
(n=177) 
47 ± 14 
(n=174) 
TR + PTCA 
80 ± 21§ 
(n=29) 
-0.4 ± 19 
(n=24) 
38 ± 14§ 
(n=27) 
-3.4 ± 14 
(n=23) 
54 ± 10§ 
(n=27) 
4.2 ± 9* 
(n=23) 
(B) TR alone (C) 
82 ± 32 § 
(n=86) 
9 ± 23* 
(n=43) 
39 ± 24 § 
(n=80) 
5 ± 13* 
(n=40) 
55 ± 13 § 
(n=79) 
-0.5 ± 8 
(n=40) 
EDV, ESV, EF = enddiastolic volume, endsystolic volume, 
ejection fraction at chronic (2) stage; A EDV, A ESV, A EF 
sequential change in enddiastolic volume, endsystolic volume 
and ejection fraction from acute to chronic stage where both 
were available; See also table III. Values are expressed as 
mean ± SD; Student t test for unpaired and paired (A) data. 
§p = 0.005 versus controls; *p = 0.05 acute versus chronic. 
Table V: Regional myocardial function of the infarct zone 
Controls TR + PTCA TR alone 
CREF-IZ (group A) (group B) (group C) 
Anterior infarction n 69 20 40 
Antero-basal % 12.2 15.7 13.7 
Antero-apical % 4.4 6.0 5.8 
Apex % 1.1 1.8 1.9 
Inferior infarction n 105 7 39 
Apex % 2.6 3.0 3.6 
Infero-apical % 6.9 10.7 10.8 
Infero-basal % 10.8 14.4 13.5 
Regional contribution to global ejection fraction (%) of the 
infarct zone (CREF-IZ) at follow-up angiography. 
Antero-basal = segments 1 - 5; Antero-apical = segments 5 - 9; 
Apex = segments 9 - 12; Infero-apical = segments 12 - 16; 
Infero-basal = segments 16-20. See also table III and figure 3. 
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Fig. 3. Sequential changes in regional contribution to global ejection fraction 
from the acute (at admission, solid line) to the chronic (before discharge, 
dotted line) stage in patients with inferior (left sided) and anterior (right 
sided) infarction treated by a combined procedure of thrombolysis and 
angioplasty (A and B) as well as treated by thrombolysis alone (C and D). 
The improvement in global ejection fraction of patients treated by angio· 
plasty following thrombolysis was due to significant improvement of the 
regional myocardial function of the infarct zone even after the disappearance 
of compensatory actions of the initially enhanced function of the noninfarct 
zone. 
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Fig. 4. Sequential changes (%) in regional contribution to global ejection 
fraction (CREF) of the infarct zone (anterior= segment 1 to 10; inferior= 
segment 11 to 20) from the acute to the chronic stage in the patients in 
whom both angiograms were available. In the group of patients successfully 
treated by thrombolysis followed by angioplasty with late patency (TR + 
PTCA), the significant increase in global ejection fraction (from 51% to 55%, 
p = 0.03) was primarily due to a 16% improvement in regional contribution to 
ejection fraction of the infarct zone. In the group of patients with persistent 
patent infarct related vessel after thrombolysis without angioplasty (TR 
alone), the regional contribution to ejection fraction of the infarct zone 
remained unchanged. 
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thrombolysis without angioplasty (group C) • Similar trends 
were observed in the regional myocardial function of the 
infarct zone (table V). 
Figures 3 and 4 show the sequential changes in regional 
myocardial function from the acute to the chronic stage in the 
patients in whom the left ventriculogram was performed at the 
acute as well as at a follow-up catheterization. In the 
angioplasty group (group B), the significant improvement in 
global ejection fraction was primarily due to a 16% increase 
in regional myocardial function of the infarct zone, as shown 
in figures 3 and 4. In the group of patients with persistent 
patent infarct-related vessel after thrombolysis without 
angioplasty (group C), the regional myocardial function of the 
infarct zone remained unchanged. 
Radionuclide Angiography 
Left ventricular ejection fraction as determined by 
radionuclide angiography at the acute stage (days 1-3), before 
discharge (days 10-20), and at three months are presented in 
table VI. Paired analysis of the sequential changes in global 
radionuclide ejection fraction from days 1-3 to days 10-20 and 
from days 1-3 to three months, respectively, showed a 
significant improvement in the patients with persistent patent 
infarct-related vessel after thrombolysis with or without 
angioplasty (groups B and C) , and this was most marked when 
intracoronary thrombolysis was followed by angioplasty (group 
B). No significant changes in radionuclide ejection fraction 
could be detected in patients treated conventionally. These 
data are in agreement with the contrast angiographic findings. 
Table VI: Radionuclide Angiography 
Controls (A) TR + PTCA (B) TR alone (C) 
RNAEF 1 43 ± 14 40 ± 15 47 ± 14§£ 
(n=200) (n=26) (n=90) §§ 
RNAEF 2 44 ± 15 49 ± 16 51 ± 15 
(n=l72) (n=49)§ (n=85) § § 
RNAEF 3 45 ± 15 56 ± 14 52 ± 15 
(n=l44) (n=l7) (n=78) 
.b. EF 2 - 1 o. 9 ± 11 10 ± 7** 4 ± 9** 
(n=l41) (n=l8) (n=76) 
.b. EF 3 - 1 1.7 ± 13 9 ± 14* 3 ± 12 
(n=ll5) (n=l4) (~=68) 
RNAEF = Radionuclide ejection fraction (%) at day 1-3 (1), day 
10-20 (2) and at 3 months (3); ~EF = sequentt~l change in 
radionuclide ejeEtion fraction. p = 0.05 and p = 0.005 
versus controls; p = 0.05 versus TR + PTCA; *p = 0.05 and 
**P = 0.005 acute versus chronic. See also tables Ill and IV. 
Q72 HBDH 
U/l 
1200 . 
900 
600 . 
300 
1136 
713* 686* 
controls TR +PTCA TR alone 
(group A) (group B)(group C) 
*p< 0. 001 vs controls 
Fig. 5. Median cumulative serum alpha-hydroxybutyrate dehydrogenase 
release in the first 72 hours after onset of symptoms (072 HBDH). 
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Enzymatic Infarct Size 
Enzymatic infarct size was estimated by cumulative HBDH 
release in the first 72 hours after onset of symptoms. As 
shown in figure 5, the median cumulative HBDH release in the 
control group (1136 U/L) was significantly higher than in the 
two other groups. 
Long-Term Follow-Up 
Median clinical follow-up of 24 months in all subsets of 
patients are presented in table VII. The clinical follow-up of 
patients treated by thrombolysis and angioplasty was most 
favourable when the patency of the infarct-related vessel 
could be demonstrated prior to discharge (group B) • These 
patients had a low reinfarction rate (6%); late coronary 
bypass surgery (13%) and/or (re)-PTCA (3%) was performed less 
frequently than in the other groups, while only 1 patient 
died. Conversely, the incidence of late reinfarction was 21% 
in the group treated by thrombolysis alone. 
Table VII: Long-term clinical follow-up (median 24 months) 
Re-infarction 
CABG 
(Re)-PTCA 
Death 
See table III. 
DISCUSSION 
Controls (A) 
n = 264 
17 (6%) 
33 (13%) 
13 (5%) 
46 (17%) 
TR + PTCA (B) 
n = 31 
2 (6%) 
4 (13%) 
1 (3%) 
1 (3%) 
TR alone (C) 
n = 102 
21 (21%) 
14 (14%) 
14 (14%) 
2 (2%) 
There have been many clinical trials of the efficacy of 
thrombolytic therapy in achieving reperfusion. However, the 
efficacy of thrombolysis in randomized trials has varied 
widely in several studies (41-48). Our data from the 
multicenter randomized trial (6-8) and the data from the GISSI 
study (49) have shown the beneficial effects of early 
thrombolysis in acute myocardial infarction. However, the very 
efficacy of this initial treatment has created a new problem: 
how to manage the patients with residual atheromatous lesions 
whose ischemic symptoms persist after thrombolysis, and who 
may constitute up to half of the patients treated. In order to 
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maintain the initial benefit achieved by thrombolysis, it is 
necessary to deal with the underlying obstruction. 
Percutaneous transluminal coronary angioplasty or surgery may 
play a valuable role in attaining these goals. 
Limitations of the Study 
Although the data from this study support the results 
from recently published randomized trials (54, 55) , there are 
limitations to the study, and the results should be 
interpreted with this in mind. The group of patients 
undergoing angioplasty following thrombolysis was relatively 
small because of the selection criteria and the fact that 
recruitment for this group occured predominantly in one of the 
participating centers. Although randomization would have been 
desirable, this would have further reduced the number of 
patients in this group. However, retrospective matched 
analysis on the basis of lesions suitable for coronary 
angioplasty show similar results (unpublished data from the 
Data Processing Center, Interuniversity Cardiology Institute 
in the Netherlands). 
Reocclusion 
The rationale behind the decision to perform angioplasty 
immediately after thrombolysis was to augment perfusion, 
reduce infarct size, and improve left ventricular function as 
well as to prevent re-occlusion. Although we have been able to 
demonstrate a favourable influence of angioplasty on left 
ventricular function and recurrent myocardial infarction, it 
is clear that the procedure does not influence the rate of 
reocclusion before discharge (Table II). This seems to be due 
to the disproportionately high incidence of reocclusion in 
those patients with a right coronary artery lesion. Why 
lesions in this artery should be susceptible to reocclusion is 
open to speculation. 
Preservation of Left Ventricular Function and Need for 
Regional Assessment 
Although the present study shows that rapid 
recanalization can be achieved by intracoronary thrombolysis 
alone with a reperfusion rate comparable with the combined 
procedure (intracoronary thrombolysis followed by additional 
angioplasty), analysis of serial global and regional left 
ventricular function demonstrated the additional benefit of 
correcting the residual obstructive lesions. Global left 
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ventricular ejection fraction was measured by contrast and 
radionuclide angiography (tables IV and VI). Both methods 
showed higher ejection fractions at the follow-up study when 
recanalization had been successful either with (group B) or 
without (group C) additional angioplasty. This finding is 
supported by analysis of regional wall motion and enzymatic 
infarct size measurement. Furthermore, in the group 
successfully treated by angioplasty, the improvement in global 
ejection fraction was more pronounced and persisted up to 
three months after the intervention. 
In most studies published thus far, the assessment of 
global ejection fraction has prevailed since it is relatively 
easily obtainable. In fact, increased motion of the non-inf-
arcted regions of the heart, often kept the global ejection 
fraction within normal limits despite severe regional 
hypokinesia in the infarction area. Therefore, analysis of 
left ventricular wall motion in the area at risk, which 
potentially should benefit most from reperfusion, must be 
carried out in order to detect any real benefit of reperfusion 
(8,50-53). In this study, the regional contribution to global 
ejection fraction of the infarct zone was most improved in the 
group of patients successfully treated by thrombolysis 
followed by angioplasty. In this subset of patients, global 
ejection fraction increased significantly (p = 0.03) from 51% 
to 55% from the acute to the chronic stage, an improvement 
primarily resulting from a 16% increase in the regional 
contribution to ejection fraction of the infarct zone (figures 
3 and 4). This finding was in accordance with the results of 
recently published randomized trials (54,55). These results 
suggest that in some patients, reperfusion may need to be 
supplemented by additional revascularization procedures, such 
as angioplasty, in order to optimize the chances of obtaining 
full functional recovery. The additional value of inunediate 
angioplasty in preserving left ventricular function and 
limiting infarct size might help to explain the observed 
reduction in one year mortality and other major cardiac 
events. The present study shows that intracoronary 
streptokinase combined with coronary angioplasty can be safely 
used to provide reperfusion in the setting of acute myocardial 
infarction. 
The high survival rate, the lower incidence of 
reinfarction, as well as the preserved regional and global 
left ventricular function in the subgroup successfully treated 
with thrombolysis and coronary angioplasty suggests that this 
combination may be the optimal mode of therapy for selected 
patients. 
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CHAPTER VII 
PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY FOR ANGINA 
PECTORIS AFTER A NON-Q-WAVE ACUTE MYOCARDIAL INFARCTION 
ABSTRACT 
Despite initially favorable prognosis in patients with 
non-Q-wave acute myocardial infarction (AMI), long-term 
mortality in this subset of patients appears to be similar to 
or even greater than that in patients with Q-wave AMI. The 
relatively poor late prognosis is primarily due to a high 
incidence of unstable angina and recurrent AMI. Between 
January 1982 and January 1987, 114 patients with suitable 
coronary narrowing underwent percutaneous transluminal 
coronary angioplasty (PTCA) for angina pectoris (present 
either at rest or during mild exertion, and despite optimal 
pharmalogic therapy), a median of 31 (range 2 to 362) days 
after a non-Q-wave AMI. Success was achieved in dilating the 
obstructed artery in 98 patients (113 of the 129 dilated 
arteries). Emergency bypass surgery was performed in 7 
patients. Mean clinical follow-up of 20 (range 3 to 59) months 
was obtained in all patients and revealed no deaths. Of the 98 
patients with successful PTCAs, 6 (6%) developed a non-fatal 
recurrent AMI and 62 (63%) were asymptomatic. However, 
recurrent angina affected 31 patients (32%) and was treated by 
repeat PTCA (n = 18), coronary bypass surgery (n = 5) or 
pharmacologic therapy (n = 8). At follow-up, 74% of the 
patients (73/98) were asymptomatic after a successful PTCA, 
and if necessary a repeat PTCA, without incidence of recurrent 
AMI, coronary bypass surgery or death. The high initial 
success rate, low incidence of subsequent death and late 
recurrent AMI and sustained symptomatic benefit suggest that 
PTCA is an effective initial treatment strategy in these 
selected patients. 
INTRODUCTION 
The clinical course of patients with non-Q-wave acute 
myocardial infarction (AMI) has been a subject of interest. 
Natural history studies have suggested that, compared with 
Q-wave AMI, non-Q-wave AMI is associated with less necrosis, 
better left ventricular function and lower in-hospital 
mortality. Despite this more favorable initial prognosis, 
long-term survival for patients with non-Q-wave AMI appears to 
be similar to or even less than that in patients with Q-wave 
AMI (1-13). The relatively high mortality rate of patients 
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with non-Q-wave AMI seems to 
subsequent recurrent AMI in 
preventable if recurrent 
revascularization. 
be related to unstable angina or 
the same area (1-10) and may be 
AMI can be averted with 
The present study describes the short-and long-term 
results of consecutive patients treated with percutaneous 
transluminal coronary angioplasty (PTCA) for severe angina 
after a non-Q-wave AMI. 
METHODS 
The study population consisted of 114 patients with a 
non-Q-wave AMI who underwent PTCA between January 1982 and 
January 1987. All had symptoms of angina, either at rest or 
during mild exertion, despite optimal pharmacologic therapy. 
They represented 8% of our total PTCA population during the 
study period. Non-Q-Wave AMI was defined in this study as 
prolonged chest pain compatible with AMI, associated with 
electrocardiographic ST-segment and T-wave abnormalities 
without progression to pathologic Q waves, but with abnormal 
elevation of the creatinine kinase level (at least twice of 
the normal value) before any intervention. Post-infarction 
angina was considered unstable if it occurred at rest lasting 
for at least 15 minutes and was associated with 
electrocardiographic manifestations of myocardial ischemia 
without evidence of further myocardial necrosis. 
Patients were selected for PTCA if the ischemia-related 
lesion was suitable for dilatation. The selection was based 
only on symptoms and coronary anatomy, and was not influenced 
by left ventricular function. PTCA was considered successful 
when a reduction of the severity of the obstruction to less 
than 50% luminal diameter narrowing was achieved with 
abolition of acute ischemic symptoms and without progression 
to AMI, emergency surgery, or death. PTCA was performed a 
median of 31 (range 2 to 362) days after non-Q-wave AMI; 53% 
of the procedures were performed within 30 days of AMI. 
Clinical and angiographic data are summarized in table I. 
After the procedure, patients were monitored for 24 hours in 
the medium care unit. They were treated with nifedipine 60 mg 
daily and acetylsalicylic acid 500 mg daily over a period of 6 
months. 
All patients were followed at the outpatient clinic. 
Survival status, recurrent AMI, angina pectoris, cardiac 
failure, bypass surgery and PTCA were recorded. The majority 
underwent symptom-limited exercise on the bicycle ergometer 
with stepwise increments of 20 Watts every minute. The 
orthogonal leads XYZ of the Frank lead system were recorded. 
An ischemic response was defined as at least a 0.1 mV ST-
segment depression, occurring 0.08 seconds after the J point. 
The maximum workload achieved was expressed as a percentage of tftf normal workload predicted for age, sex and height. 
Table I: Clinical and angiographic data 
Number of patients 
Male/female 
Age (median, yr) 
Previous CABG/PTCA 
Anterior/Inferior non-Q AMI 
Peak CK enzyme level (median, U/liter) 
Stable/unstable angina pectoris 
Therapy before procedure: 
- triple therapy (NTG i.v.)* 
- double therapy 
Median time from AMI to PTCA (days) 
Single/double/triple vessel disease 
Total occlusion 
Single-vessel dilatation 
Multivessel dilatation 
Initial global ejection fraction (%) 
114 
88/26 
57 (range 31-74) 
2/9 
73/41 
357 (range 206-972) 
61/53 
97 (35) 
17 
31 (range 2-362) 
75/33/6 
22 
100 
14 
58±8 (range 32-71) 
AMI = acute myocardial infarction; CABG coronary artery 
bypass graft; CK = creatinine phosphokinase (normal value less 
than 100 U/liter); PTCA =percutaneous transluminal coronary 
angioplasty. * Optimal pharmacologic therapy consisted of 
betablocker, calcium antagonist and nitrates, including 35 
patients who needed intravenous nitroglycerin (NTG i.v.) 
RESULTS 
From the 114 patients who underwent PTCA for angina after 
a non-Q-wave AMI, 129 lesions were dilated. Single-vessel 
dilatation was performed in 100 patients, including 16 
multilesion dilatations in the same artery. Double artery 
dilatation was performed in 13 patients and triple artery 
dilatation in 1 (table II). Success was achieved in dilating 
the obstructed artery in 98 patients (113 lesions). 
Table II: Angiographic results 
PTCA artery 
Left anterior descending 
Right 
Left circumflex 
Total 
N 
78 
31 
20 
129 
Primary success 
70 (90%) 
27 (87%) 
16 (80%) 
113 (88%) 
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Figure 1. Short- and long-term (mean, 20 months) clinical follow-up in 114 
patients undergoing coronary angioplasty (PTCA) for severe angina (AP) 
after a non-Q-wave myocardial infarction (MI). CABG = coronary artery 
bypass grafting; Rx Med = controlled by pharmacologic treatment 
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Figure 1 shows the clinical outcome of all patients. In 
16 patients, the attempted PTCA was unsuccessful: in 9 because 
the artery was occluded, in 5 because the stenosis could not 
be crossed with either the guide wire or balloon catheter, and 
in 2 because of abrupt closure or major dissection. Peri-
interventional AMI, defined by either cardiac enzyme elevation 
or new Q waves, was documented in 5 patients, of whom 3 
underwent emergency bypass surgery. 
Of the 98 successfully treated patients, 62 were 
asymptomatic and 5 developed a non-fatal recurrent AMI (1 of 
them underwent an urgent PTCA). Thirty-one patients developed 
recurrent angina and of these, 5 underwent an elective bypass 
surgery 168 (range 7 to 534) days after the initial procedure, 
8 were controlled by pharmacologic therapy, and 18 underwent a 
repeat PTCA 120 (range 1 to 300) days after the initial 
procedure. Success was achieved in re-dilating the artery in 
16 patients. 
Results of electrocardiographic exercise testing were 
available in 71% (70 of 98) of the patients, 8 (range 1 to 49) 
months after initially successful PTCA (fig. 2). The mean 
maximum workload achieved, predicted for age, sex and height, 
was 98% (range 54 to 131%). 
Clinical follow-up was obtained in all patients, at a 
mean interval of 20 (range 3 to 59) months, and is summarized 
in table III. If coronary artery bypass surgery, recurrent 
AMI, death or recurrent angina requiring pharmacologic therapy 
were to be considered events, 7 4% of the patients would be 
considered event-free at 20 months after successful PTCA, 
whereas if any cardiac recurrence, including repeat PTCA, were 
to be considered events, only 63% of patients would be 
event-free at 20 months (fig 3). 
Table III: Mean clinical follow-up of 20 (range 3 to 59) months 
initial success 
(n = 98) 
Death 
Emergency CABG 
AMI related to PTCA 
Late recurrent AMI 
Repeat PTCA 
Repeat PTCA + CABG 
Late CABG 
Pharmacologic therapy 
Event-free 
0 
0 
0 
6 
13 
6 
5 
8 
62 
Abbreviations as in table I. 
failure 
(n = 16) 
0 
7 
5 
0 
0 
0 
1 
6 
2 
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Figure 2. Results of electrocardiographic exercise testing (n = 70), 8 (range 1 
to 49) months after initially successful PTCA. A maximum workload of > 
80% and> 100% predicted for age, sex and height was achieved in 89% 
and 52% of the patients, respectively. The majority of the patients (92%) 
were symptom-free during the test; an ischemic ST-segment depression was 
documented in 27%. 
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Figure 3. If coronary artery bypass surgery (CABG), recurrent myocardial 
infarction (re-Ml), death or recurrent angina requiring pharmacologic therapy 
(Rx Med) were to be considered events, 74% of the patients would be con-
sidered event-free (Asympt.) at 20 months after initially successful angio-
plasty, whereas if any cardiac recurrence, including repeat coronary angio-
plasty (Re-PTCA) were to be considered an event, only 63% of patients 
would be event-free. 
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DISCUSSION 
The reported incidence of non-Q-wave AMI varies between 
20 and 36% of all AMis (1,3,5,12). Although non-Q-wave AMI and 
Q-wave AMI (as classified by electrocardiographic results) 
cannot always be anatomically differentiated (4,14), it seems 
likely that they differ clinically, physiologically and 
prognostically, as discussed by Spodick (15). Despite the 
initially limited area of myocardial necrosis and favorable 
short-term prognosis for patients with non-Q-wave AMI, several 
studies show substantial late morbidity and mortality rates in 
these patients (1-13). Despite marked improvement in 
pharmacologic therapy, the reported incidence of recurrent 
AMis remains high at 6 to 86% and is associated with a poor 
prognosis (1,4-6,10, 16-20). Maisel et al (5) reported a high 
mortality, both early and late, for patients with subsequent 
extension following a non-Q-wave AMI. In-hospital mortality 
rate in this subset of patients was 43%, while in those with 
Q-wave AMI was 15%. The one-year cumulative survival rates for 
patients with Q versus non-Q-wave AMI without extension were 
similar: 82% and 84%. For those with extension, however, 
one-year survival rates were 66% and 35%, respectively. This 
finding was supported by others (1,3,10,18,21). 
Several investigators suggest that coronary bypass 
surgery or PTCA is feasible and safe for patients with angina 
after non-Q-wave AMI (22-25). Our present results indicate not 
only that PTCA can be performed safely and effectively in this 
subset of patients, but also that the incidences of late 
recurrent AMI (6%) and cardiac death (0%) are lower than 
expected. However, recurrent angina occurred in 32% of our 
patients after successful PTCA, a percentage similar to that 
reported for stable angina (26). All patients were 
satisfactorily treated by repeat PTCA, coronary bypass surgery 
or pharmacologic therapy. These findings are comparable with 
the general results of the total PTCA population during the 
same period, perhaps because PTCA was performed in half of the 
patients more than 1 month after non-Q-wave AMI, thus 
hindering any significant distinction betwwen them and an 
average PTCA population. However, the time delay from 
non-Q-wave AMI to PTCA did not affect the outcome, despite the 
fact that unstable angina was more frequent among the patients 
treated within 30 days than those treated more than 30 days, 
as shown in table IV. 
Among the 22 patients with a totally occluded artery at 
the time of PTCA, attempted recanalization was successful in 
only 13 (success rate of 59%), and of these, repeat PTCA or 
coronary bypass surgery or both was necessary in 6. Of the 9 
unsuccessful cases, 3 underwent emergency bypass surgery, 5 
had residual angina controlled by pharmacologic therapy and 1 
was asymptomatic. When these patients with a totally occluded 
artery were excluded, the primary success rate became 92%. 
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Table IV: Time delay from non-Q-wave AMI to PTCA 
Number of patients 
Anterior AMI 
Unstable angina 
Initial success rate 
Emergency CABG 
AMI related to PTCA 
Late recurrent AMI 
Repeat PTCA/late CABG 
patients treated 
less than 30 days 
60 
67% 
72% 
85% 
7% 
5% 
5% 
23% 
Abbreviations as in table I 
patients treated 
more than 30 days 
54 
60% 
18% 
85% 
5% 
4% 
5% 
22% 
These findings suggest that when the artery is occluded, the 
benefits of PTCA after a non-Q-wave AMI are limited, even when 
recanalization is initially successful. 
Limitations of this study include the fact that it was 
uncontrolled and involved only patients with non-Q-wave AMI 
with recurrent anginal symptoms and anatomy suitable for PTCA. 
In fact, most patients had a single-vessel disease with 
relatively small to moderate enzymatic infarct size and might 
be expected to have a favorable outcome. However, these 
patients constituted a high-risk subgroup because of the 
presence of ongoing angina, which implied that the cardiac 
event was not yet complete and suggested that more aggressive 
invasive management could have improved clinical status and 
the condition of the myocardium. 
The high initial success rate and the low incidence of 
subsequent death and late recurrent AMI, as well as the 
sustained beneficial effect, suggest that PTCA is an e·ffective 
initial treatment strategy in patients with angina after a 
non-Q-wave AMI. 
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CHAPTER VIII 
RECOVERY OF REGIONAL MYOCARDIAL DYSFUNCTION FOLLOWING 
SUCCESSFUL CORONARY ANGIOPLASTY EARLY AFTER A NON-Q-WAVE 
MYOCARDIAL INFARCTION 
ABSTRACT 
More agressive therapy has been suggested for patients who 
sustain a non-Q wave myocardial infarction (MI) because of the 
frequency of subsequent unstable angina, recurrent MI and high 
mortality rate, when compared to patients with Q wave MI. 
Furthermore, repeated ischemic attacks early after a non-Q 
wave MI may lead to prolonged regional myocardial dysfunction. 
The present study was undertaken to investigate whether, in 
patients with angina early after a non-Q wave MI, the regional 
myocardial dysfunction of the infarct zone could be improved 
by successful coronary angioplasty. Between 1981 and 1986, 
coronary angioplasty was attempted in 61 patients within 30 
days (mean 15 ± 8) of a non-Q wave MI. All patients were 
symptomatic with 72% having unstable angina prior to 
angioplasty. The primary success rate was 86%. There were no 
deaths in this series during a mean follow-up of 20 months. 
Sequential global and regional left ventricular function were 
assessed before and 6 months after successful angioplasty. The 
global ejection fraction increased significantly from 60 ± 9 
to 67 ± 6% (p=0.0003). This significant increase in the global 
ejection fraction was primarily due to a significant 
improvement in the regional myocardial function of the infarct 
zone, even after subsidence of the compensatory 
hypercontractility of regions remote from the infarction. 
The results of the present study show not only that repeated 
ischemic attacks early after a non-Q wave MI may lead to 
prolonged regional myocardial dysfunction, but more 
importantly, that this depressed myocardium has the potential 
to achieve normal contraction after successful coronary 
angioplasty. 
INTRODUCTION 
The reported incidence of non-Q wave myocardial 
infarction (MI) varies between 20 and 36% of all acute MI 
(1-5) and seems to be increasing (6) probably as a result of 
therapeutic interventions employed before or during the acute 
symptomatic phase of MI that may minimize the extent of acute 
myocardial damage. Although non-Q wave MI and Q wave MI as 
classified by electrocardiographic results cannot always be 
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anatomically differentiated (7 ,8), it seems likely that they 
differ clinically, physiologically and prognostically as 
discussed by Spodick (9) • In particular, non-Q wave MI is 
generally associated with smaller amounts of myocardial 
necrosis, better left ventricular function and a lower 
incidence of in-hospital mortality when compared with Q wave 
MI. Despite these initially favorable features, evidence has 
accumulated that long-term mortality in these patients is 
similar to or even greater than that in patients with Q wave 
MI. The relatively high mortality rate of patients with non-Q 
wave MI seems to be related to unstable angina or subsequent 
recurrent MI in the same area (1-3,7,10-15) and may be 
prevented if recurrent MI can be averted with 
revascularization. These findings have understandably led some 
to recommend more agressive evaluation and treatment 
strategies for survivors of non-Q wave MI. The results of 
recently published data suggest that coronary angioplasty is 
an effective initial treatment strategy in patients with 
angina after a non-Q wave MI (16,17). 
Transient reduction in coronary blood flow may lead to 
prolonged post-ischemic ventricular dysfunction (18, 19). 
Repeated ischemic attacks early after a non-Q wave MI may 
aggravate regional myocardial dysfunction. The aim of this 
study was therefore to determine whether in patients with 
angina early after a non-Q wave MI, the regional myocardial 
dysfunction could be improved by coronary angioplasty. 
PATIENTS AND METHODS 
The study population consisted of 61 patients who 
underwent early coronary angioplasty between January 1982 and 
January 1987 for angina, either at rest or during submaximal 
exercise despite optimal pharmacologic therapy, within 30 days 
(mean 15 ± 8, range 2 to 30 days) after a non-Q wave MI. They 
represented 5% of our total coronary angioplasty population 
during the study period. All patients were symptomatic with 
72% having unstable angina prior to angioplasty. Non-Q wave MI 
was defined in this study as prolonged chest pain compatible 
with acute MI, associated with electrocardiographic ST-segment 
and T-wave abnormalities without progression to pathologic 
Q-waves, but with abnormal elevation of the creatinine kinase 
level (at least twice of the normal value) before any 
intervention. Post-infarction angina was considered unstable 
if it occurred at rest lasting for at least 15 minutes, 
associated with electrocardiographic manifestations of 
myocardial ischemia wj thout evidence of further myocardial 
necrosis. Patients were selected for coronary angioplasty if 
the ischemia-related lesion was suitable for dilatation. The 
selection was based only on the symptoms and the coronary 
anatomy and was not influenced by left ventricular function. 
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Angioplasty was considered successful when a reduction of the 
severity of the obstruction to less than 50% luminal diameter 
narrowing was achieved with abolition of acute ischemic 
symptoms without progression to MI, emergency surgery, or 
death. Restenosis was defined as a return of the diameter 
stenosis to more than 50% at follow-up. Clinical and 
angiographic data are summarized in table I. 
After the procedure, patients were monitored for 24 hours 
in the medium care unit. They were treated with nifedipine 60 
mg daily and acetylsalicylic acid 500 mg daily over a period 
of 6 months. All patients were followed at the outpatient 
clinic. Survival status, recurrent MI, angina pectoris, 
cardiac failure, bypass surgery and coronary angioplasty were 
recorded. Follow-up coronary and left ventricular angiography 
as well as exercise thallium-201 scintigraphy were obtained in 
the patients with initially successful angioplasty. 
Table I: Clinical characteristics 
n 
Male/female 
Age (median, yr) 
Previous CABG 
Previous PTCA 
Anterior/Inferior non-Q MI 
Peak CK enzyme level (median, U/1) 
Stable angina pectoris 
Unstable angina pectoris 
Median time from MI to PTCA (days) 
Single/double/triple vessel disease 
Total occlusion 
Single-vessel dilatation 
Multivessel dilatation 
61 
44/17 
57 (range 31-75) 
1 
2 
41/20 
387 (range 230-972) 
17 
44 
15 (range 2-30) 
44/13/4 
10 
57 
4 
CABG = coronary artery bypass graft; PTCA - percutaneous 
transluminal coronary angioplasty; MI = myocardial infarction; 
CK = creatinine phosphokinase. 
Quantitative Analysis of Left Ventricular and Coronary 
Angiography 
Global and regional left ventricular function was studied 
from the 30° right anterior oblique projection using an 
automated hardwired endocardial contour detector linked to a 
mini-computer. This method of analysis has previously been 
described in detail (20-24). The analysis of regional left 
ventricular function was based on automated, high resolution, 
frame to frame edge detection of left ventricular contour. 
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Figure 1. A. Exampleofthecomputer outputshowingtheend-diastolicand end-
systolic contours of the 30° RAO left ventriculogram. Systolic regional wall dis-
placement was determined along a system of 20 coordinates on the pattern of 
actual endocardial wall motion in normal individuals and generalized as a 
mathematical expression amenable to automatic data processing (20-24). B. 
The left ventricular end-diastolic cavity is divided into twenty half slices. The 
volume of each half slice is computed according to the given formula, R is radius 
and l is left ventricular long axis length. C. The regional contribution to global 
ejection fraction (CREF) is determined from the systolic decrease of volume of 
the half slice which corresponds to a particular wall segment. The systolic 
volume change is mainly a consequence ofthe decrease of radius (R) ofthe half 
slice. When normalized for end-diastolic volume, the systolic segmental 
volume change was considered as a parameter of regional pump function. D. 
The shaded zones represent the 10th - 90th percentiles area of CREF values in 
normal individuals. On the X-axis the CREF values of the anterior and infero-
posteriorwall areas are displayed(%), while on they-axis the segment numbers 
of the anterior wall (1-10) and of the infero-posterior wall (11-20) are depicted. 
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This system allows fast and reliable acquisition of single 
left ventricular contour, every 20 ms, all over a complete 
cardiac cycle. Figure 1 shows examples of the end-diastolic 
and end-systolic contours of the left ventriculogram as well 
as the segmental contribution to the global ejection fraction, 
as displayed by the analysis system. 
Quantitative analysis of the dilated coronary segment 
before and after angioplasty procedure and at follow-up 
coronary angiography were carried out with the 
computer-assisted Coronary Angiography Analysis System (CAAS), 
which has been described in detail previously (25,26). 
Exercise Thallium-201 Scintigraphy 
Patients performed symptom-limited exercise on the 
bicycle ergometer with stepwise increments of 20 watts every 
minute. The 3 orthogonal leads X Y Z of the Frank lead system 
were recorded. An ischemic response was defined as at least a 
0.1 mV ST-segment depression, occurring 0.08 sec after the J 
point. The maximum workload achieved was expressed as a 
percentage of the normal workload predicted for age, sex and 
height. Thallium scintigraphic imaging was performed in the 
anterior, 45 and 65 degree left anterior oblique views, 
immediately after injection of 1.5 mCi of thallium-201 at peak 
stress. The post-exercise images were obtained 4 hours later. 
Images were obtained with a Searle Phogamma V Camera and 
processed with computer interface as previously described 
(27). Defects with subsequent redistribution were considered 
to represent exercise-induced ischemia. Persistent defects 
without redistribution were considered to represent infarcted 
myocardium. 
Statistics 
Data are expressed as mean ± SD. Paired Student t tests 
were applied whenever appropriate. A p value of less than 0.05 
was considered significant. 
Table II: Angiographic data 
PTCA artery n Primary success 
Left anterior descending 40 34 (85%) 
Right 13 11 (85%) 
Left circumflex 11 10 (91%) 
Bypass graft 1 1 (100%) 
Total 65 56 (86%) 119 
RESULTS 
From the 61 patients who underwent coronary angioplasty 
for angina after a non-Q wave MI, 65 lesions were dilated 
(table II). Success was achieved in dilating the obstructed 
vessel in 52 patients (56 lesions). Clinical follow-up was 
obtained in all patients, at a mean interval of 20 (range 3 to 
59) months, and summarized in table III. In 9 patients, the 
attempted angioplasty was unsuccessful: in 5 because the 
vessel was found to be occluded at the time of attempted 
angioplasty, in 3 because the stenosis could not be crossed 
either with the guide wire or balloon catheter, and in 1 
because of major dissection. Of these 9 failure cases, 4 
underwent an emergency coronary bypass surgery, 4 were 
controlled by pharmacologic treatment, and 1 became 
asymptomatic. 
Table III: Mean clinical follow-up of 20 (range 3 to 59) months 
Acute Late 
Death 0 0 
Recurrent MI 3 3 
CABG 4 4 
Repeat PTCA 10* 
Pharmacologic therapy 8 
Asymptomatic 34 
* 2 patients underwent subsequent bypass surgery; 
abbrevations as in table I. 
Of the 52 successfully treated patients, 33 were 
asymptomatic and 2 had developed a non-fatal recurrent MI, one 
of whom underwent urgent coronary angioplasty. Seventeen 
patients developed recurrent angina and of these, 4 underwent 
elective bypass surgery, 77 (range 7 to 256) days after the 
initial procedure, 4 were controlled by pharmacologic therapy, 
and 9 underwent repeat coronary angioplasty 108 (range 1 to 
210) days after the initial procedure. Success was achieved in 
re-dilating the vessel in 8 patients. Of these, 7 patients 
were asymptomatic during the clinical follow-up and 1 
underwent elective bypass surgery after a third dilatation. 
In 2 patients the second dilatation was unsuccessful; 1 
underwent emergency bypass surgery and 1 developed a non-fatal 
recurrent MI. Furthermore, if coronary artery bypass surgery, 
recurrent MI, death or recurrent angina requ1r1ng 
pharmacologic therapy are considered events, 77% of the 
patients were event-free at 20 months after successful 
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angioplasty, while if any cardiac recurrence, including repeat 
coronary angioplasty, are considered events, only 63% of 
patients were event-free at 20 months (fig 2). 
Follow-Up Angiography 
Follow-up coronary angiography was obtained in 46 
patients (88%) at a mean of 5.1 (range 2 to 8) months after 
initially successful coronary angioplasty. Restenosis occurred 
in 16 patients (35%): 2 were asymptomatic, 10 underwent repeat 
coronary angioplasty, 2 underwent elective bypass surgery and 
2 were controlled by pharmacologic therapy. No restenosis was 
observed in 4 patients with recurrent angina after initially 
successful angioplasty, but all had triple vessel disease 
requiring either coronary bypass surgery (n 2) or 
pharmacologic treatment (n = 2). 
Computer-assisted quantitative analysis of the dilated 
coronary artery before and after the angioplasty procedure and 
at a follow-up were available in 37 patients who underwent an 
initially successful angioplasty (71%). The diameter stenosis 
was 69±11% before angioplasty, 32±9% immediately after 
angioplasty, and 34±12% at a follow-up angiography. 
Table IV: Global left ventricular hemodynamics (n 36) 
Before PTCA Follow-up P-value 
HR bpm 70 ± 12 70 ± 17 ns 
MAP mmHg 82 ± 12 85 ± 9 ns 
EDP mmHg 23 ± 10 19 ± 8 ns 
EDV ml/m2 73 ± 17 71 ± 15 ns 
ESV ml/m2 29 ± 12 24 ± 6 0.006 
sv ml/m2 44 ± 12 47 ± 11 0.08 
EF % 60 ± 9 67 ± 6 0.0003 
CI L/min/m2 3.0 ± 0.8 3.1 ± 0.8 ns 
Sequential changes in global left ventricular hemodynamics in 
the patients undergoing successful coronary angioplasty in whom 
adequate quality left ventriculogram was performed before the 
initial procedure as well as at a follow-up angiography (6 
months). HR =heart rate; MAP= mean aortic pressure; 
EDP = end-diastolic pressure; EDV = end-diastolic volume; 
ESV = end-systolic volume; SV = stroke volume; EF = global 
ejection fraction; CI = cardiac index; PTCA = percutaneous 
transluminal coronary angioplasty. 
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Figure 2. If coronary artery bypass surgery (CABG), recurrent myocardial 
infarction (re-MI}, death or recurrent angina requiring pharmacological therapy 
(RIMed} are considered events, 77% of the patients were event-free (Asympt.) 
at 20 months after initially successful angioplasty, while if any cardiac recurr-
ence, including repeat coronary angioplasty (Re-PTCA) is considered an event, 
only 63% of patients were event-free. 
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Figure 3. Sequential changes in regional contribution to global ejection fraction 
fromtheacute (before angioplasty, solid line) tothechronic(at6 months, dotted 
line) stage in patients with anterior and inferior non-a wave Myocardial infarc-
tion, undergoing successful coronary angioplasty. The initially depressed 
regional myocardial function ofthe infarct zone has the potential to achieve nor-
mal contraction after adequate reperfusion with coronaryangioplasty, resulting 
in a significant increase in global ejection fraction even after the disappearance 
of compensatory actions of the initially enhanced function of the non-ischemic 
zone. 
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Figure 4. Results of exercise thallium-201 scintigraphy (n = 37), 4.5 (range 1-11) 
months after initially succesfull angioplasty. A maximum workload of > 80% 
and> 100% predicted for age, sex and height was achieved in 92% and 54% of 
the patients, respectively. The majority of the patients (92%) were symptom-
free during the test; ST-segment depression was documented in 27%, and a 
reversible thallium-201 perfusion defect in the area supplied by dilated vessel 
was observed in 35% of the patients. 
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Quantitative Analysis of Global and Regional Left Ventricular 
Function 
Sequential left ventricular angiograms, before and 6 
(range 2 to 8) months after initially successful coronary 
angioplasty, of adequate quality sufficient to allow automated 
contour analysis were obtained in 36 patients undergoing 
successful coronary angioplasty (69%). Table IV shows the 
sequential changes in the global left ventricular function 
before coronary angioplasty and at follow-up angiography. The 
global ejection fraction increased significantly from 60±9% to 
67±6% (p=0.0003), and this was due to a significant decrease 
in end-systolic volume from 29±12 to 24±6 ml/m2 • This 
significant increase in the global ejection fraction was 
primarily due to a significant improvement in the regional 
contribution to ejection fraction of the infarct zone, as 
shown in figure 3. 
Exercise Thallium-201 Scintigraphy 
Electrocardiographic exercise testing and thallium-201 
scintigraphy was obtained in 37 patients (71%), 4.5 (range 1 
to 11) months after an initially successful angioplasty (fig 
4). A maximum workload of more than 80%, predicted for age, 
sex, and height, was achieved in 92% of the patients. 
Ninety-two percent of the patients were symptom-free during 
exercise; ischemic ST-T segment depression was induced in 27%, 
and a reversible thallium-201 perfusion defect in the area 
supplied by dilated vessel was documented in 35% of the 
patients. 
DISCUSSION 
The pathophysiologic basis of the apparent greater 
clinical instability after non-Q wave MI and the reason for 
loss of the initial prognostic advantage may be related to the 
degree of potentially jeopardized myocardium. Patients with 
non-Q wave MI appear to have more residual myocardial mass at 
risk as determined by exercise scintigraphy (4,11) for 
subsequent ischemia or necrosis. This hypothesis has been 
supported by several studies that found greater rates of 
angina, recurrent MI and sudden death among hospital survivors 
of non-Q wave MI than among those with Q wave MI (7,12,28-32). 
These findings support the concept of myocardial salvage 
through recanalization to prevent further loss of myocardium, 
for one might postulate that these patients are left with an 
"incomplete MI" with an area of the myocardium "at risk", and 
might therefore benefit from revascularization of the relevant 
artery. As coronary angioplasty might be an attractive option 
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in the management of these patients, the present study reports 
not only that coronary angioplasty can be performed safely and 
effectively in patients with angina early after a non-Q wave 
MI, but also that myocardium is capable of recovering function 
after successful coronary angioplasty. 
In most studies, the assessment of global ejection 
fraction has prevailed since it is relatively easily 
obtainable. Although there was significant improvement in 
global ejection fraction in our patients, the crucial question 
remains whether these differences can be ascribed to the 
salvage of previously jeopardized myocardium in the area 
supplied by dilated vessel. Therefore, analysis of left 
ventricular wall motion in the area at risk, which potentially 
should benefit most from correcting the residual stenosis, 
must be carried out in order to detect any real benefit of 
correcting the obstructive lesion. In fact, increased motion 
of the non-ischemic regions may keep the global ejection 
fraction within normal limits despite severe regional 
hypokinesia in the ischemic area. As this compensatory 
augmented motion in the non-ischemic area usually subsides 
chronically, the global ejection fraction has proved to be an 
unreliable and insensitive measure of assessing either the 
severity of hypokinesia in an ischemic region or the effect of 
therapeutic interventions in salvaging function. Here again, 
regional wall motion must be analyzed to adequately assess 
this effect. 
Many wall motion models have been proposed to approximate 
actual endocardial motion; this reflects the problems 
investigators have had in establishing a geometric frame work 
from which to judge whether the motion of the endocardial 
contour is normal or abnormal (33). All these methods assess 
wall motion in terms of extent of shortening at specific 
points on an axis reference system, although it is highly 
unlikely that a particular endocardial site coincides with one 
of these axes during the entire cardiac cycle. The wall motion 
analysis system we used is based on the motion pattern of 
small irregularities at the left ventricular endocardial 
border (endocardial landmarks) that can be detected in the 
contrast cineangiogram with the automated endocardial 
outlining system (20, 21) • This endocardial landmark pathway 
has been investigated in 23 normal human left ventricles and 
validated in pigs with metal endocardial markers inserted with 
a percutaneous, retrograde, transvalvular approach (22-24). 
This wall motion analysis is unaffected by the translation and 
rotation of the heart, thus permitting an actual study of the 
segmental wall motion and derived variables. 
Experimental studies (34) have shown that restriction of 
flow during reperfusion results in relative underperfusion of, 
and continued ischemia in, the subendocardium. Whole or 
partial reversal of the myocardium dysfunction occurs after 
successful coronary artery bypass surgery (35-39). The results 
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of the present study show not only that repeated ischemic 
attacks early after a non-Q wave MI may lead to prolonged 
regional myocardial dysfunction, but more importantly, that 
this "stunning" of the myocardium is capable of recovering 
function and has the potential to achieve normal contraction 
after a successful coronary angioplasty. In this study, global 
ejection fraction increased significantly from 60 ± 9 to 67 ± 
6%, an improvement primarily due to a significant improvement 
of the regional contribution to ejection fraction of the 
infarct zone even after subsequently subsidence of 
compensatory actions of the initially enhanced function of the 
non-ischemic zone (fig 3). These results suggest that in some 
patients reperfusion may need to be supplemented by additional 
procedure such as angioplasty in order to optimize the chances 
of obtaining full functional recovery. The additional value of 
angioplasty in preserving left ventricular function might help 
to explain the observed low mortality rate and other major 
cardiac events. 
On the other hand, these results might be biased by the 
selection of patients, the fact that it was uncontrolled and 
involved only patients with non-Q wave MI with both recurrent 
anginal symptoms and anatomy suitable for coronary 
angioplasty. Furthermore, myocardial dysfunction as a result 
of prolonged ischemia might improve when the ischemic attacks 
resolve spontaneously either as part of a natural healing 
process or as a result of pharmacologic therapy (40,41}. 
Therefore, randomization would have been desirable. However, 
it is difficult to justify this type of study in our patients 
population since these patients constitute a high-risk 
subgroup because of the presence of ongoing angina, either at 
rest or during submaximal exercise, despite optimal 
pharmacologic therapy. The incidence of angina recurring after 
acute MI varies from 18 to 57% (1,7,11,29,32,42-44). Such 
early post MI angina carries a poor short-and long-term 
prognosis (1,7,11,28-30,44-46). Although differences in 
pharmacologic treatment before and after angioplasty procedure 
may also play a role in the observed difference of left 
ventricular function, the present study shows that the 
regional wall motion improved selectively in the areas 
supplied by dilated artery rather than in the ventricle as a 
whole. 
We believe that the normalization of the antegrade flow 
after coronary angioplasty, evidenced by repeat angiography, 
and the sustained symptomatic benefit with no signs of 
ischemia in the majority of the patients undergoing exercise 
Thallium-201 scintigraphy, is the main reason for the observed 
recovery of myocardial function. 
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CHAPTER IX 
GENERAL COMMENTS AND CONCLUSIONS 
Coronary angioplasty has been shown to be an effective 
mode of therapy to enlarge the lumen diameter of stenosed 
coronary artery. The indications for coronary angioplasty in 
coronary artery disease have been widely expanded and so has 
the total number of angioplasty procedures. As coronary 
angioplasty might be an attractive option in the management of 
patients with acute myocardial ischemic syndromes, the present 
thesis shows not only that coronary angioplasty can be 
performed effectively in patients with acute ischemic 
syndromes, but also that global and regional left ventricular 
function can be improved after successful coronary angio-
plasty. However, these results may be biased by the selection 
of the patients and the fact that it is uncontrolled and 
involves only patients with anatomy suitable for coronary 
angioplasty. 
Coronary Angioplasty for Unstable Angina Pectoris 
Unstable angina pectoris is, by definition, an unstable 
state leading either to improvement or to culmination into 
myocardial infarction or death (1, 2) • Patients described as 
having unstable angina as originally advocated by Conti et al 
(3) can be further divided into 3 subgroups: a) recent onset 
angina pectoris; b) progressive effort angina with a 
deteriorating clinical pattern superimposed on chronic stable 
angina; and c) prolonged episodes of ischemic chest pain at 
rest. The first 2 groups of patients have a reasonably good 
prognosis and satisfactorily initial response to medical 
therapy (4-6). These patients can usually be evaluated for 
myocardial revascularization on an elective basis. Unstable 
angina is defined in this thesis as chest pain at rest lasting 
for at least 15 minutes associated with reversible electro-
cardiographic ST-T changes without clinical, electrocardio-
graphic and enzymatic evidences of further myocardial 
necrosis. The prognosis for this subset of patients has been 
shown to be significantly worse, especially if ischemic 
symptoms persist (7-10). This is the more so when optimal 
pharmacologic treatment with beta-blockers, nitrates and 
calcium-antagonists have proven to be inadequate (8,10). 
Since the causes of unstable angina are multifactorial 
(11-14) and within the same patients different 
pathophysiological mechanisms may occur at different times and 
in succession, it will be difficult to decide what optimal 
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therapy for that particular stage of the disease at that 
particular moment in time for that patient consists of. The 
uncertainty of outcome in a specific patient forces one to 
provide "maximal" treatment. Therefore, the management of 
unstable angina pectoris is first of all directed toward the 
relief of acute ischemia and secondly to the prevention of 
progression to myocardial infarction and we believe that 
immediate control of ischemia with stepwise intensification of 
pharmacologic treatment is the cornerstone of the management 
of these patients. If despite this tailored pharmacologic 
approach patients continue to have ischemic attacks, 
prolongation of what must be regarded as ineffective treatment 
should be avoided and a more definitive attempt at myocardial 
revascularization should be instituted without delay, in order 
to prevent progression to myocardial infarction and so to 
improve prognosis. 
Despite the latest substantial improvements in surgical 
techniques, cardioplegia, anaesthesia, and postoperative care, 
there is still no consensus as to the safety of surgery in the 
management of this subsets of patients and many centers 
continue to manage these patients medically. Acute surgery in 
those patients still carries a substantial risk with peri-
operative mortality rate varying from 1. 8% to 7. 7% and the 
incidence of perioperative myocardial infarction varying 
between 1% and 16.7% (15-19). In fact, in a recently published 
randomized prospective study (20), patients with unstable 
angina pectoris had similar outcomes whether they received 
pharmacologic therapy alone or surgical therapy. Coronary 
angioplasty, as an initial alternative to bypass surgery, has 
been shown to be effective for the treatment of patients with 
unstable angina either stabilized or refractory to optimal 
pharmacologic treatment (21-30) (table I). The reported lower 
success rates of 63 to 76% were achieved with the non-
steerable dilatation catheters. The more recent results were 
achieved with the more advanced steerable dilatation system 
and may therefore reflect the current state of the art. 
However, the initial success rate of coronary angioplasty in 
unstable angina remains lower than the rate of more than 90% 
achieved nowadays in patients with stable angina pectoris. 
This is mainly due to the higher complication rate in patients 
with unstable angina undergoing coronary angioplasty (table 
I). 
The reasons for this high major complication rate are 
related to the underlying pathophysiology leading to clinical 
instability and an increased risk on abrupt closure due to the 
formation of an acute occlusive thrombus (12-14,31-38). 
Although these data suggest that intracoronary thrombus is 
often present in patients with this acute coronary syndrome, 
only a few studies have examined the role of thrombolytic 
therapy (12, 39-46). Recently published randomized trials of 
thrombolysis in unstable angina further confirm the potential 
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benefit of thrombolytic therapy in this setting (43,44), 
although it is associated with a relatively high incidence of 
bleeding (43). Thrombolysis has been used in our patients as a 
treatment of abrupt vessel occlusion during coronary 
angioplasty and not as a primary or preventive therapy. The 
reason for this is, firstly, that it will be not logic to 
treat preventively all patients with unstable angina, since 
only 10% of these patients presented with acute complication. 
Secondly, that the haemorrhagic risks inherent to the 
thrombolytic therapy using either specific clot lysing agents 
or systemic fibrinolytic agents are not negligible and 
therefore may not be imposed to this population as a whole. 
This strategy has lead to the improved immediate outcome of 
coronary angioplasty for unstable angina by avoiding urgent 
surgery and procedure-related myocardial infarction (chapter 
III). This clinical observation does not pretend to answer the 
question whether thrombolytic agent should be used as part of 
the therapeutic arsenal for unstable angina in order to 
cool-off the clinical instability, but the reported experience 
should be viewed as a rescue strategy during angioplasty of 
which value should be prospectively assessed in a randomized 
fashion. 
Furthermore, future studies should be directed toward 
defining subgroups of patients with unstable angina who will 
most likely benefit from thrombolytic therapy and toward the 
design of therapeutic schemes associated with a reduced 
bleeding frequency. 
After initial successful coronary angioplasty the 
prognosis is excellent, with a low incidence of late mortality 
(up to 3%) and a low occurrence of late nonfatal myocardial 
infarction (up to 3.5%), while the angiographic restenosis 
rate and recurrence of angina after an initial successful 
coronary angioplasty appears to be comparable to those of 
patients with stable angina (21,26). 
We believe that coronary angioplasty is an effective 
treatment with a high initial success rate but with an 
increased risk of major complications in patients with either 
refractory or initially stabilized unstable angina. However, 
it should be appreciated that current results are obtained 
from selected groups of patients, those with predominantly 
single vessel disease and well preserved left ventricular 
function. To expand the potential use of coronary angioplasty 
as an alternative to coronary artery bypass surgery in 
patients with unstable angina and multivessel disease, 
dilatation of only the "culprit" lesion has been recommended 
as an initial approach to stabilize the patient's condition 
(46,47). This strategy is successful in the majority of the 
patients. However, it is associated, not unexpectedly, with a 
higher occurrence of angina pectoris after the procedure, 
which may necessitate later elective coronary artery bypass 
surgery or elective coronary angioplasty of other vessels 
(47). 
Coronary Angioplasty in Acute Myocardial Infarction 
Limitation of myocardial infarct size through salvage of 
ischemic myocardium in the region undergoing necrosis is the 
major goal in the management of patients with acute myocardial 
infarction in order to preserve cardiac function and to 
improve prognosis. The concept of limiting infarct size by 
early recanalization of occluded coronary artery in acute 
myocardial infarction has been proven in clinical practice to 
be effective and the beneficial effect of thrombolytic agents 
in acute myocardial infarction on infarct size, left 
ventricular function, clinical course and patient survival has 
been convincingly shown (48-54). Such therapy, however, is 
usually associated with an increased rate of early 
postinfarction angina and reinfarction (50,55-57). Coronary 
angioplasty has been applied as an effective treatment in the 
management of patients with acute myocardial infarction since 
1982 (55). In fact, there are 3 different strategies that 
involve angioplasty during acute myocardial infarction. 
Firstly, to perform an immediate angioplasty without any 
thrombolytic agent on board; secondly, to perform immediate 
angioplasty but in conjunction with a thrombolytic agent; and 
thirdly, to perform, for some logistic limitations or for 
clinical indications, a socalled delayed angioplasty following 
thrombolysis. The advantages and disadvantages of these 
different strategies are listed in tables II-IV. 
Table II: Immediate coronary angioplasty without preceding 
thrombolysis 
advantages: 
optimizes antegrade flow 
- potentiates mechanically the natural lysis phenomenon 
avoids the bleeding complications of thrombolytic therapy 
applicable to patients with contra indication for 
thrombolytic therapy 
economizes time and money by combining a single diagnostic 
and therapeutic laboratory session. 
disadvantages: 
potentially risk in the setting of an acute myocardial 
infarction 
"blind procedure": uncertainty as to the distal anatomy and 
the proper size of balloon to be used 
dislocation of thrombotic material 
+t 
- sudden reperfusion with reperfusion damage (02 and Ca paradox?) 
no alteration of thrombogenic state 
logistics of staffing and maintaining an interventional 
laboratory around the clock. 
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Table III: Immediate coronary angioplasty after initial 
thrombolysis 
advantages: 
- more gradual reperfusion 
better delineation of the stenotic lesion and the distal 
anatomy prior to intervention 
rationale for intervention based on critical evaluation of 
the residual stenosis 
informed choice of the balloon size. 
disadvantages: 
- delay in achievement of optimal antegrade flow 
dilatation of a "recanalized" lesion may be complicated by 
a total occlusion 
uncertainty as to the degree of completion of the lytic 
process 
loss of time and money in exchanging therapeutic equipment 
for intervention 
staffing and maintenance of an interventional laboratory 
around the clock 
Table IV: Delayed coronary angioplasty after lysis 
advantages: 
elective procedure in optimal conditions after more 
comprehensive clinical assessment 
availability of surgical back up on a non-emergency basis 
persistent lytic state may have resulted in further (and 
even complete) thrombolysis 
disadvantages: 
potentially risk for intercurrent reocclusion 
additional cost and patient discomfort due to need for a 
second procedure 
Interventional risk exposure in "asymptomatic" patients 
without scientific validation of benefit. 
Surgical emergency in patients with persisting lytic state 
and recent myocardial damage. 
138 
Table V: Success rate of immediate coronary angioplasty in 
acute myocardial infarction 
n success rate % 
Without thrombolysis 
Hartzler 1983 (58) 12 92 
Pepine 1984 (59) 8 100 
Holmes 1985 (60) 26 85 
O'Neill 1986 (62) 29 83 
Rutherford 1986 (63) 222 91 
Marco 1987 (64) 43 95 
Topol 1987 (65) 11 82 
Rothb~um 1987 (61) 151 87 
After succesful lysis 
Meyer 1982 (55) 21 81 
Serruys 1983 (66) 18 100 
Gold 1984 (67) 12 75 
Yasuno 1984 (68) 25 72 
Papapietro 1985 (69) 11 82 
Erbel 1985 (70) 46 74 
Holmes 1985 (60) 15 73 
Erbel 1986 (71) 69 65 
Kitazume 1986 (72) 16 88 
Suryapranata 1987 (73) 46 96 
Topol 1987 (65) 15 100 
Suryapranata 1988 (74) 115 89 
Stack 1988 (75) 216 90 
After failed lysis 
Gold 1984 (67) 16 69 
Holmes 1985 (60) 14 71 
Papapietro 1985 (69) 7 57 
Prida 1986 (76) 18 83 
Kitazume 1986 (72) 6 83 
Fung 1986 (77) 13 92 
Topol 1987 (65) 6 83 
The initial results of coronary angioplasty with or 
without thrombolysis are listed in table V (55. 58-77). From 
these studies it appears that coronary angioplasty is a safe 
and effective therapy in the management of patients with acute 
myocardial infarction. However, the precise role, the timing 
and patient selection for coronary angioplasty in acute 
myocardial infarction is still unsettled and requires further 
evaluation. 
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The value of coronary angioplasty during thrombolytic 
therapy has recently been analyzed in several randomized 
trials {65,71,78-80). The results summarized in table VI 
indicate that immediate angioplasty did not lead to further 
limitation of infarct size, nor to further preservation of 
global left ventricular function, although Erbel et al {71) 
reported some further improvement in regional myocardial 
function of the infarct zone after successful angioplasty in a 
subgroup of patients with anterior infarction. In addition, 
the number of patients with reocclusion in spite of immediate 
angioplasty .is disturbingly high, particularly in patients 
treated with rt-PA and angioplasty. The higher tendency to 
reocclude after rt-PA might in part be related to the 
"thrombus specificity" of rt-PA. Remnants of thrombus 
material, together with the endothelial trauma caused by 
angioplasty and subintimal bleeding may lead to higher 
tendency of thrombosis, whereas early re-thrombosis after 
coronary angioplasty in patients treated with streptokinase 
may be prevented by the depletion of fibrinogen and other 
coagulation factors due to streptokinase. Hospital mortality 
was somewhat lower after immediate angioplasty in the German 
study (71) but was higher, although not significantly, in the 
other major trials (65, 78-80) (table VI). Additional early 
revascularization was less frequently necessary after 
immediate angioplasty. Furthermore, Guerci et al (81) reported 
the results of a smaller sized randomized, prospective 
double-blind placebo controlled trial of intravenous rt-PA 
with subsequent random assignment of patients to undergo or 
not undergo delayed-elective angioplasty (72 hours). Their 
data show that early intravenous rt-PA and delayed angioplasty 
is beneficial in acute myocardial infarction. Most recently 
published studies comparing a strategy of immediate 
angioplasty with delayed-elective angioplasty showed no 
advantages over immediate angioplasty (table VI). However, 
among the patients assigned to elective angioplasty (7 days), 
18% had definite recurrent ischemia (most of which occurred 
within 24 hours of admission) requ1r1ng crossover to an 
emergency procedure (79), whereas the remaining patients had 
the procedure as planned at the seven-day point. These 
findings suggest that after successful intravenous thrombo-
lysis, the elective angioplasty strategy requires careful 
monitoring for recurrent ischemia, with early angiography and 
consideration of angioplasty when ischemia occurs. 
Future studies should be directed toward defining a 
subgroup of patients with acute myocardial infarction who will 
most likely benefit from coronary angioplasty after 
thrombolysis. More specifically, to identify the high risk 
group of patients with persistent occlusion of the 
infarct-related vessel despite early thrombolysis and to 
predict accurately the risk of reocclusion. Likewise, there is 
no single reliable marker of reperfusion available and there 
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are no angiographic parameters which allow accurate prediction 
of reocclusion. Furthermore, even the acute assessment of 
regional wall motion will not tell us the viability of the 
myocardium at risk. At present, we are conducting a randomized 
trial of early intravenous rtPA alone versus early intravenous 
rtPA followed by delayed-elective coronary angioplasty. 
Emergency angioplasty without thrombolytic therapy 
should probably be performed in patients who develop coronary 
occlusion during or after diagnostic catheterization, in whom 
mechanical recanalization could be performed without any 
delay. Furthermore, emergency angioplasty may be offered to 
those patients who are likely to benefit from thrombolytic 
therapy, but in whom such therapy cannot be performed because 
of enhanced risk of bleeding. 
Coronary Angioplasty for Early Postinfarction Angina 
The recurrence of angina after sustained myocardial 
infarction but still during the hospitalization period is 
reported to be between 18-57% and is considered to have a poor 
short- and long-term prognosis (82-87). The incidence of early 
nonfatal reinfarction in patients with early postinfarction 
angina ranges between 19-34% (82,83). Reinfarction in these 
patients is therefore a serious complication as it carries an 
Table VII: Incidence of non-Q wave myocardial infarction (NQMI) 
Reference n NQMI % 
Abbott 1973 (90) 230 78 35 
Madias 1974 (91) 104 43 41 
Rigo 1975 (92) 159 48 31 
Genovese 1976 (93) 500 22 4 
Cannom 1976 (94) 188 40 21 
Rothkopf 1979 (95) 43 10 23 
Fabricius 1979 (96) 276 98 36 
Thanavaro 1980 (97) 745 124 17 
Mahony 1980 (98) 635 141 22 
Marmor 1981 (83) 200 58 29 
BRAT Trial 1982 (99) 3837 806 21 
Krone 1983 (100) 593 94 16 
Coll 1983 (101) 458 28 6 
Maisel 1985 (102) 1253 227 22 
Connolly 1985 (103) 1221 353 29 
Theroux 1986 (104) 448 157 35 
Boden 1986 (105) 538 194 36 
Gibson 1986 (89) 241 87 36 
Huey 1987 (106) 150 35 23 
Goldberg 1987 (107) 2451 882 36 
Table VIII: Non-Q wave myocardial infarction (NQMI): incidence 
of reinfarction (RE-MI) and mortality 
RE-MI Mortality % 
Reference NQMI % Early 1-YR 2-YR 5-YR 
Abbott 1973 (90) 78 23 
Madias 1974 (91) 43 9 
Rigo 1975 (92) 48 13 19 
Madigan 1976 (87) 50 2 
Cannom 1976 (94) 40 8 33 
Kossowsky 1976 (108) 35 35 11 
Szklo 1978.(109) 283 18 28 
Fabricius 1979 (96) 98 49 
Rothkopf 1979 (95) 10 20 
Poehllman 1980 (110) 50 13 8 
Thanavaro 1980 (97) 124 3 
Hutter 1981 (88) 67 57 9 52 
Marmor 1981 (83) 58 43 12 
Hollander 1984 (111) 38 18 21 
Maisel 1985 (102) 277 8 8 12 
Connolly 1985 (103) 353 6 
Zema 1985 (112) 28 4 
Gibson 1986 (89) 87 18 9 
Gibson 1986 (113) 576 7 4 
Goldberg 1987 (107) 882 12 15 21 41 
inhospital mortality of 20-36% versus 9-13% for patients 
without reinfarction (83,85). The one year survival rate was 
76% for those with reinfarction versus 91% for those without 
reinfarction (85). Particularly non-Q wave infarctions have 
shown to be associated with a higher incidence of recurrent 
infarction (83,87-89). Tables VII and VIII summarize the 
incidence and outcome of patients with non-Q wave myocardial 
infarction (83,87-113). 
The problems of definitive therapy and the timing of 
therapy are more difficult. The high incidence of recurrent 
myocardial infarction and unstable angina in patients with 
non-Q wave myocardial infarction call for some prophylactic 
measure to prevent further loss of myocardium. One might 
postulate that these patients are left with an "incomplete 
myocardial infarction" with an area of the myocardium "at 
risk", and might therefore benefit from revascularization of 
the relevant artery. 
The first reports (114-121) of patients undergoing 
surgical revascularization early after myocardial infarction 
noted an increased operative mortality compared to that of 
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other patients undergoing revascularization months or years 
after myocardial infarction. Patients treated surgically 
within the first 7 days after myocardial infarction 
experienced ·twice the mortality of those treated surgically 
after 8 to 30 days and more than threefold the mortality of 
those treated surgically more than 30 days after myocardial 
infarction (119). However, several investigators (122-124) 
have demonstrated that surgical intervention is feasible and 
safe early in the course of non-Q wave myocardial infarction 
with the incidence of perioperative myocardial infarction 
between 1% to 10. 7%, incidence of in-hospital death between 
1.9 to 3.6%, late death in 1% and angina-free survival between 
68 to 96% during follow-up period of 15 to 29 months. Despite 
the substantial improvement in surgical techniques and 
postoperative care associated with the consequent lower 
mortality and better long-term results (125-128), there is 
still no consensus as to the safety of surgery in the early 
post myocardial infarction phase and many centers continue to 
manage these patients medically. Accordingly, current strategy 
for the management of patients with early postinfarction 
angina is aimed at delaying surgery to such a time when it can 
be performed with the least inherent risks. However, in 
patients with severe recurrent angina, the situation may 
demand an early intervention. 
Coronary angioplasty in this situation has been shown to 
be an attractive alternative to surgical revascularization 
(129-132) (Table IX). However, the procedural complications 
are definitely more frequent in this setting than with 
elective coronary angioplasty. A complication resulting in a 
myocardial infarction occurred in up to 8% and acute surgery 
was required in up to 12% of the patients (Table IX). This 
relatively high complication rate in postinfarction angina may 
be related to the state of "activity" of the ischemia prod-
ucing lesion. Intracoronary instrumentation may for a variety 
of reasons induce total vessel obstruction with resulting 
re-infarction. The available data suggest that coronary 
angioplasty performed early after acute myocardial infarction 
is an effective procedure in a subset of patients who have 
preserved but jeopardized left ventricular function, 
predominant single vessel disease, and an anatomy suitable for 
coronary angioplasty. However, it remains to be determined 
whether the same benefits can be achieved in patients with 
early postinfarction angina and multivessel disease, or in 
those who have reduced left ventricular function. 
CONCLUSION 
Recent randomized studies aimed at establishing the 
merits of current pharmacologic treatment, current bypass 
surgery and coronary angioplasty in the management of patients 
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with acute myocardial ischemic syndromes are lacking. Until 
further information becomes available we would propose the 
following practical approach. Patients with unstable angina or 
early postinfarction angina should initially receive prompt 
management with stepwise intensification of pharmacologic 
therapy in an attempt to achieve stability. Early angiography 
and revascularization is indicated if this approach fails and 
ischemic episodes continue in spite of "maximum" medical 
management. Coronary angioplasty is indicated when a stenosis, 
technically suitable for dilatation, is found to be responsi-
ble for the unstable state. The decision in favour of coronary 
angioplasty in patients with single vessel disease is easy to 
make. In the presence of multivessel disease some uncertainty 
remains. Patients with left main stem disease or severe 
multi-vessel disease should be scheduled for coronary artery 
bypass surgery. However, in selected patients with multivessel 
disease one might prefer dilatation of the ischemia related 
vessel only, as opposed to total revascularization by multiple 
dilatations or bypass surgery, since this can be performed 
faster and so reduce hospital stay. Furthermore, thrombolytic 
therapy in patients with unstable angina to reduce or treat 
complications during coronary angioplasty needs further study. 
Management of patients with an evolving myocardial 
infarction should aim at early reperfusion. Intravenous 
administration with an effective thrombolytic agent should 
begin as soon as possible, preferably before hospitalization. 
The available data on the use of coronary angioplasty are 
conflicting and no clear answers as yet have emerged about the 
additional value of angioplasty in acute myocardial 
infarction. Current data indicate that patients with acute 
myocardial infarction should be considered for delayed-
elective angiography and revascularization only when ischemia 
recurs. While immediate coronary angioplasty with or without 
thrombolysis should not be recommended as a routine procedure 
in all patients, it should be restricted to those with a 
remaining severe stenosis or those with contraindications for 
thrombolytic therapy. This approach would allow for first 
lytic treatment in community hospitals and for transfer of 
selected patients for delayed-elective evaluation and 
revascularization procedures to well-equipped centers without 
inflicting undue strain and costs on the medical system. In 
these patients an elective procedure would allow for more 
careful evaluation and decision making and is likely to result 
in a higher success rate than immediate angioplasty. However, 
it should be appreciated that this recommendation is obtained 
from studies in which the combination of rt-PA and coronary 
angioplasty is used. This combination may be the cause of the 
high acute and early reocclusion rate, which could be less if 
the combination of streptokinase and coronary angioplasty is 
used, due to the longacting systemic effects of streptokinase. 
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Coronary angioplasty has now obtained a definitive place 
in the treatment of acute myocardial ischemic syndromes. 
Research should be increased to further improve the technique, 
to accurately define the indications for and to study the 
extent (single vessel versus multivessel dilatation) and the 
timing of dilatation in this group of acutely ill patients. 
Furthermore, restenosis and reocclusion rates are currently 
disappointingly high and pose a serious problem which needs to 
be resolved, either by better pharmacologic approach or 
possibly by introduction of a prosthesis such as intravascular 
stents (133) • 
REFERENCES 
1. Cairns JA, Fantus JG, Klassen GA. Unstable angina 
pectoris. Am Heart J 1976; 92: 373-386. 
2. Scanlon PJ. The intermediate coronary syndrome. Prog 
Cardiovasc Dis 1981; 23: 351-364. 
3. Conti CR, Brawley RK, Griffith LSC, Pitt B, Humphries JO, 
Gott VL, Ross RS. Unstable angina pectoris: morbidity and 
mortality in 57 consecutive patients evaluated 
angiographically. Am J Cardiol 1973; 32: 745-750. 
4. Harris PH, Harrell FE, Lee KL, Behar VS, Rosati RA. 
Survival in medically treated coronary artery disease. 
Circulation 1979; 60: 1259-1269. 
5. Duncan B, Fulton M, Morrison SL, Lutz W, Donald KW, Kerr 
F, Kirby BJ, Julian DG, Oliver MF. Prognosis of new and 
worsening angina pectoris. Br Med J 1976; 1: 981-985. 
6. Roberts KB, Califf RM, Harrell FE, Lee KL, --pryor DB, 
Rosati RA. The prognosis for patients with new onset 
angina who have undergone cardiac catheterization. 
Circulation 1983; 68: 970-978. 
7. Krauss KR, Hutter AM, De Sanctis RW. Acute coronary 
insufficiency: course and follow-up. Arch Intern Med 1972; 
129: 808-813. 
8. Gazes PC, Mobley EM, Faris HM, Duncan RC, Humphries CB. 
Preinfarctional (unstable) angina: a prospective ten year 
follow-up. Circulation 1973; 48: 331-337. 
9. Bertolasi CA, Trong CJE, Riccitelli MA, Villamayor RM, 
Zuffardi E. Natural history of unstable angina with 
medical or surgical therapy. Chest 1976; 70: 596-605. 
10. Olson HG, Lyons KP, Aronow WS, Stinson RJ, Kuperus J, 
Waters HJ. The high-risk angina patients. Circulation 
1981; 64: 674-684. 
11._Maseri A, L'Abbate A, Baroldi G, Chierchia S, Marzilli M, 
Ballestra AM, Severu S, Parodi 0, Biagini A, Distante A, 
Pesola A. Coronary vasospasm as a possible cause of 
myocardial infarction: a conclusion derived from the study 
of "preinfarction" angina. - N Engl Med 1978; 299: 
1271-1277. 
147 
12. Mandelkorn JB, Wolf NM, Singh S, Schechter JA, Kersh RI, 
Rodgers DM, Workman MB, La Porte SM, Meister SG. 
Intracoronary thrombus in nontransmural myocardial 
infarction and in unstable angina pectoris. Am J Cardiol 
1983; 52: 1-6. 
13. Davies MJ, Thomas DC. Plaque fissuring - the cause of 
acute myocardial infarction, sudden ischemic death and 
crescendo angina. Br Heart J 1985; 53: 363-371. 
14. Falk E. Unstable angina with fatal outcome: dynamic 
coronary thrombosis leading to infarction or sudden death. 
Circulation 1985; 71: 699-708. 
15. Ahmed M, Thompson R, Seabra-Gomes R, Rickards A, Yacoub M. 
Unstable angina. A clinico arteriographic correlation and 
longterm results of early myocardial revascularization. J 
Thorac Cardiovasc Surg 1980; 79:609-
16. Brawley RK, Merrill W, Gott VL, Donahoo JS, Watkins L, 
Gardner TJ. Unstable angina pectoris. Factors influencing 
operative risk. Ann Surg 1980; 19:745. 
17. Rahimtoola SH, Nunley D, Grunkemeier G, Tepley J, Lambert 
L, Starr A. Ten year survival after coronary bypass 
surgery for unstable angina. N Engl J Med 1983; 
308:6 76-681. 
18. Cohn LH, O'Neill A, Collins JJ. Surgical treatment of 
unstable angina up to 1984. In "Unstable Angina - Current 
concepts and management". Editors PG Hugenholtz and BS 
Goldman. Schattauer-Stuttgart, New York 1985. pp 279-286. 
19. Goldman BS, Weisel RD, Christakis G, Katz A, Scully HE, 
Mickleborough LM, Baird RJ. Predictors of outcome after 
coronary artery bypass graft surgery for stable and 
unstable angina pectoris. In "Unstable Angina - Current 
concepts and managements". Editors PG Hugenholtz and BS 
Goldman. Schattauer Stuttgart, New York 1985. pp 
319-329. 
20. Luchi RJ, Scott SM, Deupree RH. Comparison of medical and 
surgical treatment for unstable angina pectoris. N Engl J 
Med 1987; 316: 977-984. 
21. Faxon DP, Detre KM, McGabe CH, Fisher L, Holmes DR, Cowley 
J, Bourassa MG, van Raden M, Ryan TJ. Role of percutaneous 
transluminal coronary angioplasty in the treatment of 
unstable angina: report from the National Heart, Lung and 
Blood Institute Percutaneous Transluminal Coronary 
Angioplasty and Coronary Artery Surgery Study Registries. 
Am J Cardiol 1983; 53 (12):131C-135C. 
22. Quigley PJ, Erwin J, Maurer BJ, Walsh MJ, Gearty GF. 
Percutaneous transluminal coronary angioplasty in unstable 
angina; comparison with stable angina. Br Heart J 1986; 
55: 227-230. 
23. de Feyter PJ, Serruys PW, Suryapranata H, Beatt K, van den 
Brand M. Coronary angioplasty early after the diagnosis of 
unstable angina. Am Heart J 1987; 114: 48-54. 
148 
24. Steffenino G, Meier B, Finci L, Rutishauer W. Follow-up 
results of treatment of unstable angina by coronary 
angioplasty. Br Heart J 1987; 57: 416-419. 
25. Williams DO, Riley RS, Singh AK, Gewirtz H, Most AS. 
Evaluation of the role of coronary angioplasty in patients 
with unstable angina pectoris. Am Heart J 1981; 102:1-9. 
26. Meyer J, Schmitz HJ, Kiesslich T, Erbel R, Krebs W, Schulz 
W, Bardos P, Minale C, Messmer BJ, Effert s. Percutaneous 
transluminal coronary angioplasty in patients with stable 
and unstable angina pectoris: analysis of early and late 
results. Am Heart J 1983; 106:973-980. 
27. de Feyter PJ, Serruys PW, van den Brand M, Balakumaran K, 
Mochtar B, Soward AL, Arnold AER, Hugenholtz PG. Emergency 
coronary angioplasty in refractory unstable angina. N Engl 
J Med 1985; 313:342-347. 
28. Timmis AD, Griffin B, Crick JCP, Sowton E. Early 
percutaneous transluminal coronary angioplasty in the 
management of unstable angina. Int J Cardiol 1987; 14: 
25-31. 
29. Plokker HWT, Ernst SMPG, Bal ET, van den Berg ECJM, Mast 
GEG, Feltz TA, Ascoop CAPL:Percutaneous transluminal 
coronary angioplasty in patients with unstable angina 
pectoris refractory to medical therapy. Cath Cardiovasc 
Diagn 1988; 14: 15-18. 
30. Sharma B, Wyeth RP, Kolath GS, Gimenez HJ, Franciosa JA. 
Percutaneous transluminal coronary angioplasty of one 
vessel for refractory unstable angina pectoris: efficacy 
in single and multivessel disease. Br Heart J 1988; 59: 
280-286. 
31. Ischinger T, Gruentzig AR, Meier B, Galan K. Coronary 
dissection and total coronary occlusion associated with 
percutaneous transluminal coronary angioplasty: 
significance of initial angiographic morphology of 
coronary stenoses. Circulation 1986; 72: 1371-1378. 
32. Mabin TA, Holmes DR, Smith HC, Vlietstra RE, Bove AA, 
Reeder GS, Chesebro J, Bresnahan JF, Orszulak TA. 
Intracoronary thrombus: role in coronary occlusion 
complicating percutaneous transluminal coronary 
angioplasty. J Am Coll Cardiol 1985; 5: 198-202. 
33. Holmes DR, Hartzler GO, Smith HC, Fuster V. Coronary 
artery thrombosis in patients with unstable angina. Br 
Heart J 1981; 45: 411-416. 
34. Capone G, Wolf NM, Meyer B, Meister SG. Frequency of 
intracoronary filling defects by angiography in angina 
pectoris at rest. Am J Cardiol 1985; 56: 403-406. 
35. Zack PM, Ischinger T, Aker UT, Dincer B, Kennedy HL. The 
occurrence of angiographically detected intracoronary 
thrombus in patients with unstable angina pectoris. Am 
Heart J 1984; 108: 1408-1412. 
149 
36. Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux 
A, Kaas R, Blanche C, Matloff J, Morgenstern L, Ganz W, 
Swan HJC, Forrester J: Coronary angioscopy in patients 
with unstable angina pectoris. N Engl J Med 1986; 315: 
913-919. 
37. Vetrovec GW, Cowley MJ, Overton H, Richardson DW. 
Intracoronary thrombus in syndromes of unstable myocardial 
ischemia. Am Heart J 1981; 102: 1202-1208. 
38. Ambrose JA, Winters SL, Arora RR, Heft JL, Goldstein J, 
Rentrop KP, Gorlin R, Fuster V. Coronary angiographic 
morphology in myocardial infarction: A link between the 
pathogenesis of unstable angina and myocardial infarction. 
J Am Coll Cardiol 1985; 6: 1233-1238. 
39. Vetrovec GW, Leinbach RC, Gold HK, 
Intracoronary thrombolysis in syndromes 
ischemia: angiographic and clinical results. 
1982; 104: 946-952. 
Cowley MJ. 
of unstable 
Am Heart J 
40. Shapiro EP, Brinker JA, Gottlieb SO, Guzman PA, Bulkley 
BH. Intracoronary thrombolysis 3 to 13 days after acute 
myocardial infarction for postinfarction angina pectoris. 
Am J Cardiol 1985; 55: 1453-1458. 
41. Lawrence JR, Shepherd JT, Bone I, Rogen AS, Fulton WFM. 
Fibrinolytic therapy in unstable angina pectoris, a 
controlled clinical trial. Throm Res 1980; 17: 767-777. 
42. Telford AM, Wilson C. Trial of heparin versus atenolol in 
prevention of myocardial infarction in intermediate 
coronary syndrome. Lancet 1981; I: 1225-1228. 
43. Gold HK, Johns JA, Heinbach RC, Yasuda T, Grossbard E, 
Zusman R, Collen D: A randomized, blinded, 
placebo-controlled trial of recombinant tissue-type 
plasminogen activator in patients with unstable angina 
pectoris. Circulation 1987; 75: 1192-1199. 
44. Topol EJ, Nicklas JM, Kander N, Walton JA, Ellis SG, Sanz 
ML, Gorman L, Pitt B: Need for definitive coronary 
revascularization despite intravenous tissue plasminogen 
activator (tPA) for unstable angina: results of a 
randomized, double-blinded, placebo-controlled trial. Am J 
Cardiol 1988; (submitted). 
45. Ambrose JA, Hjemdahl-Monsen C, Borrico S, Sherman W, Cohen 
M, Gorlin R, Fuster V. Quantitative and qualitative 
effects of intracoronary streptokinase in unstable angina 
and non-Q wave infarction. J Am Coll Cardiol 1987; 9: 
1156-1165. 
46. Wohlgelernter D, Cleman M, Highman HA, Zaret BL. 
150 
Percutaneous transluminal coronary angioplasty of the 
"culprit lesion" for management of unstable angina 
pectoris in patients with multivessel coronary artery 
disease. Am J Cardiol 1986; 58: 460-464. 
47. de Feyter PJ, Serruys PW, Arnold A, Simoons ML, Wijns W, 
Geuskens R, Soward A, van den Brand M, Hugenholtz PG. 
Coronary angioplasty of the unstable angina related vessel 
in patients with multivessel disease. Eur Heart J 1986; 7: 
460-467. 
48. ISIS Steering Committee. Intravenous streptokinase given 
within 0-4 hours of onset of myocardial infarction reduced 
mortality in ISIS-2. Lancet 1987; 1: 502-507. 
49. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, 
Fritz JK. Western Washington randomized trial of 
intracoronary streptokinase in acute myocardial 
infarction: a 12 month follow up report. N. Engl J Med 
1985; 312: 1073-1078. 
50. Simoons ML, Serruys PW, van den Brand M, Bar F, de Zwaan 
C, Res J, Verheugt FWA, Krauss XH, Remme WJ, Vermeer F, 
Lubsen J •. Improved survival after early thrombolysis in 
acute myocardial infarction. A randomised trial by the 
Interuniversity Cardiology Institute in the Netherlands. 
Lancet 1985; II:578-581. 
51. Gruppo Italiano Per la Studio Della Streptochinasi 
Nell-Infarcto Miocardio (GISSI). Effectiveness of 
intravenous thrombolytic treatment in acute myocardial 
infarction. Lancet 1986; I: 397-401. 
52. Serruys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns 
W, van den Brand M, Bar F, Krauss XH, Remme WJ, Res J, 
Verheugt FWA, van Domburg R, Lubsen J, Hugenholtz PG. 
Preservation of global and regional left ventricular 
function after early thrombolysis in acute myocardial 
infarction. JAm Coll Cardiol 1986; 7:729-742. 
53. I.S.A.M. Study Group. A prospective trial of intravenous 
streptokinase in acute myocardial infarction. (I.S.A.M.) N 
Engl J Med 1986; 314: 1465-1472. 
54. White HD, Robin ChB, Norris RM et al: Effect of 
intravenous streptokinase on left ventricular function and 
early survival after acute myocardial infarction. N Engl J 
Med 1987; 317: 850-855. 
55. Meyer J, Merx W, Schmitz H, Erbel R, Kiesslich T, Dorr R, 
Lambertz H, Bethge C, Krebs W, Bardos P, Minale C, Messmer 
BJ, Effert S. Percutaneous transluminal coronary 
angioplasty immediately after intracoronary streptolysis 
of transmural myocardial infarction. Circulation 1982; 
66:905-913. 
56. Swan JHC. Thrombolysis in acute myocardial infarction: 
treatment of the underlying coronary artery disease. 
Circulation 1982; 66: 914-916. 
57. Satler LF, Pallas RS, Bond OB, Green CE, Pearle DL, Schaer 
GL, Kent KM, Rackley CE. Assessment of residual coronary 
arterial stenosis after thrombolytic therapy during acute 
myocardial infarction. Am J Cardiol. 1987; 57: 1231-1233. 
151 
58. Hartzler GO, Rutherford BD, McConahay DR, Johnson WL Jr, 
McCallister BD, Gura GM Jr, Conn RC, Crockett JE. 
Percutaneous transluminal coronary angioplasty with and 
without thrombolytic therapy for treatment of acute 
myocardial infarction. Am Heart J 1983; 106: 965-973. 
59. Pepine CJ, Prida X, Hill JA, Feldman RL, Conti CR. 
Percutaneous transluminal coronary angioplasty in acute 
myocardial infarction. Am Heart J 1984; 107:820-822. 
60. Holmes DR, Smith HC, Vlietstra RE, Nishimara RA, Reeder 
GS, Bove AA, Bresnahan JF, Chesebro JH. Percutaneous 
transluminal coronary angioplasty, alone or in combination 
with streptokinase therapy during acute myocardial 
infarction. Mayo Clin Proc 1985; 60:449-456 
61. Rothbaum DA, Linnemeier TJ, Landin RJ, Steinmetz EF, 
Hillis JS, Hallam CC, Noble J, See MR. Emergency 
percutaneous transluminal coronary angioplasty in acute 
myocardial infarction: a 3 year experience. J Am Coll 
Cardiol 1987; 10: 264-272. 
62. O'Neill WW, Timmis GC, Bourdillon PD, Lai PY, Gangadharan 
V, Walton JA, Ramos RG, Laufer N, Gordon S, Schork A, 
Linert DP, Pitt B. A prospective randomized, trial of 
intracoronary streptokinase versus coronary angioplasty 
for acute myocardial infarction. N Eng J Med 1986; 314: 
812-818. 
63. Rutherford BD, Hartzler GO, McConahay DR, Johnson WL. 
Direct balloon angioplasty in acute myocardial infarction 
without prior use of streptokinase (abstract). J Am Coll 
Cardiol 1986; 7: 149A • 
64. Marco J, Caster L, Fajadet J. Emergency percutaneous 
transluminal coronary angioplasty without thrombolysis as 
an initial therapy in acute myocardial infarction. Int J 
Cardiol 1987; 15: 55-63. 
65. Topol EJ, O'Neill WW, Langbur AB, Walton JA Jr, Bourdillon 
PDV, Bates ER, Grines CL, Schork AM, Kline E, Pitt B. A 
randomized placebo controlled trial of intravenous 
recombinant tissue-type plasminogen activator and 
emergency coronary angioplasty in patients with acute 
myocardial infarction. Circulation 1987; 75: 420-428. 
66. Serruys PW, Wijns W, van den Brand M, Ribeiro V, Fioretti 
P, Simoons ML, Kooyman CJ, Reiber JHC, Hugenholtz PG. Is 
transluminal coronary angioplasty mandatory after 
successful thrombolysis? Quantitative coronary 
angiographic study. Br Heart J 1983; 50: 257-265. 
6 7. Gold HK, Cow ley MJ, Palacios JF, Vet rovec GW, Akins CW, 
Block PC, Leinbach RC. Combined intracoronary 
streptokinase infusion and coronary angioplasty during 
acute myocardial infarction. Am J Cardiol 1984; 
53:122C-125C. 
152 
68. Yasuno M, Saito Y, Ishida M, Suzuki K, Endo S, Takahashi 
M. Effects of percutaneous transluminal coronary 
angioplasty: intracoronary thrombolysis with urokinase in 
acute myocardial infarction. Am J Cardiol 1984; 53: 
1217-1220. 
69. Papapietro SE, Maclean WAH, Stanley AWH, Hess RG, Corley 
N, Arciniegas JG, Cooper TB. Percutaneous transluminal 
coronary angioplasty after acute intracoronary 
streptokinase in evolving acute myocardial infarction. Am 
J Cardiol 1985; 55:48-53. 
70. Erbel R, Pop T, Meinertz T, Kasper W, Schreiner G, Henkel 
B, Henrichs KJ, Pfeiffer C, Rupprecht HJ, Meyer J. 
Combined medical and mechanical recanalization in acute 
myocardial infarction. Cath Cardiovasc Diagn 1985; 
11:361-377. 
71. Erbel R, Pop T, Henrichs K, Olshausen K, Schuster CJ, 
Ruprecht H, Steuernagel C, Meyer J. Percutaneous 
transluminal coronary angioplasty after thrombolysis 
therapy: A prospective controlled randomized trial. J Am 
Coll Cardiol 1986; 8:485-495. 
72. Kitazume H, Iwama T, Suzuki A. Combined thrombolytic 
therapy and coronary angioplasty for acute myocardial 
infarction. Am Heart J 1986; 111:826-832. 
73. Suryapranata H, Serruys PW, Vermeer F, de Feyter PJ, van 
den Brand M, Simoons ML, Bar FW, Res J, van der Laarse A, 
van Domburg R, Beatt K, Lubsen J, Hugenholtz PG. Value of 
immediate coronary angioplasty following intracoronary 
thrombolysis in acute myocardial infarction. Cathet. 
Cardiovasc. Diagn. 1987; 13: 223-232. 
74. Suryapranata H, Serruys PW, de Feyter PJ, van den Brand M, 
Beatt K, van Domburg R, Kint PP, Hugenholtz PG. Coronary 
angioplasty immediately following thrombolysis in 115 
consecutive patients with acute myocardial infarction. Am 
Heart J 1988; 115: 519-529. 
75. Stack RS, O'Connor CM, Mark DB, Hinohara T, Phillips HR, 
Lee MM, Ramirez NM, O'Callaghan WG, Simonton CA, Carlson 
EB, Morris KG, Behar VS, Kong Y, Peter RH, Califf RM. 
Coronary perfusion during acute myocardial infarction with 
a combined therapy of coronary angioplasty and high-dose 
intravenous streptokinase. Circulation 1988; 77: 151-161. 
76. Prida XE, Holland P, Feldman RL, Hill JA, MacDonald RG, 
Conti R, Pepine CJ. Percutaneous transluminal coronary 
angioplasty in evolving acute myocardial infarction. Am J 
Cardiol 1986; 57:1069-1074. 
77. Fung AY, Lai P, Topol EJ, Bates ER, Bourdillon PDV, Walton 
JA, Mancini GBJ, Kryski T, Pitt B, O'Neill WW. Value of 
percutaneous transluminal coronary angioplasty after 
unsuccessful intravenous streptokinase therapy in acute 
myocardial infarction. Am J Cardiol 1986; 58: 686-691. 
153 
78. Simoons ML, Arnold AER, Betriu A, de Bono DB, Col J, 
Dougherty FC, von Essen R, Lambertz H, Lubsen J, Meier B, 
Michel PL, Raynaud P, Rutsch W, Sanz GA, Schmidt W, 
Serruys PW, Thery C, Uebis R, Vahanian A, van de Werf F, 
Willems GM, Wood D, Verstraete M. Thrombolysis with rt-PA 
in acute myocardial infarction: No additional benefit from 
immediate percutaneous transluminal coronary angioplasty. 
Lancet 1988; I: 197-202. 
79. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith 
CW, Candela RJ, Lee KL, Pitt W, Stack RS, O'Neill WW, and 
the Thrombolysis and Angioplasty in Myocardial Infarction 
Study Group. A randomized trial of immediate versus 
delayed elective angioplasty after intravenous tissue 
plasminogen activator in acute myocardial infarction. N 
Engl J Med 1987; 317: 581-588. 
80. TIMI-IIA. Preliminary . results presented at American 
College meeting 1988. To be published JAMA 1988. 
81. Guerci AD, Gerstenblith G, Brinker JA et al. A randomized 
trial of intravenous tissue plasminogen activator for 
acute myocardial infarction with subsequent randomization 
to elective coronary angioplasty. N Engl J Med 1987; 317: 
1613-1618. 
82. Stenson RE, Flamm MD, Zaret BL, McGowan RL. Transient ST 
segment elevation with postmyocardial infarction angina: 
prognostic significance. Am Heart J 1975; 89: 449-454. 
83. Marmor A, Sobel BE, Roberts R. Factors presaging early 
recurrent myocardial infarction ("Extension"). Am J 
Cardiel 1981; 48:603-610. 
84. Fioretti P, Brower RW, Balakumaran K. Early 
post-infarction angina. Incidence and prognostic 
relevance. Europ. Heart J 1986; 7: 73-77. 
85. Fraker TD, Wagner GS, Rosati RA. Extension of myocardial 
infarction: incidence and prognosis. Circulation 1979; 
60: 1126-1129. 
86. Schuster EH, Bulkley BH. Early postinfarction angina: 
ischemia at a distance and ischemia in the infarct zone. N 
Engl J Med 1981; 305:110-115. 
87. Madigan NP, Rutherford BD, Frye RL. The clinical course, 
early prognosis and coronary anatomy of subendocardial 
infarction. Am J Med 1976; 60:635-641. 
88. Hutter AM, De Sanctis RW, Flynn T, Yeatman LA. 
154 
Nontransmural myocardial infarction: a comparison of 
hospital and late clinical course of patients with that of 
matched patients with transmural anterior and transmural 
inferior myocardial infarction. Am J Cardiel 1981; 
48:595-602. 
89. Gibson RS, Beller Ga, Gheorghiade M, Nygaard TW, Watson 
DD, Huey BL, Sayre SL, Kaiser DL. The prevalence and 
clinical significance of residual myocardial ischemia 2 
weeks after uncomplicated non Q wave infarction: a 
prospective natural history study. Circulation 1986; 
73:1186-1198. 
90. Abbott JA, Scheinman MM. Nondiagnostic electrocardiogram 
in patients with acute myocardial infarction. Am J Med 
1973; 55: 608-613. 
91. Madias JE, Chahine RA, Gorlin R, Blacklow DJ. A comparison 
of transmural and nontransmural acute myocardial 
infarction. Circulation 1974; 49: 498-507. 
92. Rigo P, Murray M, Taylor DR, Weisfeldt ML, Strauss HW, 
Pitt B. Hemodynamic and prognostic findings in patients 
with transmural and nontransmural infarction. Circulation 
1975; 51: 1064-1070. 
93. Genovese MG, Salaki JS, Kennedy RJ, Grace WJ. 
Subendocardial infarction: what happens later. Am Heart J 
1976; 72: 542-543. 
94. Cannom DS, Levy W, Cohen LS. The short- and long-term 
prognosis of patients with transmural and nontransmural 
myocardial infarction. Am J Med 1976; 61: 452-458. 
95. Rothkopf M, Boerner J, Stone MJ, Smitherman TC, Buja LM, 
Parkey RW, Willerson JT. Detection of myocardial infarct 
extension by CK-B radioimmunoassay. Circulation 1979; 59: 
268-274. 
96. Fabricius-Bjerre N, Munkvad M, Knudsen JB. Subendocardial 
and transmural myocardial infarction: a five year survival 
study. Am J Med 1979; 66: 986-990. 
97. Thanavaro S, Krone RJ, Kleiger RE, Province MA, Miller JP, 
Demello VR, Oliver GC. In-hospital prognosis of patients 
with first nontransmural and transmural infarctions. 
Circulation 1980; 61:29-33. 
98. Mahony C, Hindman MC, Aronin N, Wagner GS. Prognostic 
differences in subgroups of patients with 
electrocardiographic evidence of subendocardial or 
transmural myocardial infarction. Am J Med 1980; 69: 
183-186. 
99. Beta-Blocker Heart Attack Research Group. A randomized 
trial of propranolol in patients with acute myocardial 
infarction: mortality results. JAMA 1982;247: 1707-1714. 
100.Krone RJ, Friedman E, Thanavaro S, Miller JP, Kleiger RE, 
Oliver GC. Long-term prognosis after first Q-wave 
(transmural) or .non-Q-wave (nontransmural) myocardial 
infarction: analysis of 593 patients. Am J Cardiol 1983; 
52: 234-239. 
101 Coll S, Castaner A, Sanz - G, Roig E, Magrina J, 
Navarro-Lopez F, Betriu A. Prevalence and .prognosis after 
a first nontransmural myocardial infarction. Am J Cardiol 
1983; 51: 1584-1588. 
155 
102. Maisel AS, Ahnve S, Gilpin E, Henning H, Goldberger AL, 
Collins D, Le Winter M, Ross J Jr. Prognosis after 
extension of myocardial infarct: the role of Q-wave or 
non-Q wave infarction. Circulation 1985; 71: 211- 217. 
103. Connolly DC, Elveback LR. Coronary heart disease in 
residents of Rochester, Minnesota. VI. Hospital and post 
hospital course of patients with transmural and 
subendocardial myocardial infarction. Mayo Clin Proc 
1985; 60: 375-381. 
104. Theroux P, Kouz S, Bosch X, Waters DD, Roy D, Pelletier 
GB, Dyrda I. Clinical and angiographic features of 
non-Q-wave and Q-wave myocardial infarction (abstr). 
Circulation 1986; 74 (II):303. 
105. Boden WE, Kleiger RE, Capone RJ et al. Sequential ECG, 
enzymatic and demographic features in a large prospective 
randomized trial of 538 non-Q wave myocardial infarction 
patients (abstr). Clin Res 1986; 34: 284A. 
106. Huey BL, Gheorghiade M, Crampton RS, Beller GA, Kaiser 
DL, Watson DD, Nygaard TW, Craddock GB, Sayre SL, Gibson 
RS. Acute non-Q wave myocardial infarction associated 
with early ST segment elevation Evidence for 
spontaneous coronary reperfusion and implications for 
thrombolytic trials. J Am Coll Cardiel 1987; 9: 18-25. 
107. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Non-Q wave 
myocardial infarction: recent changes in occurrence and 
prognosis - a community-wide perspective. Am Heart J 
1987; 113: 273-279. 
108. Kossowsky WA, Mohr BD, Rafii S, Lyon AF. Superimposition 
of transmural infarction following acute subendocardial 
infarction: How frequent? Chest 1976; 69: 758-761. 
109. Szklo M, Goldberg R, Kennedy HL, Tonascia JA. Survival of 
patients with nontransmural myocardial infarction: a 
population-based study. Am J Cardiel 1978; 42: 648-652. 
110. Poehlman JH, Silverman ME. Clinical characteristics, 
electrocardiographic and enzyme correlations, and 
long-term prognosis of patients with chest pain 
associated with ST depression and/or T wave inversion. Am 
Heart J 1980; 99: 173-180. 
111. Hollander G, Ozick H, Greengart A, Shani J, Lichstein E. 
High mortality early reinfarction with first 
nontransmural myocardial infarction. Am Heart J 1984; 
108: 1412-1416. 
112. Zema MJ. Q-wave, ST segment, and T-wave myocardial 
infarction. Am J Med 1985; 78: 391-398. 
113. Gibson RS, Boden w"'E, Theroux P, Strauss HD, Pratt CM, 
Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, 
Kleiger RE, Young PH, Schechtman K, Perryman MB, Roberts 
R, and the Diltiazem Reinfarction Study Group. Diltiazem 
and reinfarction in patients with non-Q-wave myocardial 
infarction: results of a double-blind, randomized 
multicenter trial. N Engl J Med 1986; 315: 423-429. 
156 
114. Johnson WD, Flemma RJ, Lepley D Jr. Direct coronary 
surgery utilizing multiple-vein bypass grafts. Ann Thorac 
Surg 1970; 9: 436-444. 
115. Cohn LH, Fogarty TJ, Daily PO. Emergency coronary artery 
bypass. Surgery 1972; 10: 821-829. 
116. Favaloro RG, Effler DB, Cheanvechai C. Acute coronary 
insufficiency (impending myocardial infarction and 
myocardial infarction) : surgical treatment by the 
saphenous vein graft technique. Am J Cardiol 1971; 28: 
598-613 
117. Piffarre R, Spinazzola A, Nemickas R, Scanlon PJ, Tobin 
JR. Emergency aorto-coronary bypass for acute myocardial 
infarction. Arch Surg 1971; 103: 525-528. 
118. Sustaita H, Chatterjee K, Matloff JM. Emergency bypass 
surgery in impending and complicated acute myocardial 
infarction. Arch Surg 1972; 105: 30-35. 
119. Dawson JT, Hall RJ, Hallman GL, Cooley DA. Mortality in 
patients undergoing coronary artery bypass surgery after 
myocardial infarction. Am J Cardiol 1974; 33: 483-486. 
120. Hill JD, Kerth WJ, Kelly JJ. Emergency aortocoronary 
bypass for impending or extending myocardial infarction. 
Circulation 1971; 43/44 (suppl I): 105-110. 
121. Reul GJ, Morris GC, Howell JF, Crawford ES, Sterlter WJ. 
Emergency coronary artery bypass grafts in the treatment 
of myocardial infarction. Circulation 1973; 47/48 (suppl 
III): 127-131. 
122. Madigan NP, Rutherford BD, Barnhorst DA, Danielson GK. 
Early saphenous vein grafting after subendocardial 
infarction: Immediate surgical results and late 
prognosis. Circulation 1977; 56 (suppl II): 1-3. 
123. Aintablian A, Hamby RI, Weiss D, Hoffman I, Voleti CO, 
Wisoff BG. Results of aortocoronary bypass surgery 
grafting in patients with subendocardial infarction: Late 
follow-up. Am J Cardiol 1978; 42:183-186. 
124. Williams DB, Ivey TD, Bailey WW, Irey SJ, Rideout JT, 
Stewart D. Postinfarction angina: Results of early 
revascularization. J Am Coll Cardiol 1983; 2: 859-864. 
125. Levine FH, Gold HK, Leinbach RC, Daggett WM, Austen WG, 
Buckley MJ. Safe early revascularization for continuing 
ischemia after acute myocardial infarction. Circulation 
1979; 60 (suppl I): 5. 
126. Jones EL, Waites TF, Craver JM, Bradford JM, Douglas JS, 
King SB, Bone DK, Dorney ER, Clements SD, Thompkins T, 
Hatcher CR. Coronary bypass for relief of persistent pain 
following acute myocardial infarction. Ann Thorac Surg 
1981; 32: 33. 
127. Nunley DL, Grunkemeier GL, Teply JF, Abbruzzese PA, Savis 
JS, Khonsari S, Starr A. Coronary bypass operation 
following acute complicated myocardial infarction. J 
Thorac Cardiovasc Surg 1983; 85: 485. 
157 
128. Singh AK, Rivera R, Cooper GN, Karlson KE. Early 
myocardial revascularization for post-infarction angina: 
Results and longterm follow-up. J Am Coll Cardiol 1985; 
6: 1121-1125. 
129. de Feyter PJ, Serruys PW, Soward A, Brand van den M, Bos 
E, Hugenholtz PG. Coronary angioplasty for early 
postinfarction unstable angina. Circulation 1986; 54: 
460-465. 
130. Holt GW, Gersh BJ, Holmes DR, Vlietstra RE, Reeder GS, 
Bresnahan JF, Smith HC. The results of percutaneous 
transluminal coronary angioplasty (PTCA) in post 
infarction angina pectoris (abstract). JAm Coll Cardiol 
1986; 7: 62A. 
131. Gottlieb SO, Brim KP, Walford GD, McGaughey M, Riegel MB, 
Brinker JA. Initial and late results of coronary 
angioplasty for early postinfarction unstable angina. 
Cath Cardiovasc Diagn 1987; 13: 93-99. 
132. Safian RD, Snyder D, Synder BA, McKay RG, Corell BH, 
Aroesty M, Pasternak RC, Bradley AB, Monrad S, Baim DS. 
Usefulness of PTCA for unstable angina pectoris after non 
Q-wave acute myocardial infarction. Am J Cardiol 1987; 
59: 263-266. 
133. Hopkins J, Savage M, Zaluwski A, Dervan JP, Goldberg S. 
Recurrent ischemia in the zone of prior myocardial 
infarction: results of coronary angioplasty of the 
infarct related artery. Am Heart J 1988; 115: 14-19. 
134. Suryapranata H, Beatt K, de Feyter PJ, Verroste J, van 
den Brand M, Zijlstra F, Serruys PW. Percutaneous 
transluminal coronary angioplasty for angina pectoris 
after a non-Q-wave acute myocardial infarction. Am J 
Cardiol 1988; 61: 240-243. 
135. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger · 
L. Intravascular stents to prevent occlusion and 
restenosis after trans luminal angioplasty. N · Engl J Med 
1987; 316: 701-706. 
158 
SAMENVATTING 
De klinische uitingen van acute ischemische hartziekten 
Z1Jn een direct gevolg van de onderliggende pathofysiologische 
mechanismen. Afhankelijk van de mate en duur van de 
verminderde myocardiale doorbloeding kunnen verschillende 
klinische syndromen, zoals plotse dood, acuut transmuraal 
infarct, acuut niet transmuraal infarct of onstabiele angina 
pectoris optreden. Recente klinische, angiografische en 
pathologische studies hebben de gemeenschappelijke 
pathofysiologische kenmerken van de mechanismen die ten 
grondslag liggen aan onstabiele angina pectoris, acuut myocard 
infarct en postinfarct angina pectoris aangetoond. 
Onstabiele angina pectoris is gedefinieerd als perioden 
van myocard ischemie in rust, zonder daaropvolgende tekenen 
van necrose. Wanneer een patient zich presenteert met klachten 
van pijn op de borst gepaard gaande met electrocardiografische 
tekenen van ischemie, kan het onderscheid tussen onstabiele 
angina pectoris en acuut myocard infarct echter moeilijk zijn. 
De onzekerheid over het uiteindelijke beloop bij de 
individuele patient noopt tot het geven van de optimale 
therapie. Het doel van interventies in deze acute situatie is 
het behoud of herstel van een adequate bloedstroom, teneinde 
ischemie op te heffen en (verdere) necrose te voorkomen met 
het uiteindelijke doel de morbiditeit en mortaliteit op korte 
en lange termijn te verbeteren. Ondanks verbeteringen in 
chirurgische techniek, cardioplegie, anesthesie, en post-
operatieve zorg, bestaat er nog steeds geen consensus over de 
rol van acute coronaire bypass chirurgie bij deze groep 
patienten. De percutane transluminale coronaire angioplastiek 
is een aantrekkelijk alternatief voor acute coronaire bypass 
chirurgie bij de behandeling van patienten met acute 
ischemische syndromen. 
In hoofdstuk II van dit proefschrift worden de resultaten 
van coronaire angioplastiek op korte en lange termijn 
beschreven bij een groep van 200 opeenvolgende patienten met 
onstabiele angina pectoris. Tevens worden hierin klinische, 
electrocardiografische, angiografische en aan de angioplastiek 
gerelateerde variabelen geanalayseerd, teneinde onafhankelijke 
risicofactoren voor complicaties te kunnen identificeren. De 
resultaten tonen aan dat coronaire angioplastiek bij 
geselecteerde patiE~nten met onstabiele angina pectoris een 
effectieve behandeling is met een goede prognose op de lange 
termijn. 
Anderzijds moet er op gewezen worden dat complicaties in 
deze acute omstandigheden vaker optreden dan bij een electief 
uitgevoerde angioplastiek voor stabiele angina pectoris. De 
oorzaak hiervan is de andere pathofysiologie gekenmerkt door 
geruptureerde plaque met ne1g1ng tot thrombus vorming. 
Hierdoor kan een kritische reductie van de myocardiale 
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bloedvoorziening optreden. Coronaire angioplastiek kan in deze 
acute situatie het gestenoseerde lumen vergroten en aldus dit 
proces onderbreken. Soms geeft coronaire angioplastiek echter 
aanleiding tot een dusdanige beschadiging van de reeds 
geulcereerde intima, waardoor het bestaande thrombogene proces 
verder versterkt wordt. Dit kan leiden tot een acute 
afsluiting gedurende of kort na de procedure. Dit is een 
argument om ten tijde van de procedure additionele therapie in 
de vorm van een thrombolyticum te geven. Daarom werd bij 
patienten met een acute occlusie kort na de ballondilatatie, 
intracoronair streptokinase toegediend. De resultaten van deze 
behandelingsstrategie worden besproken in hoofdstuk III. 
Naast het feit dat coronaire angioplastiek op veilige en 
effectieve WlJze toegepast kan worden bij patienten met 
onstabiele angina pectoris, toont de analyse van de globale en 
regionale linker ventrikel functie verder het nut aan van 
ballondilatatie bij deze patienten, zoals beschreven wordt in 
hoofdstuk IV. 
Het belangrijkste doel van de behandeling van patienten 
met een acuut myocardinfarct is de beperking van de 
infarctgrootte. Het concept om de infarctgrootte te beperken 
door vroegtijdige recanalisatie middels thrombolytica is in de 
klinische praktijk effectief gebleken. Het gebruik van 
thrombolytica in de acute fase van het myocardinfarct heeft 
echter een nieuw probleem gecreeerd: hoe behandelt men 
patienten met een reststenose na thrombolyse indien 
ischemische symptomen blijven bestaan? Teneinde het gunstige 
effect van thrombolyse te behouden, kan het noodzakelijk zijn 
om de residuele stenose ook adequaat te behandelen middels 
coronaire angioplastiek. 
De rol van coronaire angioplastiek onmiddellijk na 
thrombolyse bij het acute myocardinfarct wordt besproken in 
hoofdstukken V en VI. Hoofdstuk V beschrijft onze ervaringen 
met coronaire angioplastiek toegepast onmiddellijk na 
intracoronaire streptokinase bij ll5 opeenvolgende patienten 
met een acuut myocardinfarct. Het doel van de studie 
beschreven in hoofdstuk VI was om te onderzoeken of coronaire 
angioplastiek direct na thrombolyse een additionele waarde 
heeft bij het behouden van de regionale ventrikel functie in 
het infarctgebied. Hierbij werd gebruik gemaakt van de 
resultaten van de "Nederlandse Multicenter Thrombolyse 
Studie", waarin een deel van de patienten coronaire 
angioplastiek ondergingen. De aangetoonde verbetering van de 
globale en regionale linker ventrikel functie, tesamen met de 
lage mortaliteit en morbiditeit, suggereren dat angioplastiek 
direct na thrombolyse veilig toegepast kan worden om complete 
reperfusie in de acute fase van het myocardinfarct te 
verkrijgen. Deze additionele revascularisatie procedure kan 
bij sommige patienten noodzakelijk ZlJn om de kansen op 
volledig functioneel herstel te optimaliseren. 
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Desalniettemin, de thans beschikte gegevens over het 
gebruik van coronaire angioplastiek bij het acute 
myocardinfarct zijn tegenstrijdig en tot op heden bestaat er 
nog geen duidelijkheid over de plaats van de angioplastiek in 
deze situatie. Verder onderzoek is vereist om de exacte role 
en het optimale tijdstip van coronaire angioplastiek bij het 
acute myocardinfarct nader te bepalen. 
Het frequent voorkomen van een recidief myocardinfarct en 
onstabiele angina pectoris na een non-Q-myocardinfarct vraagt 
om profylactische maatregelen teneinde verder verlies van 
myocardweefsel te voorkomen. Het is aannemelijk dat bij deze 
groep patienten een deel van het myocard nog steeds "bedreigd" 
is na een onvolledige infarcering. De korte en lange termijn 
resultaten van 114 opeenvolgende patienten behandeld middels 
coronaire angioplastiek vanwege ernstige angina pectoris na 
non-Q-myocardinfarct worden beschreven in hoofdstuk VII. Het 
hoge succespercentage, de lage mortaliteit en morbiditeit, 
suggereren dat coronaire angioplastiek een effectieve 
behandeling is bij patienten met angina pectoris klachten na 
een doorgemaakt non-Q-myocardinfarct. 
In hoofdstuk VIII wordt de globale en regionale linker 
ventrikel functie beschreven bij patienten die coronaire 
angioplastiek ondergaan in de vroege fase na een 
non-Q-myocardinfarct. De resultaten tonen niet alleen aan dat 
herhaalde aanvallen van ischemie na een non-Q-myocardinfarct 
aanleiding kunnen geven tot langdurige myocardiale 
dysfunctie, maar dat dit "stunned" myocard zich weer kan 
herstellen na succesvolle coronaire angioplastiek. 
Coronaire angioplastiek heeft inmiddels een belangrijke 
plaats ingenomen bij de behandeling van acute ischemische 
hartziekten. De resultaten beschreven in dit proefschrift 
tonen niet alleen aan dat coronaire angioplastiek op veilige 
en effectieve wijze toegepast kan worden bij deze groep 
patienten, maar bovendien dat de linker ventrikel functie in 
staat is zich te herstellen na een succesvol uitgevoerde 
dilatatie. Nader onderzoek is echter noodzakelijk om deze 
behandelingswijze verder te ontwikkelen, de juiste indicatie 
en het beste tijdstip van deze interventie te bepalen, en de 
rol van multipele coronaire dilataties te evalueren bij deze 
groep acuut zieke patienten. 
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